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ABSTRACT
Among human genes, CFTR intron Vlll/exon 9 and apolipoprotein All intron Il/exon 3 
boundaries share the characteristic feature given by the presence of a peculiar tract of 
alternating pyrimidines and purines close to the 3’ splice site.
In the case of CFTR gene, the pyrimidine rich tract is composed by a stretch of Ts in a row 
and a stretch of alternating pyrimidines and purines (microsatellite TG dinucleotide repeats) 
and both tracts are polymorphic for their length. On the other hand, in the case of ApoAII gene 
the pyrimidine rich tract is made exclusively of alternating pyrimidines and purines 
(microsatellite TG dinucleotide repeats) and it is also polymorphic for its length in both genes. 
This apparent sequence similarity, concerning the TG tract, is contrasted by the different 
splicing pattern exhibited by the two genes. In fact, CFTR exon 9 undergoes alternative 
splicing to a variable extent, depending on the variations in length of the pyrimidine rich tract, 
whereas ApoAII exon 3 is constitutively included in mRNA. Previous studies of our group 
have shown in the CFTR intron Vlll/exon 9 context, the stretch of pyrimidines alternated with 
purines (within the UG tract) alone is not equivalent to a functional continuous polypyrimidine 
tract, contrarily to what has been observed for the apolipoprotein All gene. Moreover, the 
comparison of splice sites strength of human ApoAII exon 3 and human CFTR exon 9 has 
outlined an apparent contradiction between the splicing behavior of the two exons and the 
strength of the splice sites. In fact, both the 3’ and the 5’ splice sites of CFTR exon 9 display a 
good match with the consensus whereas the match of the ApoAII exon 3 splice sites is not 
good. Altogether these observations prompted us to investigate the mechanisms underlying the 
constitutive splicing of ApoAII exon 3 and, in particular, to characterize the cis-acting 
elements and the trans-acting factors involved in ApoAII exon 3 definition to assure its 
constitutive splicing.
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In order to study in vivo the splicing mechanism of ApoAII exon 3, we set up an eukaryotic 
expression system by cloning the whole ApoAII gene, from its promoter to the poly-A signal. 
Then, the effects of point mutations, deletions or substitutions on splicing of exon 3 were 
analyzed by RT-PCR after transient transfection in Hep3B cell line.
Deletion or replacement of the UG repeats at the 3’ splice site of intron 2 resulted in a 
significant increase in exon 3 skipping, indicating the importance of this alternated 
arrangement of U and G as a functional polypyrmidine tract or at least as an important 
sequence able to lead the exon 3 definition. Furthermore, UV-crosslinking assays showed that 
the (UG)I6 repeats of ApoAII intron 2 are recognized by TDP-43, a protein that binds 
specifically the UG tract within the context of the 3' end of CFTR intron VIII and that affects 
negatively CFTR exon 9 splicing. Next, we characterized the exonic cis-acting elements able 
to affect the splicing efficiency of ApoAII exon 3. Transient transfections of different 
constructs of the ApoAII gene system carrying deletions or point mutations showed that the 
region spanning from nucleotide 87 to 113 of human ApoAII exon 3 is important for its 
inclusion in mRNA. In particular, we mapped a core enhancer-like 9nt-sequence (ESEwt) 
close to the 5’ splice site. In order to identify trans-acting factor/s able to bind the 9nt-ESE 
within ApoAII exon 3, both Electro Mobility Shift Assay (EMSA) and UV-crosslinking 
coupled to immunoprécipitation assays were carried out. EMSA showed a broad band of 
shifted material with the ESEwt RNA, whereas no significant shift was seen with mutated 
ESE RNA. This suggested that one or more proteins interact specifically with the wild type 
ApoAII exon 3 across the 9nt-sequence. Then, UV-crosslinking followed by 
immunoprécipitation with monoclonal antibodies anti-SR proteins ASF/SF2 and anti-SC-35 
showed that ESEwt but not mutated ESE RNA was able to immunoprecipitate a band whose 
molecular weight corresponds to that of ASF/SF2 and, even if to a lower extent, also a band
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whose molecular weight corresponds to that of SC35. Thus, these results provided an evidence 
that at least two SR proteins are able to interact with the sequence across the ESE sequence. 
Subsequently, the relevance of ESE position within an internal intron (and therefore with other 
flanking cis-acting elements) was also tested. Both in vitro and in vivo experiments showed 
that the ApoAII exon 3 ESE works only if it is localized within an internal exon and not if it is 
placed within the first or the last exon. These results also suggested the presence of other 
splicing regulatory elements within the flanking intronic regions of ApoAII exon 3. Thus, to 
explore intron 2 and 3 for the presence of cis-acting elements able to affect the splicing of 
exon 3, a series of deletions within both introns were carried out. Thus, we found at least one 
regulatory element placed within intron 3 that regulates positively exon 3 inclusion.
In conclusion, the constitutive splicing of ApoAII exon 3 seems to be the result of the balance 
between positive and negative action of the regulatory elements found in the exon 3 and its 
flanking introns. Future studies will be aimed at identifying the factors interacting with the 
intronic regulatory elements and at defining a possible model to explain the mechanism of 
ApoAII exon 3 constitutive splicing by integrating the network of interactions among the 
identified cis-acting elements and trans-acting factors.
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ABBREVIATIONS
The standard abbreviations used in this dissertation follow lUPAC rules. All the abbreviations 
are defined also in the text when they are introduced for the first time. The abbreviations
mentioned only once are not included in this list.
bp Base pairs
nt Nucleotides
aa Amino acid
kb Kilobase
kDa Kilodalton
dNTPs Deoxynucleoside triphosphate (A, C, G and T)
N Nucleotide (A or C or G or T)
DNA Deoxyribonucleic acid
cDNA Copy DNA
ESE Exonic Splicing Enhancer
ISE Intronic Splicing Enhancer
ESS Exonic Splicing Silencer
ISS Intronic Splicing Silencer
snRNA Small nuclear RNA
snRNP Small nuclear ribonucleoprotein particles
hnRNP Heterogenous ribonuclear protein
SR Arginine-serine rich protein
ss Splice site
NMD Nonsense-mediated decay
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DTT Dithiothreitol
EDTA Ethylenediamine tetra-acetic acid
IPTG Isopropyl-b-d-thiogalactopyranoside
TBE Tris-borate-EDTA (buffer)
PBS Phosphate buffer saline
ddH^O Double-distilled water
Pu Purine
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1. INTRODUCTION
Pre-mRNA SPLICING
Overview of pre-mRNA processing
Eukaryotes genes are often interrupted by intervening sequences (introns or TVS) that must be 
removed during gene expression. RNA splicing is the process by which these intervening 
sequences are precisely removed and the flanking, functional sequences (exons) are joined 
together. Therefore, RNA splicing is one of the major steps in the control of gene expression 
in eukaryotes.
Pre mRNA splicing is one of the latest stages recognized in the flow of genetic information 
from gene to protein. The presence of introns was first described in the non-coding regions of 
adenovirus (Berget et al., 1977; Chow et al., 1977) but was quickly shown to be a common 
feature of cellular genes. In fact, in 1977 Jeffreys and Flavell described the presence of “large 
insert” in the coding sequence of rabbit beta-globin gene. In 1978, Chambon and his 
colleagues reported the positions where the coding sequences for ovalbumin mRNA were 
interrupted in the genome (Breathnach et al., 1978). Moreover, they found repeated sequences 
at exon-intron boundaries that share common features, and this led to the proposal that there 
are unique excision-ligation points common to all boundaries (Breathnach et al., 1978).
In pre-mRNA splicing, introns are removed and exons are ligated together by a two-step 
transestérification reactions carried out by the spliceosome, a dynamic 60S ribonucleoprotein 
particle (Staley and Guthrie, 1998). Formation of the spliceosome at particular splice junctions 
is triggered by recognition of the 5' splice site by the U1 snRNP and of the 3' splice site by 
U2AF, followed by the U2 snRNP. It is unclear whether the spliceosome is assembled from 
larger complexes, such as the recently identified penta-snRNP, which contains the U l, U2,
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U4, U5 and U6 snRNAs (Stevens et al., 2002) or the 200S InRNP (large nuclear 
ribonucleoprotein particle), which contains additional non-snRNP RNA processing factors 
(Yitzhaki et al., 1996), or by the sequential addition of snRNP and non-snRNP factors as was 
previously supposed
Chemistry of splicing
From a chemical point of view, the reactions involved in pre-mRNA splicing are quite simple: 
the exchange of one substituent on a phophodiester bond for another. Although the 
intermediates and products of splicing were characterized some years ago, the reaction 
mechanisms have been established with certainty only recently, and the pre-mRNA structural 
features that are important for the transestérification reactions are just now being investigated. 
If the reactions are protein- or RNA- catalyzed also remains an open question.
Splicing occurs in two steps involving two sequential transestérification reactions (Moore et 
al., 1993). The first step involves cleavage at the 5’ splice site to yield a 5’ exon intermediate 
(exonl) with a free 3’-OH terminus. Concurrently, the 5’ end of the intron (IVS) is joined, via 
a 2’-5’ phosphodiester bond, to an adenosine residue within the intron (the branch site) 
generally located within 100 nucleotides of the 3’ splice site. This forms the so-called lariat 
intermediate RNA containing a branched intron with attached 3’ exon (exon 2), The exon 1 
and I VS-exon 2 intermediates are subsequently resolved by cleavage at the 3 splice site and 
ligation of the two exons via a 3’-5’ phosphodiester bond. This yields two products: spliced 
exons and excised lariat intron with a 3’-OH terminus.
Although ATP hydrolysis is required for intron excision from pre-mRNA, none of the 
phosphates in the spliced products is derived from exogenous ATP. Rather the splice site 
phosphates are conserved in the products (Konarska et al., 1985; Lin et al., 1985; Padgett et 
al., 1984). In addition, it had been found that neither step of pre mRNA splicing could be
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separated into bond- breaking and bond- forming reactions. Consistent with these 
observations, it has been shown that both steps proceed via direct “in line” SN2 displacement 
mechanism. Thus the first step involves direct nucleophilic attack by the 2’ OH of the branch 
site adenosine on the phosphate at the 5’ splice site. This displaces the 3’ oxygen of the 5’ 
exon by way of a pentacoordinate transition state. In the second step, the same 3’ OH of the 5’ 
exon, which had been the leaving group in the first reaction, reverses its role and acts as a 
nucleophile at the 3’ splice site phosphate to similarly displace the 3’ end of the intron. 
Interestingly, these direct displacement reactions parallels the known reaction mechanism of 
group I self-splicing introns and are therefore consistent with the notion that pre-mRNA 
splicing is an RNA-catalyzed process.
Splicing is a part o f a co-transcriptional process
From the point of view of RNA Polymerase II (Pol II), the transcription process includes pre­
initiation complex formation, transcription initiation, elongation, termination and dissociation 
of Pol II from the DNA template (Fig. 1.1). The transcript also undergoes pre-mRNA 
processing steps including: (1) 5' end capping, in which the 5' triphosphate of the pre-mRNA 
is cleaved and a guanosine monophosphate is added and subsequently methylated to produce 
mTGpppN; (2) editing, in which individual pre-mRNA residues are converted to alternative 
bases (e.g. adenosine is converted to inosine by base deamination) to produce mRNAs 
encoding distinct protein products; (3) splicing, in which introns are removed and exons are 
ligated together by the spliceosome; (4) 3' end formation, which involves pre-mRNA cleavage 
and synthesis of the poly(A) tail; and paradoxically (5) degradation.
A priori, each of these modifications might occur independently of the others, since most can 
occur in in vitro reconstituted systems on purified pre-mRNA substrates. However, many 
studies have revealed functional relationships among these processes and each (with the
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exception of editing) has been shown to be co-transcriptional, at least some of the time. 
Importantly, a number of trans acting factors required for pre-mRNA processing directly bind 
to Pol II, which stimulates processing, and, in some cases, processing feeds back to Pol II 
activity. This has led to the proposal that RNA transcription and processing occur in a “gene 
expression factory” composed of machines linked together for the purposes of efficiency and 
regulation (Bentley, 2002; Cook, 1999; Maniatis and Reed, 2002; Proudfoot et al., 2002).
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Figure 1.1. Transcriptional coupling of pre-mRNA processing. The transcription cycle is depicted starting at 
the top right and proceeding in a clock-wise fashion. Processing factors may be recruited to the PIC at the 
promoter (TATA) by GTFs (TFllD, IID; TFIIH, IIH) and transcriptional activators (TAs). Hypophosphorylated 
RNAP 11 (green “ tadpole” depicted with a CTD “ tail” ). IIH phosphorylates the CTD (red stars) soon after 
initiation, which recruits CE. Associations retained between the CTD and various factors during elongation are 
not shown for simplicity. CBC mediates 5Vterminal exon definition. IVSs are denoted by the gold DNA. SR 
proteins and the CTD facilitate intemal exon definition. Intron definition occurs when splice sites are paired 
across introns (Prp40 is shown assisting this process). 3V-End processing is mediated by 
cleavage/polyadenylation factors assembled at the poly(A) site (AATAAA) and is assisted by the CBC and 
splicing factors (SFs). These interactions mediate 3Vterminal exon definition. Transcription termination is 
accompanied by CTD dephosphorylation (proposed to occur by Fcpl). Figure taken from Howe et al (Howe, 
2002)
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By the time, pre-mRNAs (hnRNAs) emerge from the transcription complex, and throughout 
the time they are in the nucleus they are associated with proteins. The most abundant cellular 
proteins that bind hnRNA are the heterogeneous nuclear ribonucleoprotein (hnRNP) that 
together, formed the hnRNP particles [reviewed in (Dreyfuss et al., 1993)]. Some members of 
this family of proteins have helix-unwinding activity and seem to function primarily to 
maintain the transcript in a single-stranded state. They influence the structure of hnRNA thus 
facilitating the interaction of hnRNA sequences with the other components that are needed for 
its processing event. hnRNP proteins may also play important roles in the interaction of 
hnRNA with other nuclear structures, in nucleocytoplasmic transport of mRNA, and in other 
cellular processes (Visa et al., 1996). The dynamic structures within the nuclei, called 
speckles, are places of localization of many transcription and splicing factors. (Zeng et al., 
1997). Upon the activation of the genes, those factors are recruited to the sites of transcription, 
bind to the hnRNA in the highly ordered cooperative way, thus driving a processing event and 
then return to the speckles between rounds of active pre-mRNA synthesis for recycling and 
reactivation (Sleeman and Lamond, 1999). The cooperativity is shown for transcription and 
splicing processes which occur contemporarily and influence each other (reviewed in 
(Bentley, 1999; Corden and Patturajan, 1997).
The Spliceosomal Complex
Two of the main functions of the spliceosomal snRNPs are to recognize the 5’ and 3’ 
intron/exon boundaries and to assemble onto these sites the macromolecular enzyme that 
catalyze the splicing reaction. In mammals four distinct spliceosomal complexes, which form 
in the temporal order E, A, B and C, have been detected (Reed, 1997) (Figure 1.2). These 
general steps in spliceosomal assembly are now well understood, with some variations in the 
model proposed few years ago.
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General model for spliceosome assembly and spliceosome cycle
Assembly of the major spliceosome is initiated by the ATP-independent recognition of the 5’ 
splice site by the U l snRNP, which leads to the formation of the spliceosomal complex E. 
This interaction is mediated by base pairing of the U l snRNA with the 5’ splice site, as well as 
by protein-protein and protein-pre-mRNA interaction involving U1-70K and Ul-C proteins 
(Will, 1997). Novel insights into the spliceosomal assembly are coming from studies in S. 
cerevisae in which has been shown that the first proteins that interact with the 5’ splice site 
during the commitment complex (E complex counterpart) formation are the cap-binding 
complex protein CBC80 and seven U l snRNP (Zhang and Rosbash, 1999). Metazoan 
homologues of some of these proteins have been identified, indicating that similar interaction 
may occur in E complex. One of these proteins is Nam8 or TIAl in metazoan, which affects 
splice-site recognition (Puig et al., 1999).
Another important event that occurs during formation of the E complex is the recognition of 
the 3’ end of the intron. In higher eukaryotes, the 3’ splice site and adjacent pyrimidine tract 
are identified through interactions with a dimeric splicing factor U2AF. This, in turn, helps 
recruitment of the U2 snRNP to the branchpoint together with a branchpoint binding protein 
(BBPorSFl).
The current model of assembly proposes that U2 snRNP first associate in an ATP-dependent 
manner in the A complex. However, U2 snRNP has now been identified as a component of a 
purified, functional E complex. U2 snRNP association with the E complex occurs in the 
absence of ATP and does not require branch point sequence interaction. The interpretation of 
this data is that U2 snRNP first binds loosely to the pre-mRNA in the E complex via the 
integral U2-snRNP-associated protein SF3b, and then an ATP- dependent process leads to 
stable binding of U2-snRNP to the branch point sequence in the A complex and this is 
facilitated by the presence of other proteins such as SF3A and SFl (Das et al., 2000).
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Figure 1.2 The spliceosome cycle is shown. The figure summarizes each of the steps, in the order that they 
occur, and the energy requirement, if any. There are 5 snRNPs involved: U l, U2, U4, U5 and U6 (adapted from 
Moore et al. 1993).
The next major event after A complex assembly is the binding of U4/U5»U6 tri-snRNPs at the 
5’ splice site to form the B complex. At this time many structural snRNPs rearrangements 
occur leading to the formation of a complex RNA-RNA network within the spliceosome. 
U4/U6 base pairing interaction is disrupted and U6 snRNA base pairs with U2 snRNA and 
also the 5 ’ splice site. Furthermore, U5 snRNA loop I base pairs with exon sequence at the 5 ’ 
splice site and later with exon sequences at 3 ’ splice site. The 5’ and 3 ’ splice sites are also 
contacted by the U5-220 KDa protein (Umen and Guthrie, 1995), which has been reported to 
affect also the tertiary interaction between the splice sites and U6 snRNA (Collins and 
Guthrie, 1999). Recent studies report that tri-snRNPs interact with the 5’ splice site and the 
upstream 5’ exon at earlier step in spliceosome assembly than previously thought (Maroney et 
al., 2000). These interactions occur in an ATP-dependent manner in the absence of stable U2
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snRNP binding and appear to be guided, in part, by the U5 associated protein U5-220KDa. In 
this view, formation of B complex does not reflect “recruitment” but rather a stabilization that 
occurs as a consequence of interspliceosomal RNA-RNA rearrangements such as 
replacements of U l by U6 and formation of U2/U6 helices that are prerequisite for the 
formation of the catalytically competent complex C.
An unsolved problem is the catalysis of RNA in pre-mRNA splicing, although is widely 
believed that it is mediated by RNA. Spliceosome is a metallo-enzyme (Sontheimer et al., 
1997; Steitz and Steitz, 1993) and from recent studies has been shown that U6 snRNA 
coordinates metal ion thus contributing to pre-mRNA splicing (Yean et al., 2000). U6 is a 
good candidate for catalysis because is highly conserved through evolution and also forms 
intramolecular and intermolecular helices that are analogous to auto catalytic group II introns 
(Yu et al., 1995).
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CONSTITUTIVE SPLICING 
Cis-acting elements
The question of splice-site choice is closely connected to the problem of normal recognition of 
constitutive splice sites. A feature shared by both regulatory sequences and splice-site signals 
is that they are usually short and often degenerate. Cis-acting determinants that influence 
com peting splicing pathways include relative strength of 5 ’ splice site, the branch point 
sequence, the polypyrimidine tract, the proximity between 5 ’ splice site and branch point, 
sequences between the branch point-polypyrimidine tract and 3 ’ splice site (Figure 1.3). In 
some cases, the formation of pre-mRNA secondary structure participates in the regulation of 
splice site selection by modifying the physical distance within introns, or being involved in the 
definition of the exon. Moreover, additional exonic or intronic sequences are often involved in 
the correct recognition of splice sites, when sub optimal splice sites are present. These 
sequences can act by increasing the recognition or decreasing it and are respectively named 
enhancers or silencers.
5’ splice site Branch Point 3’ splice site
5’ exon
A /C
3' exonIntron
80 100 100 6080 90 80 100 8060 80 100 100 95 70 80 45
Figure 1.3 Schematic representation of exon-intron boundaries and consensus sequences for 5’ and 3’ 
splice sites and branch point. Black boxes are exons, Y indicates a pyrimidine and N means any base. Yn 
means region of about 15 pyrimidines. The bolded A is the branch point. The frequencies of each nucleotide in a 
specific position are indicated.
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Exon/intron architectural requirements
In most cases, vertebrate genes consist of multiple small exons separated by intervening 
sequences that can be significantly larger. The average size of exons is 137 nucleotides and 
exons longer than 300 nucleotides or shorter than 50 nucleotides, even existing, seems to be 
not favored by splicing machinery (Hawkins, 1988). Artificially shortening an internal exon 
leads to inefficient recognition (Dominski and Kole, 1991; Dominski and Kole, 1992) 
presumably due to both deletion of exon accessory sequences and steric hindrance of factors 
such as U l and U2 snRNPs.
Moreover, a compensatory relationship between exon and intron size has been proposed. In 
fact. Sterner et al. observed that large internal exons are problematic for recognition if they are 
flanked by large introns, suggested that naturally occurring large vertebrates exons might be 
flanked by small introns (Sterner et al., 1996).
The 5' and 3^  splice sites requirements
Splice site strength is an important determinant in splice site selection (fig. 1.4). Consensus 
sequences are limited to 4 bases at the 3’ intron/exon junction and to 9 bases at the 5’ 
exon/intron junction (Shapiro and Senapathy, 1987). It is shown that mutating one of the first 
two bases (AG) in intron, immediately upstream of 3’ splice site (YAG/G), as well as GU in 
intron, immediately downstream of 5’ splice site (A/C)AG/GUPuAGU) completely abolish 
splicing (Langford et al., 1984). Studies of alternative splicing have shown that mutations that 
improve the match of weak splice sites to the consensus can led to the constitutive recognition 
of alternatively skipped exon (Del Gatto and Breathnach, 1995; Huh and Hynes, 1993; Muro 
et al., 1998), also the use of the normal 3' splice site can be restored either improving the 
match of a cryptic branch site to the branch site consensus or by introducing mutant U2 
snRNAs with greater complementarity to the cryptic branch site (Zhuang and Weiner, 1989).
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Figure 1.4 Splice signal motifs in different organisms. Sequence motifs for the 5'ss (A), branch site (fi), and 
3'ss (Q  are displayed. The height of each letter is proportional to the frequency of the corresponding base at the 
given position, and bases are listed in descending order of frequency from top to bottom. The RelEnt (in bits) of 
the motif model used relative to the background transcript base composition is also shown. The splice junctions 
and branch point are marked by inverted triangles. Figure taken from Lim et al (Lim and Burge, 2001)
Mutations affecting splice sites are common in human genetic disease. In fact, a survey 
performed more than a decade ago found that 15% of point mutants that result in human 
genetic disease affect pre-mRNA splicing (Krawczak et al., 1992). The majority of these are 
single-point mutations affecting the conserved bases at the donor or acceptor splice sites. 
(Cooper DN, 1995).
A study of more than a hundred splice-site mutations showed that point mutations affecting 
the 5' donor splice site were more common than those at the 3' acceptor site (62% vs 26%). At 
the 5' donor splice site, mutations affecting the G residue at position +1 are the most common, 
followed by mutations at position +5. Mutations at these two positions are thought to 
significantly reduce the pairing of the donor splice site with the complementary site in the 
small nuclear libonucleoprotein particle UlsnRNP, which is one of the first steps in the 
complex process of pre mRNA splicing (Kramer, 1996; Krawczak et al., 1992; Wittop Koning 
and Schumperli, 1994)
At the 3' acceptor site, mutations affecting the conserved -2 and -1 sites (A and G
dinucleotides respectively) are most common, although mutations affecting the +1 site are also
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observed (Ariffin et al., 2003; Ikeda et al., 2001). Mutations at donor or acceptor sites can lead 
to exon skipping, intron retention or insertions and deletions due to utilization of cryptic splice 
sites.
The polypyrimidine tract
The adjacent polypyrimidine tract can affect the recognition of the branch point sequences in 
the metazoan (Mullen et al., 1991; Reed, 1989). It has been shown that progressive deletion of 
the polypyrimidine tract abolish lariat formation, spliceosome assembly and splicing (Mullen 
et al., 1991; Roscigno et al., 1993). The polypyrimidine tract is one of the important cis-acting 
sequence elements directing intron removal in pre-mRNA splicing. It is known that 
polypyrimidine tract deletion or mutation decreases the splicing efficiency as well as the 
elongated length of pyrimidine in row can led to improved efficiency of splicing (Roscigno et 
al., 1993).
Despite the important role of polypyrimidine tract in splicing, there appears to be a great 
flexibility in the specific sequence of a given tract.
Further studies have demonstrated by cis-competition assay that the polypyrimidine strength is 
not only determined by its length but also by its composition (Coolidge et al., 1997). The best 
polypyrimidine tract is composed by a poly-uridine tract, whereas, a poly-cytidine tract is not 
functional (Roscigno et al., 1993). Then, proximity of the polypyrimidine tract to the 3’ splice 
site becomes important when the pyrimidine length is limiting. In fact, limiting number of 
continuous uridines to six demands that these uridines are placed immediately adjacent to the 
3’ splice site AG. On the other hand, a polypyrimidine tract with 11 uridine is a highly 
competitive pyrimidine stretch regardless of distance between the branch point and 
polypyrimidine tract itself (Coolidge et al., 1997). It is shown that functional pyrimidine tracts 
do not absolutely require continuous uridines. In constitutively included exon 3 of the human
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Apolipoprotein-AII (Apo All) the “polypyrimidine tract” is composed of a (GT)16 
dinucleotide repeats (Shelley et al., 1985). In this case it is likely that total uridine content may 
relate to the splicing efficiency.
The branch site
While in yeast there is an invariant branch point sequence (UACUAAC) which base paired 
with U2 snRNA, in metazoan this sequence is not highly conserved (Fig. 1.4). However, 
several lines of evidence have led to the belief that the mammalian branch point is specified 
primarily by its proximity to the 3’ splice site. Most branch points have been mapped within 
18-40 nucleotides of the 3’ splice site (Reed and Maniatis, 1985; Ruskin et al., 1985). 
However there are cases in which the branch point located more than 40 nucleotides from the 
3’ splice site is functional and essential for the regulation of alternative splicing. In the rat a- 
tropomyosin gene intron 2, the branch point lies 172 nucleotides upstream from the 3’ splice 
site. This proximity to the 5’ splice site of exon 2 enforces mutually exclusive behavior of 
exons 2 and 3, because the splicing factors are unable to bind productively to the two elements 
simultaneously and form active spliceosome (Smith et al., 1989).
Generally, the mutation of the adenine residue involved in the lariat formation strongly 
reduces splicing efficiency of the downstream exon (Reed and Maniatis, 1988).
Relative strength and cooperation between signals
Several studies have disclosed the synergy existing either between the 5’ and 3’ splice sites or 
between the polypyrimidine tract and the branch point.
It has been demonstrated that strong sequence within the 5’ splice site of an exon can promote 
the use of its own 3’ splice site (Nasim et al., 1990). On the other hand, sequences, upstream
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the 3’ splice site of an exon can facilitate the use of a downstream 5’ splice site (Tsukahara et 
al., 1994).
The polypyrimidine tract determines the location of the branch point sequence and indirectly 
the 3’ splice site (that is usually the first AG downstream the branch point). It is also shown 
that a strong polypyrimidine tract can partially balance a weak branch point sequence. 
Likewise, a strong branch point site can partially balance a weak polypyrimidine tract (Buvoli 
et al., 1997). Finally, also the distance between the branch point sequence and the pyrimidine 
tract is critical for efficient lariat formation (Gattoni et al., 1988).
Enhancers and silencers
As previously highlighted, higher eukaryotes have large introns defined by more degenerate 
splicing signals with respect to yeast genes. Additional intronic and exonic sequences are often 
necessary for efficient and accurate choice of the correct splice site. These auxiliary elements 
are often conserved between species and perhaps between similarly regulated genes, but they 
contain degenerate sequence motifs, making it difficult to identify them. They can be exonic 
or intronic. When localized in introns they can lie upstream, downstream, or flanking both 
sides of the regulated exon. Intronic elements can also be proximal (within 100 nucleotides) or 
distal (more than one kilobase away from the regulated exon), although they are often located 
close to the exon. And finally, auxiliary elements can enhance or repress splice-site selection. 
Depending on their location and their effect on the recognition of alternative splice sites, the 
elements are referred to as exonic splicing enhancers (ESE) or silencers (ESS) or intronic 
splicing enhancers (ISE) or silencers (ISS).
Most splicing enhancers are located within 100 nucleotides of the 3’ splice site but are not 
active when are located further away (Tian and Maniatis, 1994). However in Drosophila 
melanogaster doublesex pre-mRNA, the dsx enhancer element functions when located 300
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nucleotides downstream of the regulated 3’ splice site (Tian and Maniatis, 1993). Studies have 
demonstrated that the activity of a splicing enhancer decreases as a function of distance from 
the 3’ splice site. Indeed, when a strong enhancer and a weak enhancer are compared, the first 
one has a higher ability to function at a great distance from the 3’ splice site (Graveley et al., 
1998).
Most enhancer elements obtain contained extended purine-rich sequences (more than 65% 
purine rich), but a second, novel class of sequences lacking stretches of purines was also 
identified (Tian and Kole, 1995). In fact, studies conducted by Schaal and Maniatis identified 
pyrimidine-rich enhancers that are more than 67% pyrimidine-rich and function such as strong 
enhancers (Schaal and Maniatis, 1999b).
In addition to sequences that promote exon inclusion, there are sequences that inhibit splicing, 
so called exonic or intronic splicing silencers. The silencers are less well characterized; they 
can be purine or pyrimidine-rich and bind a diverse array of proteins (Fairbrother and Chasin, 
2000). A negative element (CAAGG) involved in the down regulation of fibronectin EDA 
exon inclusion was identified within EDA exon (Caputi et al., 1994), where it seems to be 
determinant for RNA conformation (Muro et al., 1999). An example of intronic splicing 
silencer is described for CFTR exon 9 alternative splicing. This extended region in intron 9 
acts like silencer by recruiting SR proteins (Pagani et al., 2000).
Negative effect of silencers can be due to the interaction with protein factors. A well-known 
factor that inhibits splicing is PTB (polypyrimidine tract binding protein). It recognizes 
pyrimidine-rich elements both in introns and in exons and can function either by antagonizing 
U2AF65 action or creating a region of silencing across the down regulated exon (Wagner et 
al., 1999).
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The negative effect on splicing of an inhibitory protein that is bound to a juxtaposed exonic 
splicing silencer (ESS) of a silencer might be antagonized by SR protein bound to an ESE 
(Fig. 1.3b).
The RNA secondary structure
The cis-acting elements regulating constitutive and alternative splicing interacts with trans­
acting factors. The secondary structures that pre-mRNA creates might influence directly this 
kind of interaction.
There are many studies that proposed the RNA secondary structure as a regulator of 
alternative splicing. In the case of rat calcitonin/CGRP pre-mRNA splicing, the 3’ splice 
acceptor of exon 4 forms a stable stem-loop structure. Mutations that destabilize the stem 
abolish the usage of this splice acceptor site in vitro (Coleman and Roesser, 1998). Also other 
cis-acting elements are subjected to this kind of regulation. In fact, in fibronectin EDA exon 
there are an ESS and an ESE. Functional studies coupled to secondary structure analysis 
suggest that the role of the ESS element may be exclusively to ensure the proper RNA 
conformation and raise the possibility that the display of the ESE in a loop position may 
represent a significant feature of the exon splicing regulatory region (Muro et al., 1999). 
Moreover, an example of 5’ splice site mutation that affects a stem-loop structure can be found 
in the tau gene. In this case the disruption of secondary structure increase exon 10 inclusion 
and this result in the production of an aberrant protein isoform that leads to neuro­
degeneration (Grover et al., 1999).
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TRANS ACTING FACTORS 
Protein components involved in splicing
Protein components of the splicing machinery, involved in splicing event are the small nuclear 
ribonucleoprotein particles (snRNPs) and other non-snRNP essential splicing factors. Most of 
these proteins share very similar structural characteristics such as different number of RNA 
binding motifs and/or protein binding domains.
Small Nuclear Ribonucleoprotein Particles (snRNPs)
The snRNP particles form part of the catalytic macromolecular complex called spliceosome. 
Each snRNP particle consists of snRNA molecule complexed with a set of eight Sm or Sm- 
like proteins and several particle specific proteins (Will, 1997). The major spliceosomal 
snRNPs U l, U2, U4, U5 and U6 are responsible for splicing the vast majority of pre-mRNA 
introns (so-called U2-type introns). A group of less abundant snRNPs, U ll, U12, U4atac and 
U6atac, together with U5, are subunits of the so-called minor spliceosome that splices a rare 
class of pre-mRNA introns, denoted U l 2-type (Burge and Sharp, 1999). 
snRNAs U l, U2, U4, U5 and U6 are characterized by their small size, metabolic stability and 
a high degree of sequence conservation (Kambach et al., 1999). Not all the snRNA show 
extensive complementarity to consensus splice sites sequences, only U l and U2, and U6 to a 
minor extent.
The snRNAs are transcribed by RNA polymerase II (with the only exception of U6, and 
presumably U6atac snRNA, that is transcribed by RNA polymerase III and entirely assembled 
in the nucleus). The other pre-snRNAs must be transported to the cytoplasm where snRNPs 
assembly with the Sm proteins is initiated and then reimported into the nucleus thanks to the
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bipartite “snRNP nuclear localization signal” (NLS) formed by m3 G cap and the Sm core 
domain (Fischer et ah, 1993).
The U4 and U6 snRNAs are extensively base paired (amounting to >20 base pairs) in the 
U4/U6 snRNP. They associate in the nucleus forming a larger ribonucleoprotein complex. The 
U5 snRNA then assemble in an ATP dependent reaction with the U4/U6 snRNP giving the 
U4/U6»U5 three-snRNPs particle (Konarska and Sharp, 1987).
The structural core of snRNPs is formed by eight proteins, called Sm proteins, B’, B, D l, D2, 
D3, E, F and G. This class of common proteins plays an essential role in the biogenesis of the 
snRNPs. The Sm proteins form three distinct heteromeric complexes prior to their interaction 
with the highly conserved Sm site (PuAU4-6GPu flanked by two stem-loop structures) of the 
U l, U2, U4 and U5 snRNAs (Raker et al., 1996).
Sm-like proteins belonging to the Sm protein family are specifically required for the assembly 
of U6 snRNA. This subclass of Sm-like proteins shares the conserved structural motif 
characteristic of all Sm-proteins family members (Mayes et al., 1999), but can be isolated as a 
heteromeric complex in the absence of U6 snRNA (Achsel et al., 1999).
Besides Sm proteins, there are other particle-specific proteins that associate with snRNAs 
(Will, 1997). U1-70K and Ul-A proteins bind directly to the RNA and are involved in the 
splice site recognition and selection, while Ul-C associates via protein-protein interactions 
with U1-70K and other Sm proteins. A subset of U2 snRNP proteins also plays a critical role 
in tethering the U2 snRNP to the pre-mRNA. These proteins include the heteromeric splicing 
factors SF3a and SF3b (Brosi et al., 1993) and bind the 20-nucleotide region just upstream of 
the branch site in a sequence-independent manner (Champion-Arnaud and Reed, 1994; Gozani 
et al., 1996).
At least five different proteins associate with U4/U6 snRNP, including a 15.5 KDa protein, 
polypeptides of 20, 60 and 90 KDa that form complex with one another (Teigelkamp et al.,
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1998). U5 snRNP particle presents a complex protein composition. U5 220KDa protein cross­
links to both 5’ and 3’ splice sites, as well as to the exon flanking these two splice sites (Umen 
and Guthrie, 1995).
hnRNP proteins
Immediately after transcription, primary transcripts are associated with a set of abundant 
factors, called heterogeneous ribonuclear proteins (hnRNPs). hnRNP proteins are located 
throughout the nucleus and some of them are extremely abundant (-100 million copies per 
nucleus), while others are present only in small amounts (Hanamura et al., 1998; Kamma et 
al., 1995; Markovtsov et al., 2000; Teigelkamp et al., 1998). hnRNPs remain associated with 
pre-mRNA until processing is completed and with mature mRNAs during nucleocytoplasmic 
transport (Izaurralde and Mattaj, 1995; Michael et al., 1995). By associating with pre-mRNAs, 
hnRNP proteins are able to affect the interactions of pre-mRNAs with components of the RNA 
processing machinery (Dreyfuss et al., 1993). A subset of hnRNPs shuttles continuously 
between the nucleus and the cytoplasm. hnRNPs share structural properties with protein 
components of stable spliceosomal particles (e.g. snRNPs) or splicing regulators, since they 
contain common RNA-binding and auxiliary domains. Contrarily to snRNPs, hnRNPs 
complexes are unusually large and composed by diverse RNA-protein complexes. They 
typically contain numerous proteins and are highly dynamic.
At least 20 major hnRNP proteins exist in human cells, with molecular weight ranging from 
34 to 120 kDa (Dreyfuss et al., 1993). Multiple isoforms of hnRNP proteins are produced by 
alternative processing of the genes coding for these proteins. This diversity is further increased 
by post-translational modification of potential physiological significance, including 
dimethylation of arginine side chains and phosphorylation. Most hnRNP proteins have RNA- 
binding ability, attributable in many cases to RNP domains or other RNA-binding motifs. The
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structure of the members of this family varies considerably: (a) hnRNP I (also known as the 
polypyrimidine-tract-binding protein), L and M contain four RNP domains; (b) hnRNP A/B 
proteins contain two RNP domains at the N-terminus and a Gly-rich auxiliary domain at the 
carboxy end; (c) hnRNP C proteins contain a single RNP domain at the N-terminus (d) hnRNP 
E l and E2 proteins contain three KH domains.
Most hnRNP proteins have general RNA-binding activity, but individual proteins display 
preference for specific sequences. However, hnRNP proteins generally do not bind specific 
sites exclusively but recognize different RNAs with a wide spectrum of affinities. Preferred 
sequences tend nevertheless to coincide with sites of functional importance in pre-mRNA 
processing, suggesting that hnRNP proteins may form specialized complexes or indirectly 
recruit other factors to such sites. RNA binding is further modulated by cooperative protein- 
protein interactions. The array of hnRNP proteins bound to a given hnRNA is determined by 
the RNA sequence (Dreyfuss et al., 1993).
Under conditions of competition for distinct binding sites, each mRNA associates with a 
unique set of hnRNP proteins, and the composition of these complexes is likely to change 
during the processing and transport of hnRNAs. hnRNP proteins function in early processing 
events by associating with nascent transcripts. hnRNP A1 modulates splice site selection by 
antagonizing the activity of serine-arginine-rich splicing factors (SR proteins, see below) 
(Caceres et al., 1994). In fact in at least some cases, hnRNP A1 cooperatively binds exonic 
splicing silencer sequences within the same exon and blocks binding of the SR proteins to 
exonic splicing enhancers (Zhu J, 2001).
Alternative splicing is a major mechanism to control the expression of viral and cellular genes, 
and variations in the intracellular concentration of antagonistic splicing factors may affect 
tissue-specific and developmental regulation of gene expression. The amount of hnRNP A1 
varies during the cell cycle, but the physiological significance of this variation remains
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unclear. Splicing regulation by hnRNP A1 requires both RNP domains; both domains are also 
required for in vitro specific RNA recognition.
SR proteins
SR proteins are a family of pre-mRNA splicing factors that share a common structure 
comprising one or two RNP domains at the N-terminus and a domain rich in arginine-serine 
dipeptides at the C-terminus (RS domain). Other proteins (for example snRNP associated 
factors such as U l 70K) share this structural organization. However, the term SR proteins 
refers to ten major polypeptides ranging from 20 to 75 kDa in size that share the ability to 
modulate splice site choice. SR proteins are essential pre-mRNA splicing factors and critical 
regulators of the selection of both constitutive and alternative splice sites. They are present in 
all eukaryotes except yeast, where true alternative splicing does not occur.
SR proteins have been implicated in many steps of spliceosome assembly, from recognition of 
the 5’ splice site at the earliest step of splicing (Kohtz et al., 1994; Zuo and Manley, 1994) to 
binding and regulation of exonic-enhancer sequences that stimulate use of sub optimal splice 
sites. SR proteins differ for the presence or absence of the second RNP domain and for the 
length of the RS domain; when present, the sequence of the second domain is often divergent 
from the canonical consensus sequence (Fu, 1995; Manley and Tacke, 1996). It is apparent 
that sequence-specific binding to distinct pre-mRNAs is crucial for the function of these 
proteins in the earliest steps of spliceosome assembly (Fu, 1993; Manley and Tacke, 1996). 
Constitutive as well as alternative and tissue-specific splicing seem to be regulated by the 
different RNA-binding specificities observed for different SR proteins (Fu, 1993; Tacke et al., 
1997; Tacke and Manley, 1995) The RNP domain(s) are essential for the activity of all 
members of this family (Chandler et al., 1997) and define the RNA-binding specificity of 
individual proteins (Wu and Maniatis, 1993).
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Alternative splicing is a common mechanism to regulate gene expression in a cell-type 
specific manner, because it allows the synthesis of different proteins from the same gene. 
Since cell-type specific differences are observed in SR proteins distribution, it has been 
suggested that each cell type might have different concentrations of each SR protein (Fu, 
1993). Their activity in alternative splicing is antagonized by members of the hnRNP A/B 
family. Thus, the counteracting activities of these two families of antagonistic factors can 
regulate alternative splicing both in vitro and in vivo (Caceres et al., 1994), suggesting that the 
physiological concentration of competing splicing factors may be important for regulation of 
splice site selection. The activity of SR proteins in regulation of alternative splicing is closely 
connected with the role of exonic enhancer sequences. In fact, these trans acting factors 
interact with the ESEs enhancing the selection of particular splice sites in order to promote 
inclusion of alternative exons with weak splice sites in the pre-mRNA (Cartegni L, 2002) 
probably by recruiting components of the splicing machinery to the nearby intron (Reed,
1996) (Fig. 1.5a), or by antagonizing the negative effect on splicing of an inhibitory protein 
that is bound to a juxtaposed exonic splicing silencer (ESS) (Fig. 1.5b).
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Figure 1.5 Models of SR protein action in exonic-splicing-enhancer-dependent splicing, a) RS-domain- 
dependent mechanism. An SR protein binds to an exonic splicing enhancer (ESE) through its RNA-recognition 
motifs (RRM) and contacts the splicing factor U2AF35 (U2 auxiliary factor) and/or U1-70K at the adjacent splice 
sites through its RS domain. The U2AF splicing factor consists of two subunits (U2AF65 and U2AF35), and the 
large subunit binds to the polypyrimidine (Y) tract, which here is interrupted by purines (R) and is therefore part 
of a weak 3' splice site. U2AF65 also promotes binding of U2 snRNP to the branch site. U2AF35 recognizes the 
3' splice-site AG dinucleotide. The U l snRNP particle binds to the upstream and downstream 5' splice sites 
through base paring of the U l snRNA; the 70K polypeptide of each U l snRNP particle is shown. The three sets 
of splicing-factor-pre-mRNA interactions (U2AF-3' splice site, U l snRNP-5' splice site and SR protein-ESE) 
are strengthened by the protein-protein interactions (blue arrows) that are mediated by the RS domain. For some 
ESE-dependent pre-mRNAs, indirect interactions (black arrows) are bridged by the splicing co-activator Srml60, 
which stimulates splicing of some ESE-dependent pre-mRNAs and also interacts with the U2 small nuclear 
ribonucleoprotein (snRNP) 15. b) RS-domain-independent mechanism. Here, the main function of the SR protein 
that is bound to an ESE is to antagonize the negative effect on splicing of an inhibitory protein that is bound to a 
juxtaposed exonic splicing silencer (ESS). The SR protein is shown without its RS domain, although this domain 
is normally present and might still promote U2AF binding, or other domains might be involved in protein-protein 
interactions. Inhibitory interactions are shown (red), as is a putative stimulatory interaction (double-headed 
arrow). These models are not mutually exclusive, and the splicing of some introns might involve a combination 
of these mechanisms Figure adapted from Cartegni et al. (Cartegni L, 2002)
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The structural organization of SR proteins and their ability to interact with other proteins 
suggest a model for their function, where the RNA-binding domain(s) provide specificity for 
certain mRNAs (or classes of mRNAs) by recognizing specific RNA signals, while the RS 
domain may recruit other factors during spliceosome assembly by protein-protein interactions 
(Valcarcel and Green, 1996)
Activity of SR proteins is regulated through phosphorylation/dephosphorylation cycles. In 
fact, SR proteins are phosphorylated in vivo at multiple serine residues within the RS domain 
(Colwill et al., 1996a; Colwill et al., 1996b; Gui et al., 1994). Phosphorylation and 
déphosphorylation seem to be crucial to define the organization of splicing inside the cell 
nucleus by affecting the RNA-binding activity and sub nuclear localization of RS-domain 
containing proteins (Misteli et al., 1997). Phosphorylation is important for specific RNA 
recognition, since the high positive charge of unphosphorylated RS domains masks the 
specificity of the RNP domains and enhances non-specific binding (Tacke et al., 1997; Xiao 
and Manley, 1997). Protein-protein interactions are enhanced by phosphorylation (Xiao and 
Manley, 1997), which also affects the subnuclear localization of splicing factors, causing their 
release from storage sites of splicing components (Colwill et al., 1996b; Xiao and Manley,
1997).
Splicing-dependent exon-exon junction complex
Recent studies have shown that several proteins become associated with spliced mRNAs that 
acquire and/or lose factors in a splicing-dependent, sequence-independent manner (Le Hir et 
al., 2000b). In vitro splicing experiments showed that mRNP complexes produced by splicing 
have a different mobility on a non-denaturing gel compared to mRNP complexes containing 
intronless mRNAs with identical sequences (Luo and Reed, 1999). It has been shown that 
mRNA is bound to a complex of proteins that is deposited at a site of 20-24 nt upstream of an
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exon-exon junction (Kataoka et al., 2000; Le Hir et al., 2000a; Luo and Reed, 1999). This 
“exon junction complex” (ETC) can include at least 7 proteins, although not all of them may 
be present simultaneously: RNPSl (Mayeda et al., 1999), SRmlôO (Blencowe et al., 1998), 
DEK (McGarvey et al., 2000), TAP (Bear et al., 1999), Aly/REF (Zhou et al., 2000), Y14 
(Kataoka et al., 2000), Upf3 (Kim et al., 2001) and Mago (Le Hir et al., 2001).
Human RNPSl was shown to interact with SR proteins and strongly activate splicing of both 
constitutively and alternatively spliced pre-mRNAs (Mayeda et al., 1999). DEK co-purifies 
with SR proteins as well and can interact with SRml60 in vitro (McGarvey et al., 2000). 
However, the specificity of its association with spliced mRNA is less than that of other 
components. SRml60 enhances splicing of specific pre-mRNAs through interactions with 
snRNPs and other SR proteins (Le Hir et al., 2000a). Several lines of evidence suggest that 
TAP play a major role in cellular mRNA export pathway. In fact, TAP shuttles from the 
nucleus to the cytoplasm (Bear et al., 1999). Then, it interacts with nucleoporins in vitro and 
localizes to nuclear pores as well as to the nucleoplasm (Katahira et al., 1999). Finally, 
tethering TAP to unspliced mRNA enhanced the export, especially in the presence of the 
cofactor, pl5/NXTl (Guzik et al., 2001). Other RBD-containing proteins, Y14 and Aly/REF, 
also bind efficiently and preferentially to spliced mRNAs. Y14 and Aly/REF shuttle between 
the nucleus and the cytoplasm suggesting that these proteins play roles in the export of mRNA 
to the cytoplasm and/or in cytoplasmic processes. In fact, Aly/REF was found to stimulate 
mRNA export (Rodrigues et al., 2001; Zhou et al., 2000). Mammalian Aly/REF can interact 
directly with TAP and RNA at the same time in vitro suggesting that Aly/REF recruits TAP to 
mRNA.
Recent studies provide direct evidence that hUpfS is part of the splicing-dependent exon-exon 
junction complex (Kim et al., 2001; Lykke-Andersen et al., 2001). hUpf3 associates with 
spliced mRNAs at -20nt relative to exon-exon junctions and interacts with specific
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components of the complex, Y14 and RNPSl. Furthermore, tethering of RNPSl or Y14 to the 
3’ untranslated region triggered nonsense mediated decay of the mRNA. Thus the splicing- 
dependent, position-specific binding of hUpfS to mRNAs through interactions with RNPSl 
and/or Y14 likely provides the long-sought link between splicing and the NMD pathway. 
Magoh protein (human homolog of Drosophila mago), binds avidly and directly to Y14 and 
TAP, but not to other known components of the complex, and is found in Y14-containing 
mRNPs in vivo. Importantly, Magoh also binds to mRNAs produced by splicing upstream 
(approximately 20 nucleotides) of exon-exon junctions and its binding to mRNA persists after 
export. These experiments thus reveal specific protein-protein interactions among the proteins 
of the splicing-dependent mRNP complex and suggest an important role for the highly 
evolutionarily conserved magoh protein in this complex.
The functions of SRml60, DEK, RNPSl, and Y14 in post-splicing events are not yet clear. 
These spliced mRNA-associated proteins were found to form a stable complex at 
approximately -20nt relative to exon-exon junctions in vitro and in Xenopus oocytes (Le Hir et 
al., 2000b) (Fig. 1.6). The complex appears to be dynamic since Aly/REF rapidly dissociates 
during export (or immediately after export) while Y14 persists in the same position on 
mRNAs in the cytoplasm (Kim and Dreyfus, 2001). The size of the complex was estimated to 
be 335 kDa in vitro and the shortest RNA fragment that is bound to the complex was of 8 
nucleotides in length (Le Hir et al., 2000b). However, it remains to be determined whether this 
complex is assembled at every exon-exon junction of the mRNA or only at some specific 
junctions. Apparently, the variety of components that form this complex makes it likely that it 
can be involved in several processes. Two functions in particular, mRNA export and 
nonsense-mediated decay, are likely functions for the splicing-dependent exon-exon junction 
complex.
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splice junction pairing: Exon dejînition and Intron definition
Although the snRNPs are some of the responsible for locating intron-exon junctions by base 
pairing, this alone does not explain how authentic splice sites are recognized when sequences 
that match the consensus splice sites are likely to occur elsewhere in the pre-mRNA; and how 
the splicing machinery joins the exons in the correct order. How the snRNPs and splicing 
proteins recognize the proper sequences is largely unknown. How splicing occurs in the 
correct order has been explained. Some studies have shown that splicing factors bind to RNA 
polymerase II and proposed that the factors assemble onto the pre-mRNA as the RNA emerges 
from the transcription complex (Du and Warren, 1997; Misteli and Spector, 1999; Yuryev et 
al., 1996). Presumably, this helps distinguish introns and exons and so an snRNP at a given 5' 
splice site will see only the next emerging 3' splice site because sites further along the 
transcript have not yet been synthesized. This might also prevent exon skipping.
Regarding the correct joining of exons, in 1990 Susan Berget proposed a model based on 
pairing between the splice sites across an exon (Robberson et al., 1990). This model stems 
from the observations that in human and, more in general in vertebrates a typical primary 
transcript can be until 30 kilobases long and contains about ten exons separated by much 
larger and more variably sized introns. The discrepancy between the length of human exons in 
comparison with that of introns (Hawkins, 1988) led to the "exon definition" model of 
splicing in which splice sites are first paired across exons, with subsequent spliceosome 
assembly proceeding through pairing of exon units. In the alternative "intron definition" 
model, splice sites are initially paired across introns rather than exons (Fig. 1.6).
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Figure 1.6 Exon definition versus Intron definition. In the “Exon definition” model the exons are recognized 
as a unit during early spliceosome assembly. Multiple factors interact with exonic sequences defining the 5’ and 
the 3’ splice site of the exons. In the “Intron definition” mechanism the introns are recognized as a unit. Multiple 
factors favour the 5’ and the 3’ splice site pairing of the introns.
Intron definition is thought to be the predominant mode of splicing in transcripts containing 
short introns and long exons. Several lines of evidence support the “exon definition” model. 
Moreover, it is apparent that both exon definition and intron definition might occur in different 
parts of the pre-mRNA of the same gene.
Evidence for Berget's “exon definition” model arises from the observation that the first and the 
last exon should require a special mechanism for their recognition. It was shown that the 5’ 
capping and the 5’ splice site are necessary to define the first exon (Izaurralde et al., 1994). On 
the other hand, last exon is defined by 3' splice site and polyadenylation signal (Gunderson et 
al., 1994). Moreover, it was shown that exon length might affect splicing. In fact, a minimal 
separation of the sites seems to be required to prevent steric hindrance of the factors that 
recognize the splice sites bordering an exon. This indication is supported by the observation 
that a constitutively recognized internal exon was skipped by in vivo splicing machinery if its 
size was smaller than 50 nucleotides (Dominski and Kole, 1991). In addition. Black et al. 
(Black, 1991) have shown that extension of the 18-nucleotide N1 exon of the mouse c-src
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gene up to 109 nucleotides leads to its constitutive inclusion. This finding suggested that the 
exon is normally skipped because it is too short to allow spliceosomes to assemble at both 
ends simultaneously. On the other hand, the expansion in vitro of internal exons to length 
above 300 nucleotides leads to activation of the cryptic splice site inside the exon or to exon 
skipping (Berget, 1995) indicating that splicing efficiency is affected by length. In fact, less 
than 1% of the known internal exons in vertebrate are longer than 400 nucleotides. Additional 
support for the “exon definition” model derives from in vitro (Kuo et al., 1991; Talerico and 
Berget, 1990) and in vivo experiments (Dominski and Kole, 1991; Dominski and Kole, 1994; 
Xu et al., 1993). These studies revealed how the strength of splice sites can affect the splicing 
of both the introns flanking the exon and not only of the intron bearing the mutated splice site, 
as predicted from the “intron definition model”. The intron definition model suggests that the 
intron is the unit recognized by the splicing machinery and proposes a scanning mechanism 
where the 5' and 3' splice signals (5'ss and 3'ss) are initially recognized and paired across the 
intron. (Lang and Spritz, 1983). Evidence supporting such a mechanism arises from 
observations made in yeast, where messengers often have unique introns and their length is 
usually below 100 nucleotides (Goguel and Rosbash, 1993) and Drosophila where most exons 
are 100 to 180 nucleotides in length (Hawkins, 1988). In vertebrate most exons are small and 
are flanked by long introns. However, some exceptionally long exon exists and when an 
expanded exon is placed in a gene in which the flanking introns are small, the exon is 
constitutively included. Experiments on a three exons minigene, containing short intronic 
sequences, showed that an expanded size of the middle exon up to 1400 nucleotides does not 
lead to exon skipping (Chen and Chasin, 1994).
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Alternative splicing
Alternative RNA splicing is the process that allows the selection of different combination of 
splice sites within precursor mRNA. This process is seen in nearly all metazoan organisms as 
a means for producing functionally diverse polypeptides from a single gene (Lopez, 1998). 
Alternative splicing is especially common in vertebrates. Alignment of EST sequences and 
mapping the resulting mRNA families to the human genome provided a minimum estimate 
that 35% of human genes show variably spliced products (Croft et al., 2000). However, since 
ESTs derive from a limited number of tissues or developmental stages, and cover a little 
portion of each mRNA, the true percentage is likely much higher. There are also remarkable 
examples of hundreds and even thousands of functionally divergent mRNAs and protein being 
produced from a single gene. A recent discovery in Drosophila is a fascinating example of the 
extremely high number of proteins that can be produced from one gene. The DSCAM gene 
presents different exons used in a mutually exclusive manner. For each of these exons there 
are different numbers of alternative forms. If all the combinations of these exons were used, 
the single DSCAM gene would produce 38,016 different DSCAM proteins (Schmucker et al., 
2000). Variation in mRNA structures takes many different forms (Lopez, 1998). Exons can be 
spliced into the mRNA or skipped. Introns that are normally excised can be retained in the 
mRNA. The position of either 5’ or 3’ splice sites can shift to make exons longer or shorter.
In addition to these changes in splicing, alterations in transcriptional start site or 
polyadenylation site also allow production of multiple mRNAs. All of these changes in mRNA 
structure can be regulated in diverse ways, depending on sexual genotype, cellular 
differentiation, or the activation of particular cell signaling pathways.
The mechanisms that determine which splice site are utilized and how this selection is 
regulated in different cell types or developmental stages have still not been precisely defined.
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Much progress has been made in identifying the cis-acting elements and the trans-acting 
factors involved in the alternative splicing.
The human Apolipoprotein A ll exon 3 as a model to study the influence of atypical 
polypyrimidine tract (GU) on splicing
The Apolipoprotein A ll gene
The human apolipoprotein All gene (ApoAll) encodes apolipoprotein All, a major constituent 
of the high-density lipoprotein (HDL) particles that play important roles in reverse cholesterol 
transport and lipid metabolism. Transcription of ApoAII occurs primarily in the liver 
(Hussain, 1990) and is controlled by a complex array of positive and negative regulatory 
elements located -911 to +29 bp relative to the cap site of the gene (Chambaz et al., 1991). 
The position of known transcription-factor-binding sites, relative to the exons of the gene, is 
shown in Figure 1.7. Very few genetic variants, either at the ApoAII gene itself, or in its 
upstream promoter, have been identified. To date, no protein-level polymorphism of ApoAII 
has been reported (Civeira et al., 1992). Furthermore, only one rare variant, a splice-junction 
mutation at the start of the third intron of the gene that results in complete lack of ApoAII 
expression in two individuals from a single family (Deeb et al., 1990), has ever been 
identified; however, the ApoAII deficiency associated with this mutation has no effect on 
HDL cholesterol levels.
At the DNA level, three polymorphisms have been described previously: a multiallelic (GT) 
microsatellite in the second intron of the gene (Weber and May, 1989) (position 1671 in Fig. 
1.7); a C->T single nucleotide polymorphism located 528 bp 3’ of the gene within an Alu 
repeat sequence (Civeira et al., 1992) (position 2994 in Fig. 1.7) and identified originally as a
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MspI restriction fragment length polymorphism (Scott et al., 1985); and a C->T SNP located 
in the third intron (Dupuy-Gorce et al., 1996) (position 2233 in Fig. 1.7).
Interestingly, mierosatellite sequenees, sueh as (GT)n repeats, constitute probably one of the 
best source of multiallelie microsatellite-polymorphisms in the human genome (Tautz and 
Renz, 1984; Weber and May, 1989). Although the function of these microsatellites is 
unknown, it is known that their mutation rate is very high and it has been suggested that they 
can operate as hot spots for recombination (Heilman et al., 1988) or be involved in gene 
regulation (Wittig et al., 1992).
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Figure 1.7. Schematic representation of the apoA-II gene. Several regulatory elements are located in the 
promoter region (-911 to +29), which can be divided into three functional regions. Arrows indicate the presence 
of direct repeats in the promoter region. Also, the first intron appears to contain negative regulatory elements 
(NRE I and II). ca, CAAT box; ta, TATA box; pa, polyadenylation signal. Polymorphic sites are indicated by an 
asterisk: 1*, GT repeat region; 2*, G-to-A transition that affects the donor splice site of third intron; 3*, C-to-T 
transition near the acceptor splice site of intron 3 that also modifies a 55tNI restriction site; 4*, C-to-T transition 
that modifies an Mspl restriction site within the 3' Alu element. Figure adapted from Blanco-Vaca et al (2001)
48
Polymorphic (GT)n within the 3' splice site of human ApoAII intron 2
Polymorphic (GT) microsatellites have been found in different human genes close to the 
3’splice site of some exons. Cardiac muscle actin intron 4, Apolipoprotein All intron 2, and 
CFTR intron 8, share the peculiar feature of including these polymorphic microsatellites 
within the polypyrimidine tracts (Fig. 1.8).
3 ' s p l i c e  s i t e  5 ' s p l i c e  s i t e
c - a - a c t i n  ( t  g )25  a c t c g t t c c c a g / G T A T G G . . , A T T  A A G / g  t  a  a  a g a  a
Apo Al l  ( t  g) m g g g c a g  /  G A G C T T . . . G G C  C A A / g  t  a  a  g t  c  t
hCFTR ( t  g)m t n a a c a g /  G G A T T T . . . G G C  A A G / g  t  a  g t  t  c  t
mCFIR t o t t c a a t g a a t a g / G G A T T  T . . .G  G C C A A / g  t  a  a  g t  c t
C onsensus ( Y ) n n  c a g / G T  . . .  C A G / g t a a g t a c
Figure 1.8. Comparison of splice sites from the human Apo A ll exon 3, human CFTR exon 9, human a  
cardiac actin and mouse CFTR exon 9 with consensus sequences for 5’ and 3’ splice sites. 3’- and 5’-splice 
sites of the different genes (upper line) are compared with consensus sequences (lower line). Y pyrimidine. Upper 
case, exons; lower case, introns.
On one hand, in the intron 8 of the CFTR gene, there are two polymorphic elements 
juxtaposed each other, a polythymidine tract and immediately upstream a GT repeats. Both are 
adjacent to the splice junction intron 8/exon9. The number of GT repeats ranges from 9 to 13 
and their distance from the 3’splice site is variable, due to the presence of the T tract also 
polymorphic for its length.
A population study suggested the negative influence of GT stretch on correct splicing of exon 
9 by analyzing the genotype of patients affected by congenital bilateral absence of vas 
deferens (CBAVD). The patients were found to carry a high number of GT repeats, while 
healthy subjects harbored a low number of GT repeats. The conclusions of the studies carried 
out by Cuppens et al. was that a longer GT repeats would place the branch point A nucleotide 
of the lariat in a less favorable position for splicing (Cuppens et al., 1998). In fact, the putative
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branch points of CFTR intron 8 is placed at about -40 bases upstream of the 3’ splice site 
depending on the length of the GT/T tracts.
Then, in vivo studies demonstrated the relevance of the GT repeats for the splicing of CFTR 
exon 9 when they are located within the polypyrimidine tract region. Niksic et al showed that 
the increase in the length of the GT repeats within the 3’ splice site of intron 8 is directly 
correlated with a detrimental effect in the inclusion of exon 9 in pre-mRNA (Niksic et al.,
1999). In addition, it was observed that the deletion of the T tract resulted in 100% of exon 9 
skipping, and this finding strongly indicated that the GT tract alone is not able to work as a 
functional polypyrimidine tract in the CFTR intron 8 context.
On the other hand, the second intron of the human ApoAII also presents a polymorphic GT 
tract in the polypyrimidine region. In this case 10 different alleles of the ApoA-II (GT)n repeat 
polymorphism have been identified, corresponding to 12-21 repeats. Allelic distributions 
show that four alleles [(GT)13, (GT)14, (GT)16 and (GT)19] account for 94.6% of the total. 
The most frequent allele is the (GT)19 (33.4%), the second most common is the (GT)16 allele 
(28.9%), followed by the (GT)13 (17.4%), and the (GT)14 alleles (14.9%) (Brousseau et al., 
2002).
Association studies have shown a significant correlation of the (GT)19 allele with a decrease 
of plasma ApoAII concentration, whereas no correlation with the alleles (GT)13, (GT)14, 
(GT)16 and ApoA-II plasma concentration has been found. In fact, the (CA)19 allele was 
associated with a decrease in total cholesterol as well as significantly decreased ApoA-II and 
LpA-II:A-I plasma levels. (Brousseau et al., 2002).
Then, in vivo studies have indicated that the GT repeats within ApoAII intron 2 are important 
for exon 3 splicing (Shelley et al., 1985). In fact, these studies have shown not only that this 
(GT)n polymorphisms located near the acceptor site of intron 2 works efficiently as a 
polypyrimidine tract when n=16 (Shelley et al., 1985), but also that the six nucleotides
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(GT)2GG, which directly replace this tract in a deletion mutant of the 3' splice site of ApoA-II 
intron 2, are sufficient to direct the splicing process efficiently and correctly (Shelley and 
Baralle, 1987).
The use of a poly GT repeats as a functional polypyrimidine tract has been also studied by in 
vitro experiments where the GT repeats works in different contexts (Coolidge et al., 1997). 
Lastly, 12 different (GT)n microsatellite alleles have been detected within the intron 4 of the 
human cardiac actin gene (Litt and Luty, 1989). Although no studies have been carried out in 
order to study the possible effects of this polymorphic GT repeats with transcription or 
splicing process of cardiac actin exon 5, so far no alternative splicing of this exon has been 
described.
Considering all these studies, it is evident that the apparent similarity of the polypyrimidine 
tract, concerning the GT repeats, is contrasted by the different splicing pattern exhibited by 
CFTR exon 9, ApoAII exon 3 and cardiac actin exon 5. In fact, CFTR exon 9 undergoes 
alternative splicing to a variable extent, whereas ApoA-II exon 3 and cardiac actin exon 5 are 
always constitutively included in the mRNA.
The alternated purine-pyrimidine tracts are known for their propensity to adopt a Z-DNA 
conformation that show to play an active role in transcription. Since there are several lines of 
evidence that in eukaryotes the splicing can occur co-transcriptionally (Eick, 1990), the 
presence of a Z-DNA forming region might interfere with the splicing process.
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AIM of the RESEARCH
The 3’ splice site of the second intron of the human Apolipoprotein All gene is unique 
because a stretch of alternating guanine and thymine residues, (GT)i6GGGCAG, replaces the 
polypyrimidine tract usually associated with 3' splice junctions. Previous studies have 
demonstrated that it is important for the constitutive splicing of ApoAII exon 3. In fact, 
transient transfections of progressive 5’ deletion mutants have shown that (GT) 2  is the 
minimum number of repeats at the 3' end of Apo All intron 2 that are required to direct 
efficient exon 3 splicing. When all the (GT) repeats were deleted, the 3’ splice site of ApoAII 
intron 2 became completely non-functional and exon 3 was totally skipped.
Interestingly, the human Apolipoprotein All intron 2 shares the peculiar architecture of the 3’ 
splice site based on a stretch of alternating guanine and thymine residues, with the eighth 
intron of human CFTR gene. The polypyrimidine tract of human CFTR intron 8 is composed 
by a (GT)9 _i3  tract followed by a polythymidine tract.
In spite of the presence of a (GT) tract within the polypyrimidine tract of the Apo All intron 2 
and the human CFTR intron 8, it is evident the striking difference in the splicing behavior of 
the downstream exons: human Apo All exon 3 is constitutively spliced whereas the human 
CFTR exon 9 undergoes alternative splicing.
These observations suggest the possible presence of accessory cis-elements within the Apo 
All exon 3 and/or the flanking introns that can support its constitutive inclusion in ApoAII 
pre-mRNA.
The aim of the present thesis was to investigate the mechanisms underlying the constitutive 
splicing of ApoAII exon 3 and, in particular, to characterize the cis-acting elements and the 
trans-acting factors involved in ApoAII exon 3 definition.
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2. RESULTS 
Analysis of the ApoAII exon 3 splice sites
Current consensus indicates that exon definition is mediated at least in part by SR proteins 
bridging between the small nuclear ribonucleoprotein (snRNP) U1 at a downstream 5’ splice 
site and the U2AF heterodimer at the upstream 3’ splice site. It has been previously mentioned 
that CFTR exon 9 and ApoAII exon 3 share the almost unique characteristic of a polymorphic 
(GU) tract at or close to the 3’ AG dinucleotide. However, the influence of the (GU) tract on 
splicing efficiency seems to be different. In fact, for the CFTR exon 9, the longer is the (GU) 
tract the higher levels of exon 9 exclusion are observed. In the ApoAII exon 3, variations in 
the length of (GU) tract do not seem to affect the splicing efficiency of exon 3 that is 
constitutively included in pre-mRNA. These observations suggest that the context of these two 
genes may differ in critical elements affecting splicing. The more obvious difference is the 
short U tract in the CFTR 3’ splice site but it cannot explain the dramatic different behavior.
As a first approach, we wished to examine whether an association exists between the different 
splicing behavior of human ApoAII exon 3, human CFTR exon 9 and splice site strength. 
Therefore, we compared the base sequence composition of the 5’ and 3’ splice sites of the 
human ApoAII exon 3, human CFTR exon 9 and considered also mouse ApoAII exon 3 that is 
constitutively spliced likewise human ApoAII exon 3 but has a more classical polypyrimidine 
tract. The strength of these splice sites were calculated according to the Splice Site Prediction 
by Neural Network program (SSPNN, http://www.fruitfly.org/seq_tools/splice.html).
Human and mouse 5’ splice junctions are identical until base +8 of intron 3. Both deviate from 
the consensus sequence at position -1, where the consensus base G is replaced by another 
purine. A, and in position +7 and +8, where the consensus bases A and C are replaced by C 
and T, respectively (Fig. 2.1).
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The analysis of the 3’ splice junction shows that human and mouse have a good match with 
the consensus even if they contain a different pyrimidine (C in human and T in mouse) in 
position-3 (Fig. 2.1). The human ApoAII exon 3 ’’polypyrimidine tract” is composed of 
(GU)n repeats that range in different individuals between 16 and 19 being 16 the more 
frequent allele. Conversely, the mouse polypyrimidine tract does not present (GU) repeats.
ACCEPTOR DONOR
inAII u cau u g cu g g ca g u cu a ca u g ca g a g g cu g u g a u cu a u g u u u g u g u a g /G A G C U U U .. .GGCCAA/guaagucu  
hAII gcu gaaaagagu gu gu gu gu gu gu gu gu gu gu gu gu gu gu gu gggcag /G A G C U U U .. .GGCCAA/guaagucu  
hCFTR u u u u a u u u u u gau gu gu gu gu gu gu gu gu gu gu gu gu u u u u u u aacag / GGAUUUG. . . GGCAAG/guaguucu 
Consensus (Y)n yag/GU   YAG/guraguac
Figure 2.1. Comparison of splice sites from the mouse and human ApoAII exon 3 with human CFTR exon
9. Acceptor and donor splice sites (centre) of mouse (mAII), human ApoAII exon 3 (hAII) and human CFTR 
exon 9 (hCFTR) aligned are compared with consensus sequences (bold lower line). Y pyrimidine and R purine, 
upper case, exons; lower case, introns.
The comparison of the 5’ splice junction of CFTR exon 9 with the consensus sequence shows 
that it differs in position +4, where consensus base A is replaced by another purine, G, and in 
position +5, where the consensus purine G is replaced by a pyrimidine T. Therefore, the 5’ 
splice sites of both human and mouse ApoAII exon 3 are closer to the consensus than the 5’ 
splice site of human CFTR exon 9. Regarding the analysis of the 3’ splice site of CFTR exon 
9, it presents a good match with the consensus, but the region between the branchpoint and the 
3’ splice junction contains two polymorphic stretches: a polythymidine tract presenting four 
allelic variants in the population (with 3, 5, 7 or 9 thymidines) and, immediately upstream of 
the poly-T, another polymorphic tract containing an alternating pyrimidine/purine (GT) 
dinucleotide repetition with 5 allelic variants (with 9, 10,11,12, or 13 repeats).
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The human CFTR exon 9 polypyrimidine tract seems to be stronger than that of both human
and mouse ApoAII exon 3 because of the presence of a poly-T tract.
After comparison of the splice sites of these three exons, we calculated their strength using the 
Splice Site Prediction by Neural Network Program (SSPNN ). In general, sequences that have 
a higher score (maximum 1.0 that is the consensus sequence) are considered to be stronger. 
The program was able to find the authentic 5’ and 3’ splice sites of human CFTR exon 9
whose scores are 0.83 and 0.91, respectively (Fig. 2.2).
A
B
1 gacaaactca 
51 tttttaacag 
101 ACAATA6AAA 
151 TCACTTCTTG 
201 AGGACAGTT6 
251 ttttgttctt
tcttttattt
GGATTTGGGG
AACTTCTAAT
GTACTCCTGT
TTGGCGGTTG
cactattaag
ttgatgtgtg
AATTATTTGA
GGTGATGACA
CCTGAAAGAT
CTGGATCCAC
aacttaattt
tgtgtgtgtg
GAAAGCAAAA
GCCTCTTCTT
ATTAATTTCA
TGGAGCAGGC
ggtgtccatg
tgtgtgtgtt
CAAAACAATA
CAGTAATTTC
AGATAGAAAG
AAGgtagttc
tctcttttt
50
100
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Donor site predictions:
Start End Score Exon Intron
237 251 0.83 AGGCAAG gtagttct
Acceptor site predictions:
Start End Score Intron Exon
40 80 0.91 gtgtgtgtgtttttttaacag GGATTTGGGGAATTATTTGA
Figure 2.2. Human CFTR exon 9 splice site prediction by Neural Network. A) The 300 bp sequence 
encompassing exon 9 (upper case bold) and its flanking intronic regions was analyzed using the Splice Site 
Prediction by Neural Network program. B) Results of splice site predictions with 0.1 as minimum score for both 
donor and acceptor splice sites.
In the mouse ApoAII exon 3, the program identified the authentic 5’ splice site (with the 
maximum possible score, i.e. 1.0) (Figure 2.3-B). In addition six possible 3’ splice sites were 
also highlighted in a score range included between 0.57 and 0.99, being the score of the 
functional one 0.76.
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1 ggctgaagcc 
51 CTAGGCCATA 
101 GTCACCATCT
151 ggaaagaagg 
201 tataggttga 
251 tctaaagtcc 
301 tagcaggaca 
351 ggggtgtgag 
401 ctgtgatcta 
451 CAGGATATGC 
501 TGGCAAAGAT 
551 CCAAgtaagt
catctaacgg
GTCTGCCATC
GTAGCCTGGA
tgctgagagt
gtgcatcagc
aaaaacccaa
ccaatttggg
gggagaccgg
tgtttgtgta
AGAGCCTGTT
TTGGTGGAGA
ctctgggaga
cagtgttctt
ATGAAGCTGC
AGgtgaggtt
cttggctgcc
cagcggactc
accaaaccaa
gaaggggcta
gattcattgc
gGAGCTTTGG
CACTCAGTAC
AGGCCAAGAC
gaactcaaag
tctcaccagC
TCGCAATGGT
ttgatacggg
caactctctt
aacaggaaga
aaccaacaac
aaagctgggg
tggcagtcta
TTAAGAGACA
TTTCAGAGCA
CTCAGAGATT
ggctacagga
AGCACTGTTC
CGCACTGCTG
ggaaaccaaa
gtgcttcttg
ttattctctt
agaaaatacc
tgggtcctgt
catgcagagg
GGCGGACGGA
TGACTGAATA
CAGAGCCAGG
ctgcttcagg
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Donor site predictions:
start End Score Exon Intron
116 130 0.77 CTGGAAG gtgaggtt
153 167 0.35 AAAGAAG gtgetgag
548 562 1.00 AGGCCAA gtaagtct
Acceptor site predictions :
Start End Score Intron Exon
19 59 0.77 ggcagtgttctttctcaccag CAGCACTGTTCCTAGGCCAT
34 74 0.62 caccagcagcactgttcctag GCCATAGTCTGCCATCATGA
185 225 0.99 tctcttgtgcttcttgtatag GTTGAGTGCATCAGCCAGCG
237 277 0.57 aagattattctctttctaaag TCCAAAAACCCAAACCAAAC
401 441 0.76 ctgtgatctatgtttgtgtag GAGCTTTGGTTAAGAGACAG
ctgttcactcagtactttcag AGCATGACTGAATATGGCAA
Figure 2.3. Mouse ApoAII exon 3 splice site prediction by Neural Network. A) The 600bp sequence 
encompassing exon 1, intron 1 and exon 2 was analyzed using the Splice Site Prediction by Neural Network 
program. B) Results of splice site predictions with 0.1 as minimum score for both donor and acceptor splice sites. 
The authentic donor and acceptor splice sites are boxed.
The calculated scores for the human ApoAII exon 3 demonstrate that the authentic donor 
splice site is ranked as the best possible 5’ splice site (score=1.0) within the 600bp 
encompassing the genomic region between ApoAII exon 2 and exon 3. On the other hand the 
authentic 3’ splice site of ApoAII exon 3 is not ranked among the possible 3’ splice sites 
within the same genomic region (at least with both donor and acceptor cutoff 0.1) whilst five 
cryptic 3’ splice sites (whose scores ranged from 0.11 up to 0.99) are also identified, (Figure 
2.4).
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451
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B
Donor
gcttcagtgt
CACTGTTACC
TCTGCAGCCT
atgtgctggt
cgactggcaa
cagaaagccc
gagagctggg
tgctgtggac
tgtgtgggca
AGAGCCTGGT
CTGATGGAGA
ctcagggcaa
cccccaaacc
AACATGAAGC
TGAAGgtggg
ggttatagct
ccaaagggct
atccaaagat
gtgggtactg
ccagctgaaa
gGAGCTTTGG
TTCTCAGTAC
AGGTCAAGAG
ggggttcagg
cccaccaccc
TGCTCGCAGC
tgtgatatgg
acctatctgc
caaaaggaag
ctggctggat
gcagaggtat
agagtgtgtg
TTCGGAGACA
TTCCAGACCG
CCCAGAGCTT
ggctgtggaa
tcttcctagG
AACTGTGCTA
agagggggcc
ctgtgctctt
atcattccct
acctttttgg
ggcaggaggc
tgtgtgtgtg
GGCAAAGGAG
TGACTGACTA
CAGGCCGAGG
ctgtGGAGAG
CCGCCCTCCC
CTCCTCACCA
aaaagggaga
atatccaggt
ctctaaagcc
ggagggggca
caggattcac
tgtgtgtgtg
CCATGTGTGG
TGGCAAGGAC
CCAAgtaagt
AAAGAAGGGA
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site predictions:
start End Score Exon Intron
109 123 0.84 CTTGAAG gtgggtgt
304 318 0.11 AGCTGGG gtgggtac
320 334 0.82 GGCAGAG gtatQcrca
538 552 1.00 AGGCCAA gtaagtct
Acceptor site predictions:
Start End Score Intron Exon
19 59 0.99 cccccaccaccctcttcctag GCCGCCCTCCCCACTGTTAC
87 127 0.21 gctactcctcaccatctgcag CCTTGAAGGTGGGTGTGATA
178 218 0.77 tgcctgtgctcttatatccag GTCTGGCAACCAAAGGGCTC
228 268 0.11 aagatcattccctctctaaag CCCAGAAAGCCCATCCAAAG
456 496 0.85 ctggtttctcagtacttccag ACCGTGACTGACTATGGCAA
Figure 2.4. Human ApoAII exon 3 splice site prediction by Neural Network. A) The 600bp sequence 
encompassing exon 1, intron 1 and exon 2 was analyzed using the Splice Site Prediction by Neural Network 
program. B) Results of splice site predictions with 0.1 as minimum score for both donor and acceptor splice sites. 
The authentic donor splice sites is boxed.
Overall these observations predict that the authentic acceptor splice site of human ApoAII 
exon 3 is very weak because of the peculiar polypyrimidine tract structure based just on (GT) 
dinucleotide repeats.
The apparent weakness of human ApoAII exon 3 acceptor splice site (strength <0.1) in 
comparison with the human CFTR exon 9 acceptor splice site (strength =0.91) is in striking 
contrast with the splicing behavior of the two exons. In fact, human ApoAII exon 3 is 
constitutively included in mRNA whilst human CFTR exon 9 is alternatively spliced.
Hence, it is plausible that novel accessory cis-acting elements (not identified by current 
programs for 3’ splice site analysis) might be involved in ApoAII exon 3 definition to assure 
its constitutive splicing.
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“in vivo” and “in vitro” systems for the study of ApoAII exon 3 splicing
In order to study the relevance of the splice site strength and map the possible cis acting 
elements involved in the ApoAII exon 3 definition, we used both “in vivo” and “in vitro” 
splicing systems. For the “in vivo” approach, we generated an eukaryotic gene expression 
system by cloning the whole 3.2 kb ApoAII gene from the promoter to its polyadenylation site 
(pApo-WT, Figure 2.5).
In comparison with the minigene system widely used to study other splicing models (Kwok et 
al., 2003; Muro et al., 1999; Shin et al., 2003; Webb et al., 2003) where only one exon and its 
flanking regions are cloned in an heterologous gene context (minigene), the ApoAII 
expression system that we generated contains all the elements necessary for its transcription 
and RNA processing that are present in the endogenous ApoAII gene. Such a construct should 
allow the study of the cis-acting elements affecting ApoAII exon 3 splicing in a context as 
close as possible as the proper genomic ApoAII context.
Suitable restriction sites within intron II and intron III of the cloned ApoAII gene were 
included in order to generate an interchangeable cassette to study the regulatory sequences 
encompassing this region.
We have chosen to use the Hep3B human liver cell line in these studies because the 
endogenous ApoAII gene is expressed in the liver (Hussain, 1990), and hence this cell line 
provides an environment as close as possible as the natural one. Previous studies have 
demonstrated that ApoAII is expressed exclusively in liver and intestine derived cells. The 
expression is directed by a DNA sequences located in a 259 bp region centred 782 bp 
upstream from the transcription initiation site which is absolutely required for tissue specific 
transcription from the Apo All promoter (Shelley and Baralle, 1987b). A target sequence was 
included in the ApoAII construct at the end of exon 4, to allow the specific amplification of 
pApo-wt derived RNA with specifics primers (see materials and methods) that differentiate
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between the transfected and the endogenously expressed ApoAII gene in the human 
hepatocarcinoma (Hep3B) cell line.
Xhol prom oter region exon 1 exon 2 exon 3 exon 4 SacII
169bp ' ' 301 bp 397bp
1183bp 37bp 76bp ^  I33bp ^  245bp Poly A signal
Sail EcoRl Noll /  Clal
Figure 2.5. Schematic representation of pApo construct. The whole Apo All gene from the promoter region to 
the poly A signal was cloned into XhoI-SacII sites of pBluescript plasmid. Sail and EcoRI sites were included in 
IVS2 and IVS3 respectively. Size of every exon (white boxes) and introns (solid lines) as well as position of 
relevant restriction enzymes target sites are shown. Primers used for RTFCR are shown as superimposed arrows 
annealing in exon 1 and exon 4.
The splicing pattern of the pApo-wt gene system was assessed by transient transfection of 
Hep3B cells. 48h after the transfection the cells were harvested, the RNA was extracted and 
treated with DNAse to free RNA preparations from residual plasmid. After reverse 
transcription using a primer specific for the pApo-wt construct or the endogenous gene, the 
splicing pattern was then determined by PCR amplification.
The splicing efficiency of the ApoAII construct in Hep3B cells was similar to that observed 
for the endogenous gene (Fig. 2.6). In fact, the splicing pattern of the pApo-wt gene system 
showed to overlap that of the endogenous ApoAII gene, displaying a nearly 95% of exon 3 
inclusion (Fig. 2.6). An identical strategy was used in all the following experiments using 
mutated versions of the pApo-wt gene construct.
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Endogenous ApoAII pApo-WT
(ex3+)-
(ex3-)-
(ex3+)-
(ex3-)-
Figure 2.6. Endogenous Apolipoprotein A ll and pApo-wt construct splicing pattern. Analysis of pre-mRNA 
splicing of endogenous Apolipoprotein All gene and pApo construct in Hep 3B cell line. The size of PCR 
products including (365bp) and excluding (232bp) exon 3 are indicated. Amplicons were separated on 2.0% 
(w/v) agarose gel. The primers used for PCR amplification of the endogenous ApoAII were Ex I-1221 S and Rev 
Cla/Not, whereas for the pApo-wt Ex I-I22I S and Not/Cla rev.
For the “in vitro” approach, we used the mouse a-tropomyosin region encompassing exon 2 
and 3 separated by a synthetic intron sequence (Deirdre et al., 1995) (PY7 vector, a kind gift 
of Dr. C.W.J. Smith from Cambridge University) as model substrate where to test the role and 
the relevance of constitutive and accessory splicing elements of ApoAII exon 3 through “in 
vitro” splicing assays.
To this end, the wild type or mutated versions of the whole ApoAII exon 3 and its 
polypyrimidine tract were cloned in the PY7 construct replacing the corresponding elements 
of the a-tropomyosin gene. The effects of these changes were tested by “in vitro” splicing 
experiments under standard conditions.
60
Influence of the 3’ splice site strength on splicing of ApoAII exon 3 
In vivo effects of (GT) 16 tract deletion and replacement
Previous experiments in our group have shown that when the T tract is removed from human 
CFTR intron 8, total exon 9 exclusion occurs (Niksic et al., 1999). Moreover, it was shown 
that an increase of the number of (GT) dinucleotide repeats reduces the efficiency of exon 9 
inclusion. This splicing pattern is in contrast with what is observed in the ApoAII context 
where exon 3 inclusion reaches a proportion of 95%. Therefore, in the context of ApoAII the 
(GT) dinucleotide repeats seem to work as a functional polypyrimidine tract. In order to test 
this hypothesis we deleted the whole (GT) dinucleotide repeats from the ApoAII intron 2 
[(Agt) in Fig.2.7]. As a control, a sequence containing (CA)I6 dinucleotide repeats was used 
to replace the (GT)I6 tract maintaining the same length (ca)x(gt), (Fig. 2.7). We found that 
both the deletion and the replacement of the (GT) tract resulted in total exon 3 exclusion.
pApo-wt
tgaaaagag (gt ) ^^gggcag GAGCTTT GGCCAA gtaagtc
133 bp
(ex3+)-
GGCCAA gtaagtcGAGCTTTtgaaaagag ,gggcag
(ca)x(gt)
tgaaaagag (ca) ^gggcag GAGCTTT GGCCAA gtaagtc
133 bp
Figure 2.7. In vivo effect of GT deletion/replacement. A) Partial sequence of exon 3 and flanking introns 
showing the modifications within the 3’ splice site. B) Analysis by denaturing polyacrilamide gel electrophoresis 
of pre-mRNA splicing pattern of human Apo All constructs in Hep 3B cells. The relevance of the GT tract at the 
3’ splice site of exon 3 was assessed by deletion and replacement by CA tract.
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At this point we have a clear cut difference between CFTR exon 9 and ApoAII exon 3. It was 
necessary to test another context to see if, as assumed, ApoAII exon 3 is peculiar and the GU 
tract does not usually work as polypyrimidine tract in other contexts. Using a minigene system 
for the mouse Fibronectin EDA exon, we found that the substitution of the EDA exon 
polypyrimidine tract with the ApoAII (GT)I6 tract resulted in the total EDA exon exclusion 
(Fig. 2.8).
A
EDA-wt ■ ■ i
...cacaacttgcttttcacataacctcttaccattaatttgcctaacagACATTGAT...
...cacaacagagtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgggcagACATTGAT...
EDA
B
EDA+ 
<■ EDA-
Figure 2.8. Effects of ApoAII-(GT)16 replacement within the polypyrimidine tract of mouse EDA exon. A)
Schematic representation of the a-globin/fibronectin reporter system used to test the ApoAII (GT)I6 
polypyrimidine tract in a heterologous system. a-Globin and fibronectin EDA exons are indicated in black and 
grey, respectively. The black circle indicates the polypyrimidine tract. The primers used in the RT-PCR assay are 
indicated by the superimposed arrows. The sequence of the mouse EDA and the ApoAII exon 3 polypyrimidine 
tracts are shown. B) Splicing pattern analysis by ethidium bromide staining of a 2% agarose gel electrophoresis 
of the RT-PCR product derived from cellular RNA. The replacement of EDA polypyrimidine tract with the 
ApoAII one resulted in total EDA exclusion.
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On one hand, these results indicate the relevance of the (GU)16 dinucleotide repeats as a 
functional “polypyrimidine tract” in the ApoAII context. On the other hand, previous studies 
on CFTR exon 9 and the results with EDA model not only suggest that the (GU)16 tract alone 
is a weak polypyrimidine tract but also that the ApoAII exon 3 context should contain specific 
cis-acting elements that may counteract the weakness of its polypyrimidine tract.
A 45 kDa protein interacts with the 3^  splice site o f ApoAII exon 3
Buratti et al have reported the identification of TDP-43 as a splicing regulator that specifically 
binds the polymorphic (GU) repeats within the 3'-splice site of CFTR exon 9 (Buratti et al., 
2001). Originally, TDP-43 was isolated following its binding to the pyrimidine rich motifs of 
Human Immunodeficiency Viruses type I TAR DNA sequence where is likely to be critical in 
the control of gene expression (Ou et al., 1995). In fact, it is a potent inhibitor of HIV-1 gene 
expression, during the early phase the HIV-1 cycle. The structural organization of this protein 
is similar to other RNA binding proteins: it contains three RRM (RNA recognition motifs) and 
a glycine rich domain. The group of cellular proteins to which TDP-43 belongs binds to a 
variety of different RNAs (Dreyfuss et al., 1993; Kenan et al., 1991). Interestingly, Ou et al. 
have demonstrated binding ability of this protein for the double stranded DNA, exclusively for 
polypyrimidine sequences containing at least 8 pyrimidines in the row (Ou et al., 1995). In 
contrast with these findings, previous studies in our group have shown that short RNA 
sequence consisting of alternated pyrimidine/purine, are successfully recognized and bound by 
TDP-43. Moreover TDP-43 can efficiently bind a number of (UG) repeats equal to or greater 
than six and there is a relationship between the number of (UG) repeats and the efficiency of 
binding (Buratti and Baralle, 2001).
63
In fact, UG but not U repeats within the intron 8 of human CFTR mRNA binds TDP-43.
Up to now, it is not clear which is the function, if any, of this cellular factor in the splicing 
regulation. It is possible that the increase in length of the UG tract would result in an increase 
of the binding affinity for this protein. Alternatively, the UG tract might bind more molecules 
of TDP-43, where number of the bound molecules could increase with the increasing number 
of UG repeats. In fact, the glycine rich domain of the TDP-43 suggests its ability to form 
protein-protein interaction.
Through its binding to UG sequence, TDP-43 might influence splicing assembling in two 
ways: its binding might indirectly mask poly U stretch modulating the binding efficiency of 
U2AF65 to the polypyrimidine tract or, alternatively, TDP-43 could directly be involved in the 
formation of new no favored protein-protein interaction with other proteins of the splicing 
machinery thus affecting exon 9 recognition. In any case, it is conceivable that binding of 
TDP-43 to the UG tract might lower exon 9 definition by acting as a “disturbing” element 
placed in proximity of its 3’ splice site junction.
TDP-43 has never been described as affecting the splicing process and its exact cellular 
function has remained elusive (Ou et al., 1995). Therefore, we wished to test if TDP-43 was 
also able to bind the (GU) repeats in the ApoAII context.
To this aim, UV-crosslinking experiments were carried out with a construct where the ApoAII 
exon 2, intron 2 and exon 3 were cloned in the pBluescript SK vector under the T7 promoter 
control [Fig.2.9A, mgApo-wt(GT) 16]. A mutant version of this construct where the (GT) 
repeats within the polypyrimidine tract were deleted was also generated [Fig. 2.9A, mgApo- 
A(GT)]. The two RNAs were in vitro transcribed in presence of the a-^^P-UTP and incubated 
with HeLa nuclear extracts. The RNA-protein interactions were made permanent by UV 
crosslinking exposure, and unprotected RNAs were degraded by RNAse treatment. After
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separation of the ^^P-labeled proteins by SDS-PAGE, the gel was dried and exposed to 
autoradiographic films.
Comparing the pattern of proteins interacting with the two RNAs, it was apparent that among 
the numerous proteins that could be crosslinked to the labeled RNAs a cellular protein of 
apparent molecular weight over 47.5 kDa could be observed only in the mgApo-WT RNA 
which contained the (GU) repeats but not mgApo-AGT RNA that lacked the repeats 
(Fig.2.9B). This results were consistent with what was observed for the CFTR exon 9 GU tract 
(Buratti and Baralle, 2001; Buratti et al., 2001), in which crosslinked TDP-43 migrated near 
the 47.5 kDa marker. In order to confirm the identity of the 47.5 kDa protein, UV-crosslinking 
assays followed by immunoprécipitation with polyclonal antibodies anti-TDP-43 were carried 
out. Figure 2.9C shows that the anti-TDP-43 antibodies were able to immunoprecipitate a 47.5 
kDa protein-mgApo-wt RNA complex, whereas no proteins were immunoprecipitated with 
mgApo-AGT RNA. Therefore, this experiment confirmed that TDP-43 is able to bind the 
(GU)16 repeats in the ApoAII intron 2 context.
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mgApo-wt(GT)jg
(g t) i
mgApo-A(GT)
B
/ / / /
83-
175-
62-
62-
47,5-
47,5-
Hepaiin 4- +
mgApo-wt mgApo
(GT),g A(GT)
Figure 2.9. Effect of the GT tract deletion on RNA/protein interaction A)Scheme of two Apo All minigenes 
spanning from exon 2 to intron 3 (up to base 2022) with or without the TG tract within intron 2. B) UV 
crosslinking reactions of RNA transcripts synthesized from the constructs by the T7 RNA polymerase and 
linearized with Hindlll. Transcripts mgApo-wt(GT)^6 and mgApo-A(GT), were incubated with HeLa nuclear 
extract either under standard conditions or using Heparin as unspecific competitor concentration at the final 
concentration of 5 fig/fih. After UV irradiation, samples were RNase digested, resolved on SDS-PAGE and 
autorradiographed. Positions of molecular weight marker are indicated. C) Immunoprécipitation following UV 
cross-linking of labeled mgApo-wt(GT)i6 and mgApo-A(GT) transcripts with increasing dilutions of anti TDP- 
43. Positions of molecular weight marker are indicated.
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5’ splice site involvement in the recognition of the ApoAII exon 3
The analysis of the strength of the splice sites showed that the 5’ splice site of the ApoAII 
exon 3 has a good match with the consensus. In order to test the relevance of the 5’ splice site 
for ApoAII exon 3 definition, it was mutagenized away from the consensus (Fig. 2.I0A, 
pApoAII A5’ construct). This experiment showed that the deletion of the wild-type 5’ splice 
site resulted as expected in the exon 3 exclusion in the ApoAII mRNA and not in intron 
retention (Fig. 2.I0B) suggesting the “exon definition” as the mechanism by which the exon is 
recognized and spliced (Robberson et al., 1990). Moreover, this result suggests that the 
efficient inclusioh of exon 3 might be due to the presence of exonic regulatory elements 
similarly to what happens in other examples of splicing according to the “exon definition” 
model.
A B / V
pApo-wt
a g ( g t ) i jg g g c a g GAGCTTT GGCCAA g t a a g t
133 bp
(ex3+)- •
pApoAII AS’ &
a g (g t)i«gggcag GAGCTTT GGCCGA c a t a c t
1.33 bp (ex3-)- •
I 2
Figure 2.10. Effect of ApoAII exon 3 5’ splice site mutation on Apo exon 3 splicing. A) Partial sequence of 
exon 3 and flanking introns showing the mutations within the 5’splice site. The 5’splice site of exon 3 was 
mutagenized as follows (CCAA/gtaagt CCGA/catact). B) Analysis by denaturing polyacrilamide gel 
electrophoresis of pre-mRNA splicing pattern of human Apo All constructs in Hep 3B cells.
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This radical change on the 5’ splice site gives little information about more subtle modulating 
elements. Hence we tried to lower the strength of the human ApoAII exon 3 5’ splice site 
(SSPNN score=1.0) by replacement of the splice junction and the 266bp of intron 3 with the 
5’splice site of human CFTR exon 9 (SSPNN score 0.83) and the 266bp of its flanking intron 
9 (Fig. 2.11 A, construct pApo/hCF5’). In this construct, the previously characterized ISS 
regulatory element of CFTR intron 9 was not included (Pagani et al., 2000).
As a control, another construct was prepared where the ApoAII mouse 5’ splice site (SSPNN 
score=1.0) was used for the replacement (Fig. 2.1 lA, construct pApo/mApo5’). Transient 
transfections of the pApo/hCF5’ construct resulted in an increase up to 40% of ApoAII exon 3 
skipping in comparison with pApo-WT (Fig. 2.1 IB). Interestingly, the replacement with the 
mouse ApoAII 5’ splice site and its intronic flanking sequences resulted also in an increase up 
to 20% of exon 3 skipping (Fig. 2.1 IB).
On one hand, the experiments with pApo/hCF5’ construct further suggest that the 3’ splice site 
of human ApoAII exon 3 is weak. In fact, it is apparent that the authentic strong 5’ splice site 
is necessary to balance a weak 3’ splice site. On the other hand, the experiment with 
pApo/mApo5’ construct suggests that, in comparison with the murine counterpart, other 
accessory regulatory elements might be present also within the human ApoAII intron 3 and 
that support exon 3 definition.
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pApo/hCFS’
(gOl6 ^  
IVS2 -------
(ex3+)-
pApo-wt
IVS2
IVS2
hex3
hex 3
hex 3
mcx3
hex9
mIVS3
IVS3
IVS9
Figure 2.11. Effect of the human ApoAII 5 ’ splice site replacement by mouse ApoAII 5’ splice site and 
human CFTR 5 splice site. A) The main features of the constructs used for transient transfection in Hep 3B 
cells are shown. Mouse ApoAII 5’splice site and CFTR 5’splice site are shown in blue and red, respectively. B) 
Analysis by denaturing polyacrilamide gel electrophoresis of pre-mRNA splicing pattern of hybrid Apo All 
constructs in Hep 3B cells. The horizontal arrow on the RT-PCR results indicates aberrant splicing products 
originated from cryptic 3’ and 5’ splice sites located in the hybrid exon and intron respectively (y )
Mapping of regulatory elements within ApoAII exon 3
The different splicing pattern exhibited by human CFTR exon 9 and human ApoAII exon 3 
cannot be explained simply with a different strength of the splice sites. In fact, the results 
described above suggest the presence of regulatory elements possibly localized both within 
exon 3 and in the downstream intron. Since the splicing regulatory elements of CFTR exon 9 
were previously characterized, to identify which sequences in the human ApoAII exon 3 were 
important for its definition we generated hybrid constructs between the ApoAII exon 3 and 
CFTR exon 9. To this aim, the ApoAII exon 3 was progressively replaced with CFTR exon 9 
and the constructs were transfected into Hep3B cells.
The first series of hybrids generated was a set of five CFTR/ApoAII constructs, in which the 
exon 3 was progressively replaced by CFTR exon 9 and its 3 ’ splice site with the allelic
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configuration (GU)11T5. The constructs were named by indicating the number of ApoAII 
exon 3 nucleotides replaced by CFTR exon 9 (i.e. 18,39, 60, 87, 113) (Fig.2.12).
pApo-wt
<gi)i6 I -
133 bp
pCF/Apo 18
115 bp
pCF/Apo 39
39 bp 94 bp
pCF/Apo 60
pCF/Apo 87
60 bp
87 bp
73 bp
46 bp
1VS8
pCF/Apo 113
113 bp 20 bp
B
(ex+)-
(ex-)-
1 2  3 4 5 6
Figure 2.12. Effect of the progressive Apo A ll exon 3 replacement by CFTR exon 9. A) The schemes of the 
CFTR IVS8-exon 9 (red)/ApoAII exon 3-IVS3 (white) hybrids constructs used for transient transfections in Hep 
3B cells are shown. The size of such replacements is also indicated. B) Analysis of pre-mRNA splicing of 
CFTR/Apo All hybrids constructs by RT-PCR. After the 30 cycles of PCR, radioactive CTP was added to each 
reaction and other 5 cycles more were added. The PCR products were separated on 7M urea 8% acrylamide gel. 
The horizontal arrow on the RT-PCR results indicates aberrant splicing products originated from cryptic 3’splice 
sites located in the hybrid exon 3 (▲ ).
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In comparison with the splicing pattern of pApo-wt, pCF/Apol8 construct showed an increase 
of exon 3 inclusion up to 97% indicating, as expected, that the CFTR (GT)1IT5 
polypyrimidine tract is stronger than the ApoAII (GT)16 polypyrimidine tract.
Then, pCF/Apo39 and pCF/Apo60 constructs showed the activation of cryptic 3’ splice sites 
introduced with the extension of the CFTR sequence from nucleotides 39 to 60. This cryptic 
splice site has been previously characterized (Niksic et al., 1999). More interestingly, the two 
last constructs showed a striking difference in their splicing pattern. The transfection of 
pCF/Apo87 construct showed 100% inclusion of exon 3, whereas pCF/Apoll3 construct 
showed 70% exclusion of exon 3 (Fig. 2.12B lanes 5 and 6). This result suggests the presence 
of a regulatory element localized within the 26bp in between pCF/Apo87 and pCF/Apoll3 
constructs. The different splicing pattern of pCF/Apo87 and pCF/Apoll3 constructs might be 
due to the removal of an enhancer element placed within the 26bp of ApoAII exon 3. 
Nevertheless, in principle, it should be noticed that the different splicing pattern might also 
depend on the addition of a silencer element introduced with the 26bp of the CFTR exon 9. 
However, considering that previous mapping studies did not highlight the presence of any 
exonic CFTR regulatory element in this 26nt-range, we focused the attention on the enhancer­
like sequence possibly removed from ApoAII exon 3.
To identify sequences within this 26bp region that contributed to efficient exon 3 splicing, we 
constructed three 21 bp-overlapping deletions encompassing the 26bp sequence (Fig.2.13A). 
The three constructs (A1843-63, A1854-74, A1866-86) were transiently expressed in Hep3B 
and the RNA was analyzed by RT-PCR (Fig. 2.13B).
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cexon 3
pApo-wt
AGGTCAAGAGCCCAGAGCTTCAQGCCGA GGCCAA /  g t a a g t . .
A 1843-63
TCAAGAGCCCAGAGCTTCAGGCCGA GGCCAA /  g t a a g t . . .
A 1854-74
GAGCTTCAGGCCGA GGCCAA /  g t a a g t - .
(6X3-)-
A 1866-86
GA GGCCAA /  g t a a g t - .
Figure 2.13. Effect of the overlapping deletions within Apo A ll exon 3. A) Scheme and sequence of the 
overlapping 21 nt-deletions within exon 3. The rectangular box indicates the place in exon 3 were the putative 
ESE is located. Only A1843-63 construct deleted the whole ESE region. B) Analysis by denaturing 
polyacrilamide gel electrophoresis of pre-mRNA splicing of the constructs carrying the deletions by RT-PCR. 
After the 30 cycles of PCR, radioactive a-^^P-CTP was added to each reaction and other and 5 cycles more were 
added. The PCR products were separated on 7M urea 8% acrylamide gel.
W hereas the A1854-74 and the A1866-86 deletions resulted in an increase of the exon 3 
skipping up to 60% and 55%, respectively, the A 1843-63 deletion caused a 90% exon 3 
exclusion. Therefore, most of the ESE-like activity seems to be localized within the sequence 
interested by the first deletion. Hence, considering that a large number of ESEs are purine- 
rich, we outlined a 9bp-core region localized in the 1852-1860 nucleotide range (boxed 
sequence in figure 2.14C) that seems to belong to this class of enhancers.
At this point, in order to map finely which base(s) in such sequence was directly affecting 
exon 3 definition, point mutations within the 1852-1860 tract were carried out. Each base at a 
time was replaced by its complementary one generating nine different constructs that were 
used to transfect Hep3B cell line (Fig 2.14B).
W hile most of the substitutions did not have a significant effect on exon 3 processing in 
Hep3B cells, G92C, A99T and, more noticeably, A97T caused 15%, 60% and 85% of exon 3 
skipping, respectively (Fig 2.14C).
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Figure 2.14. Effect of point mutations within the Apo A ll exon 3 putative ESE. A) ESE sequence within the 
Apo All exon 3. The number above each base corresponds to their position in the exon. B) scheme of the carried 
out point mutations. Briefly, each base at a time in the ESE was replaced by its complementary. Changes are 
indicated in bolded capital letters (diagonal). C) Analysis by denaturing polyacrilamide gel electrophoresis of 
pre-mRNA splicing of the constructs carrying the point mutations by RT-PCR. After the 30 cycles of PGR, 
radioactive CTP was added to each reaction and other and 5 cycles more were added. The PGR products were 
separated on 7M urea 8% acrylamide gel. Grey arrows indicate the strongest effect in exon3 skipping, shown by 
three of the constructs carrying point mutations at bases 92, 97 and 99.
Screening of human ApoAII exon 3 for SR proteins consensus sequences
Often ESEs are cw-acting elements that work as binding sites for serine/arginine-rich (SR) 
proteins, a family of essential splicing factors that are also involved both in constitutive and 
alternative splicing. SR proteins promote splicing of adjacent introns. Although ESEs were 
initially grouped into two broad sequence-com position classes, purine-rich and AC-rich 
motifs, it is now apparent that under splicing conditions each SR protein recognizes specific, 
albeit degenerate and partially redundant, sequence motifs. D ifferent studies aim ed at 
obtaining a reliable prediction of genuine ESEs led to the calculation of score matrices derived 
from the functional consensus sequences of several SR proteins. In this way, it was possible to 
identify new ESEs and to show that high-score motifs are enriched in exons and are often
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clustered in regions containing natural ESEs (Cartegni L, 2002; Cartegni et al., 2003; 
Fairbrother et al., 2002).
However, the predictive value of available score matrices was tested in vivo in different 
splicing models obtaining controversial results (Pagani et al., 2003). One explanation for the 
different exon 3 splicing pattern observed with A97T substitution might be that the nucleotide 
change might have differentially affected the SR protein profiles in the wild type sequence. 
Therefore, we calculated the available scoring matrices for SF2/ASF, SC35, SRp40, and 
SRp55 for the human ApoAII exon 3 wild type and A97T sequence using the scoring matrices 
that are available at the website http://exon.cshl.org/ESE.
In general, the results reported in Figure 2.15 show that the potential SR protein binding sites 
are clustered at the edges and in the center of exon 3. Then, in particular, one SF2/ASF 
potential site starting at nucleotide 90 (CTGATGG) was identified in the sequence range 
encompassing the 91-97 nucleotide core that we have found to work as ESE “in vivo” . On the 
other hand, no differences in the calculated m atrix scores for the four SR proteins were 
apparent for A97T substitution in comparison with the wild type sequence. W e also tested if 
the other substitutions we found to affect the splicing efficiency of ApoAII exon 3 (G92C and 
A99T) might be in correlation with the alteration of some matrix score. However, also in this 
case we were not able to highlight any difference in the calculated matrix scores (data not 
shown).
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Protein : SF2/ASF Protein : SC35
Pos. Motif Score Pos. Motif Score
16 GACAGGC 2.201027 9 GTTCGGAG 2.398949
22 CAAAGGA 3.674958 27 GAGCCATG 2.506436
52 CTCAGTA 2.742420 47 GGTTTCTC 2.632476
63 CAGACCG 3. 038339 64 AGACCGTG 2.773595
73 CTGACTA 3.100305 107 GAGCCCAG 2.76
90 CTGATGG 1.969825 115 AGCTTCAG 2.68
112 CAGAGCT 2.807766
121 AGGCCGA 2.396903
Protein : SRp40 Protein ; SRp55
Pos. Motif Score Pos. Motif Score
15 AGACAGG 4.453238 33 TGTGTG 2.820871
51 TCTCAGT 2.895393 35 TGTGGA 3.405071
53 TCAGTAC 2.943888 57 TACTTC 3.223246
62 CCAGACC 3.095127 78 TATGGC 3.161
70 TGACTGA 2.875395
111 CCAGAGC 3.400748
117 CTTCAGG 4.608378
Figure 2.15. High-score SR protein motifs in exon 3 of Apo AIL Motif distribution in exon 3 of Apo All. The 
133-nt sequence of exon 3 in Apo All was searched with four nucleotide-frequency matrices derived from pools 
of functional enhancer sequences selected iteratively in vitro (Liu et al., 2001). Motif scores reflect the extent of 
matching to a degenerate consensus, adjusted for background nucleotide composition, and only the scores above 
the threshold for each SR protein are shown. ASF/SF2, SC35, SRp40 and SRp55 are represented by colours red, 
blue, green and yellow respectively. The height of each bar indicates the score value, the position along the x axis 
indicates its location along the exon and the width of the bar represents the length of the motif.
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As already mentioned the predictive value of available score matrices was not absolute at least 
when tested “in vivo” in different splicing models (Pagani et al., 2003; Sironi et al., 2002). 
Therefore the observations made for the ApoAII exon 3 did not necessarily exclude splicing 
factor interactions in this region and testing these sequences experimentally was necessary.
Interaction of SR proteins with ApoAII 9nt-ESE
In order to identify the trans-acting factors able to bind the 9nt enhancer like sequence within 
ApoAII exon 3, both EMSA and UV-cross linking assays were performed. For the EMSA 
experiment, two in vitro transcribed RNAs containing either the 9nt wild type core region of 
the ApoAII exon 3 (ESE-wt) or not (AESE) were incubated with HeLa nuclear extract in 
presence of the non-specific competitor heparin (see materials and methods) (Fig.2.16A). As 
shown in Fig. 2 .I6B , ESE-wt RNA showed a broad band of shifted material, whereas no 
significant shift was observed with the AESE RNA. Therefore, this result suggests that one or 
more proteins might interact specifically with the wild type ApoAII exon 3 across the 9nt- 
sequence.
exon 3
H indlllKpnl Complex
ESE wt GGUACCUAUGGCAAGGACC UGAUGGAGA AGGUCAAGAGAAGCUU
AESE GGUACCUAUGGCAAGGACC XXXXXXXXX AGGUCAAGAGAAGCUU
Free RNA
NE
Figure 2.16. Electro mobility shift assay of ApoAII exon 3 ESE. A) Scheme of the constructs carrying wild 
type (ESE wt) or mutated (AESE) exonic splicing enhancer of ApoAII exon 3 used for the EMSA. B) 
Radiolabeled RNAs were incubated with HeLa nuclear extract (NE) for 20 min at RT. Complexes were then 
fractionated on a 4% non-denaturing polyacrylamide gel. The position of bound or free RNA is indicated.
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The nature of the protein(s) that bind to the wild type ApoAII exon 3 across the 9 nt-sequence 
was then investigated by UV cross-linking of RNA-protein complexes (see materials and 
methods).
^^P-labeled ESEwt, AESE, A97T RNA probes (Fig. 2.I7A) were incubated with HeLa nuclear 
extract and were cross-linked to proteins by exposure to UV light; the resulting ^^P-labeled 
protein(s) were separated by SDS-PAGE. Fig.2.I7B shows no differences in the pattern of UV 
cross-linked proteins obtained with these three different constructs.
The fact that no differences in the UV crosslinking have been observed might be ascribed to 
the high background of proteins in the molecular weight range in which the SR proteins 
migrate, also considering the fact that they are not abundant proteins.
ESE wt
AESE
ESE A97T
exon 3
K pn l
i n B
H in d lll
GGUACCUAUGGCAAGGACC UGAUGGAGA AGGUCAAGAGAAGCUU
GGUACCUAUGGCAAGGACC XXXXXXXXXX AGGUCAAGAGAAGCUU
GGUACCUAUGGCAAGGACC UGAUGGUGA AGGUCAAGAGAAGCUU
83-
62 -
47.5-
32.5-
Figure 2.17. Effect of ESE deletion or mutation on RNA/protein interaction A) Schematic representation of 
the plasmids used, wild type (ESE wt), deletion (AESE) and point mutated (ESE A97T) exon 3 enhancer. B) 10% 
PAGE-SDS analysis of UV cross-linking assay using HeLa nuclear extract with uniformly labeled RNA of all 
three constructs linearized with the restriction enzyme Hindlll.
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As we have not observed differences in the protein pattern by UV-crosslinking, in order to test 
the possible recruitment of different SR proteins by ApoAII 9nt-ESE, UV-crosslinking assays 
followed by immunoprécipitation with monoclonal antibodies were carried out. The constructs 
used for these experiments were ESE-wt, ESE A97T and another mutant of ESE, A1843-63, 
with a deletion of 21nt including the 9nt-ESE (Fig. 2.ISA).
To outline possible differences in the ability to interact with specific members of the SR 
proteins family by ESE-wt RNA in comparison with ESE A97T and A1843-63 RNAs, the UV- 
crosslinked samples were subsequently immunoprecipitated with the mAb 96 anti-SF2/ASF 
monoclonal antibody (Fig. 2.1 SB) and anti-SC35 monoclonal antibody (Fig.2.18C). Moreover, 
an ESE derived from the human fibronectin EDA was in vitro transcribed to be used as a 
positive control for ASF/SF2 and SC35 interactions (Buratti et al. Mol Cell Biol in press).
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122 bp
ESE wt 
ESE A97T 
A1843-63
...UAUGGCAAGGACC UGAUGGAGA AGGUCAAGAG...
...UAUGGCAAGGACC UGAUGGUGA AGGUCAAGAG™
..UAU-------------------------------------------GUCAAGAG...
 GAATTC
 GAATTC
 GAATTC
B
it-
Z '
Vfab Anti SF2/A SF Mab Ami Sc35
Figure 2.18. Specific interaction of SR proteins with the ESE within Apo A ll exon 3. A) Partial sequence of 
the constructs used for UV crosslinking followed by immunoprécipitation. Three constructs containing exon 3 
(with the intact, point mutated and deleted ESE) plus portions of the flanking introns 2 and 3 are shown. B) 10% 
PAGE-SDS analysis of immunoprécipitation with an anti-ASF/SF2 monoclonal antibody following UV cross- 
linking of labeled RNAs: ESEwt, ESEA97T and A1843-63 along with EDA as a positive control. The arrow 
indicates the 36-38 kDa immunoprecipitated product at the same level of the positive control. C) 10% PAGE- 
SDS analysis of immunoprécipitation with an anti-SC35 monoclonal antibody following UV cross-linking of 
labeled RNAs: ESEwt, ESEA97T and A1843-63 along with EDA as a positive control. The arrows indicate a 35 
and a 40 kDa immunoprecipitated product at the same level of the positive control.
The results show a protein that can be specifically immunoprecipitated by the mAh 96 
(Fig.2.18B, lane 1) and by anti-SC35 (Fig.2.18C, lane 1) following UV crosslinking with 
nuclear extract of a labeled ESE-wt RNA, but not with the ESE A97T and A1843-63 control 
RNAs (Fig.2.18B and 2.18C, lane 2 and 3). Importantly, the proteins UV crosslinked with the 
migration control EDA-exon RNA and immunoprecipitated by anti-SC35 and mAb 96 have 
the same electophoretic mobility of those present in ESE-wt. In this way, the identity of the 
proteins was confirmed. Thus, these results provide an evidence that at least two SR proteins 
are able to interact with the sequence across the ESE sequence and it is also consistent with
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the result obtained in the EMSA study where a clear difference in the RNA-protein complex 
formation with a construct containing the ESE wt and AESE is observed.
Effect of SR proteins and hnRNP A1 overexpression on splicing of ApoAII exon 3
Both constitutive and alternative splicing of many genes are affected by the intracellular 
concentrations of antagonistic splicing factors of the SR family and hnRNPAl. Initially, to 
evidence the possible role of hnRNPAl on ApoAII exon 3 splicing, we tested the effect of the 
overexpression of this protein by cotransfecting a plasmid carrying the hnRNPAl coding 
sequence along with the pApo-wt construct. This construct was used because its transfection 
results in more that 90% of exon 3 inclusion in pre-mRNA.
As a control, two different SR proteins (ASF/SF2 and SC35), known to have opposing effects 
on splicing in comparison with hnRNP A l, were also cotransfected with pApo-wt construct. 
Figure 2.19B shows that, neither ASF/SF2 nor SC35 modified the ApoAII exon 3 splicing 
pattern, whereas hnRNPAl caused a 20% of exon 3 skipping as compared with the empty 
expression vector. This result is consistent with other splicing models where hnRNPAl- 
overexpression shows to induce exon skipping (Caceres et al., 1994; Pagani et al., 2000).
It is more difficult to highlight the putative positive effect of SR proteins because the wild type 
construct shows already a very high exon 3 inclusion rate. We have used the A1866-86 
construct (scheme in Fig. 2.13A) because this deletion causes about 55% of exon 3 skipping 
without covering the 9 bp-core region of the ApoAII exon 3 ESE (Fig.2.19A). In consequence 
a positive effect of SF2 or SC35 interacting in the ESE region will be more visible. We have 
tested cotransfections of the A l866-86 construct with constructs expressing the SR proteins 
SRp20, SRp55, SRp75, ASF/SF2 and SC35. Figure 2.19C shows that cotransfections of 
A l866-86 with SRp55, SRp75, ASF/SF2 and SC35 promoted exon 3 inclusion when 
compared with the cotransfection with the empty vector. The effect is not dramatic but this
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may be due to the fact that the 1866-86 deletion, occurring just 5nt downstream of the ApoAII 
exon 3 ESE core region, partially alters the RNA secondary structure of the region so 
interfering with the correct display of the ESE. The results obtained with SRp55 and SRp75 
overexpression suggest the possibility that also these splicing factors might be involved in the 
mechanism underlying exon 3 splicing. Both ASF/SF2 and SC35, whose specific interaction to 
the ESE had already been demonstrated by UV crosslinking/immunoprecipitation (Fig.2.18 B 
and C), have a positive effect on exon 3 inclusion. On the other hand, SRp20 overexpression 
caused an increase of exon 3 exclusion (Fig.2.19B, 85%). Such an effect requires further 
experiments in order to map the binding site of this SR protein within the exon 3 and its 
flanking intronic sequences.
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Figure 2.19. Effect of overexpression of some SR proteins and hnRNPAl on Apo A ll exon 3 splicing A)
Partial sequence of the constructs used for cotransfection with SR proteins or hnRNPAl. Both constructs present 
the intact ESE (box), but A l866-86 presents a 21-nt deletion that cause a 50% of exon 3 exclusion.. B) Splicing 
pattern analysis by agarose gel electrophoresis of the cotransfection of construct pApo-wt with Ijig of SR 
proteins (ASE/SE2, SC35) and hnRNPAl coding plasmid. Proportion of exon 3 exclusion was determined by 
densitometry using the total densitometric units of 3-k and 3- amplicons as 100%. C) Splicing pattern analysis by 
denaturing polyacrilamide gel electrophoresis of the cotransfection of construct A l866-86 with 1 and 2/ig of SR 
proteins 20, 55, 75, ASE/SE2 and SC35. These results represent three independent experiments. The arrow on the 
RT-PCR, C, indicates an aberrant splicing product originated from a cryptic 3’splice site located in the exon 3.
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The position of ApoAII ESE within an internal exon is crucial for its function
Several studies have shown that splicing of pre-mRNAs containing weak 3' splice sites 
requires splicing enhancer elements for activity (Lynch and Maniatis, 1996; Ryner and Baker, 
1991; Tian and Maniatis, 1992). Therefore, in order to verify the possible relationships 
between the 9nt-enhancer and the 3’ splice site of ApoAII exon 3, we created a construct 
spanning from the (GT)I6 polypyrimidine tract to the end of the ApoAII exon 3 that replaced 
the corresponding region of the tropomyosin exon 3 (Fig. 2.20A, ESE-wt). Then, we generated 
a similar construct carrying a mutated version of the 9nt-ESE (Fig. 2.20A, ESE-A97T). Both 
constructs were used for in vitro splicing assays along with the original PY7 plasmid. If it 
there was a connection between the ESE function and the 3’ splice site of ApoAII exon 3, the 
splicing of ApoAII exon 3 should occur. Otherwise, no processing of the intervening sequence 
should be observed leading to the accumulation of RNA precursor. In contrast to what was 
observed “in vivo”, i.e. 90% of exon 3 skipping in presence of the A97T substitution, both 
ESE-wt and ESE-A97T were spliced apparently with the similar efficiency (Fig. 2.20B).
exon 2 exon 3 1
ApoESE-wt
(G T ),s  g g g c a g  /  GAGCTTT^.AGGACC TGATGGAGA AGGTCAAGAGCCCAGAGCTTCAGGCCGAGGCCAA/
ApoESE-A97T
(GT) ,5  g g g c a g  /  GAGCTTT-.AGGACC t g a t g g t g a  a g g tc a a g a g c c c a g a g c t t c a g g c c g a g g c c a a /
PY7 ApoESE-wt ApoESE-A97T
CZHZJ
cxn
Tinicdir) 0 0 1 2  0 1
Figure 2.20. In vitro study of the effect 
of A97T mutation on the Apo A ll exon
3 ESE A) Scheme of the two constructs 
used for in vitro splicing. Apo All exon 3 
(ESE-wt and ESE-A97T) and its 
polypyrim idine tract replaced the 
corresponding region of the tropomyosin 
exon 3 in the PY7 plasmid. B) In vitro 
splicing analysis by denaturing gel 
electrophoresis of the ESE A97T mutation 
effect. Labeled RNA was incubated with 
HeLa nuclear extract and the products of 
the splicing reaction were resolved on 7M 
urea 8% acrylamide gel. The initial 
transcripts and splicing intermediates are 
depicted on the sides of the gel and the 
incubation times are indicated at the 
bottom.
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The observation that there were no differences in the splicing efficiency of both ApoESE-wt 
and ApoESE-A97T constructs in vitro suggested that the context of the PY7 construct might 
alter the ApoAII-ESE-dependant splicing of exon 3, In particular, the fact that the ApoAII 
ESE occurs within the “last” exon of the PY7 minigene system might affect the function of 
this ESE, normally placed within an internal exon.
In order to confirm this hypothesis (i.e., that the position of the ApoAII ESE within an internal 
exon is crucial for its function), we created a two-exon ApoAII system for “in vivo” 
experiments. For this purpose, two constructs were generated where intron 2 (pcDNApo- 
IVS2) or intron 3 (pcDNApo-IVS3) were reinserted in their natural position within the 
ApoAII cDNA. In this way, in the pcDNApo-IVS2 construct, intron 2 is in between of two 
exons where exon 1 and exon 2 forms the virtual “first exon” whilst exon 3 and exon 4 forms 
the virtual second and “last exon” (Fig. 2.21 A).
On the other hand, in the pcDNApo-IVS3 construct, intron 3 is in between of two exons where 
exon 1, exon 2 and exon 3 form the virtual “first exon” whilst exon 4 alone forms the virtual 
second and “last exon” (Fig. 2.21A).
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Figure 2.21. Relevance of the Apo A ll exon 3 ESE position in in vivo studies. A) Scheme of the constructs 
used for transient transfection in Hep 3B cells. Intron 2 was introduced in its natural position in the Apo All 
cDNA carrying the wt or the mutated A97T ESE (V  ) pcDNApo-IVS2 ESEwt and pcDNApo-IVS2 ESE A97T 
respectively. Intron 3 was introduced in its natural position in the Apo All cDNA carrying the wt or the mutated 
A97T ESE, pcDNApo-IVS3 ESEwt and pcDNApo-IVS3 ESE A97T respectively. B) Splicing pattern analysis by 
RT-PCR on 2% agarose gel. Full intron processing was obtained with all the constructs generated.
Afterwards, using pcDNApo-IVS2 and pcDNApo-IVS3 as templates, two mutants were 
created carrying the A97T mutation that was previously shown to inactivate the ApoAII exon 
3 ESE (Fig. 2.21A). Therefore, in the peDNApo-IVS2-A97T construct, the mutated ESE was 
localized within the virtual second and “last exon”, whereas in the pcDNApo-IVS3-A97T 
construct, the mutated ESE was localized within the virtual ‘first exon’ (Fig. 2.21 A).
In the natural context (i.e. within an internal exon), the ESE works properly and exon 3 is 
constitutively included in the pre-mRNA (Fig. 2.21 lane 2). When it is disrupted, exon 3 
undergoes alternative splicing (fig 2.21 lane 3)
Similarly to what observed with the “in vitro” experiments, if the ESE function was 
independent from its localization, we would expect to find no processing of intron 2 or intron
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3 “in vivo” when the ESE is mutagenized (A97T). Instead, shifting the context of the ESE to 
the first or the last exon, we have observed that both introns 2 and 3 are efficiently spliced out 
in spite of the disruption of the ESE (Fig.2.21 lanes 5 and 7). Overall, these results support the 
hypothesis that ESE-dependant mechanism of splicing works only if the ESE is placed in an 
internal exon.
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As a final demonstration of this hypothesis, we transferred ApoAII exon 3 and its flanking 
intronic sequences into an heterologous system. We used the a-globin/fibronectin reporter 
system (PTB), a minigene system used in our laboratory to study alternative splicing of 
several exons. The wild type and A97T ApoAII exon 3 with its flanking intronic regions (174 
nt of intron 2 and 116 nt of intron 3) were cloned into the third intron of the PTB construct 
(Fig. 2.22A).
133
116174 :# -! exon 3
IVS 3IVS 2
(ex+)-
(ex-)-
Figure 2.22. Apo A ll exon3 ESE works 
only when located within internal 
exons. A) Apo All exon 3 (with the ESE­
wt or ESE A97T) and portions of its 
flanking introns was introduced in a- 
globin/fibronectin reporter system (PTB) 
as heterologous context. a-Globin, 
fibronectin EDB, and human Apo All 
exons are indicated in black, grey, and 
white boxes, respectively. The black 
circle indicates the polymorphic GT tract. 
The primers used in the RT-PCR assay 
are indicated by the superimposed 
arrows. N del sites are indicated. The 
length of the relevant Apo All fragments 
(intron 2, exon 3, and intron 3) is 
indicated. B) Splicing pattern analysis by 
RT-PCR on 2% agarose gel. The effect 
of the A97T mutation was recovered 
when the ESE is located in an internal 
exon.
Transfections of pApo-wt/PTB construct resulted in full inclusion of exon 3 in mRNA while 
pApo-ESEA97T/PTB construct showed exon 3 skipping (Fig. 2.22B lanes 3 and 4).
These results show that the ESE works also when ApoAII exon 3 is placed in between of two 
other exons in a heterologous system, so confirming that its effects are evident only when it is 
located within an internal exon.
Moreover, these results might indicate the presence of other splicing regulatory elements 
within the flanking intronic regions of ApoAII exon 3.
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Order of intron removal in the ApoAII gene
The peculiar distribution of different cis-acting elements within the constitutive ApoAII exon 
3 and its flanking introns led us to consider that it might reflect a splicing mechanism 
involving a particular order of intron removal. We determined the order of intron splicing in 
the ApoAII gene using an RT-PCR-based approach described by Kessler et al. (Kessler et al., 
1993). In this experiment, only the observation of the partially spliced intermediates is 
instructive, since products containing all the introns may derive from the primary RNA 
transcript and are uninformative for the order of intron splicing. Figure 2.23A shows the 
strategy used to understand the order of intron removal. We used two sets of primers: in the 
first set, the forward primer was located in ApoAII exon 1 and the reverse primer in intron 3, 
whereas the second pair included a forward primer in intron 2 and a reverse primer in exon 4. 
With the first set of primer, a 610bp PCR products was observed along with the no spliced 
pre-mRNA spanning from exon 1 to intron 3 (771 bp). The 610 bp band was found to 
correspond to exon 1-exon 2-intron 2-exon 3- intron 3 pre-mRNA (Fig 2.23A right panel). 
These results seems to indicate that in the ApoAII gene, intron 1 is preferentially spliced 
before intron 2. In contrast, the second set of primers amplified the spliced intron 2-exon 3- 
exon 4 intermediate (478 bp), with traces of the unspliced product (875 bp) (Fig 2.23B right 
panel). These results seems to indicate that in the ApoAII gene, intron 3 is preferentially 
spliced before intron 2. Therefore, taken together these data suggest that the intron 2 is the last 
intron in being processed, whereas the order removal of intron 1 and 3 is not clear and will be 
tested in future experiments with different combinations of primers.
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Figure 2.23. Splicing order of ApoAII introns 1, 2 and 3. A) RT-PCR products obtained for the first set of 
primers, separated on a 2% agarose gel. For each reaction, a PCR amplification was performed without prior 
reverse transcription (-RT) to exclude DNA contamination. The bands correspond to the unspliced product (771 
bp) and the spliced exon 1-exon 2-intron 2-exon 3-intron 3 (610 bp), demonstrating splicing of intron 1 before 
intron 2. B) RT-PCR products obtained for the second set of primers separated on a 2% agarose gel. The bands 
correspond to the unspliced product (875 bp) and the spliced intron 2-exon 3-exon 4 (478 bp) demonstrating 
splicing of intron 3 before intron 2.
Mapping of regulatory elements within intronic regions flanking ApoAII exon 3
The possibility of the existence of splicing regulatory elements within the intronic regions 
flanking ApoAII exon 3 is suggested both by the experiments with human/mouse hybrid and 
by all the data related to the effect of the ESE within exon 3 in relationships with the 
simultaneous presence of upstream and downstream introns. In order to verify the presence of 
intronic regulatory elements and map their position, a series of constructs was prepared. 
Initially, we screened the exon 3 flanking intronic regions looking for possible cis-acting 
elements whose sequence might resemble previously described modulators of splicing. We 
noticed the presence of three G runs in intron 3 just 10 bp downstream of the exon 3 donor 
splice site (Gl, G2 and G3 in Fig.2.24A). Previous studies have shown that G runs are 
distributed throughout human introns and represent an enhancer-like element which seems to
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strengthen the 5’ splice site of constitutive introns in chicken tropomyosin, human alpha- 
globin and human growth hormone. We have, therefore, explored the possible effects of G 
runs on the regulation of the splicing of the ApoAII exon 3. To this aim, we first created 
mutants where the first two and all the three G runs were disrupted by point mutations (legend 
of Fig.2.24B). However, the transient transfection of this mutant did not show significant 
changes of the ApoAII exon 3 splicing pattern in comparison with the pApo-WT construct. A 
slight effect was only observed when the last G run (i.e. G3) was mutagenized causing a 
nearly 10% of exon 3 skipping (Fig.2.24C). Thus, it is reasonable to exclude that these G runs 
within intron 3 have a significant role in the splicing of exon 3.
tccgctcgagcccgggaggtggaggttgcagtgagccgagatcatgccattacgctccagcctgagcaacaagagcaaaactctgtctcaggaaaacaaacaaaaaaacctgcacatatacttctgaatttaa
aacaaaagttaaaaaacaaagatttcttggtctctggtcactacctccctcatcagctttgcgcctccactgtcaccctcaggaatgrtccacatactcagcgagtatgcttggggggcaaaagggtgaaaga
tacaaaagcttctgatatctatttaactgatttcacccaaatgctttgaacctgggaatgtacctctccccctcccccacccccaacaggagtgagacaagggccagggctattgcccctgctgactcaatat
tggctaatcactgcctagaactgataaggtgatcaaatgaccaggtgccttcaacctttaccctggtagaagcctcttattcacctcttttcctgccagagccctccattgggagggqacgggcggaagctqt
tttctgaatttgttttactgggggtagggtatgttcagtgatcagcat.ccaggtcattctgggctctcct.gtti:tctcccegtct:Gat.tacacati:aactcaaaaacggacaagatGatti:acacttgccctc
ttacccgaccctcattccccrtaacccccatagccctcaaccctgtccc‘tgatttcaattcctttctcctttGttctgctccccaatatctctct.gccaagttgcagi:aaagtgggataaggt^tgagaga-î:gag
atctacccataatggaataaagacaccatgagctttccatggtatgatgggttgatggtattccatgggttgatatgtcagagctttccagagaaataacttggaatcctgcttcctgttgcattcaagtcca
aggacctcagatctcaaaaqaatgaacctcaaatatacctgaagtgtacccccttagcctccactaagaqctgtaccccct.gcctGtcaccccat.caccatgaqtctt.ccatqtgcttgtcctctcct.ccccc
atttctccaacttgtttatcctcacataatccctgccccactgggcccatccatagtGcctgtcacctgacagggggtgggtaaacagacaggtatatagccccttcctctccagccagggcaggcacagaca
ccaaggacaqagacgctggctaggtaagataaggaggcaagatgtgtgagcagcatccaaagaggcctgggcttcagttgtggagagggagagagccaggttggaatgggcagGaggtagggagatcGctggg
gaggagctgaagcccatttggcttcagtgtcccccaaacccccaccaccctcttcctaggccgccctcccceurtgttaccaacatgaagctgctcgcagcaactgtgctactcctcaccatctgcagccttga
aggtgggtgt:gatatggagagggggccaaaagggagaatgtgctggtggttatagctacctatctgcctgtgctct:tatatccaggtcgact.ggeaaecaaagggctcaaaaggaagatcattccct.ctct.aa
agcccagaaagcccatccaaagatctggctggatacctttttbgggagggggcagagagctggggtgggtaotggcagaggtat.ggcaggaggccaggattcactqc:,qtgqasccaqctgaaaagagtgtgt[
bAaAAqg>lCAAflAq CCC*q*qCTTCAOOCCq>OQCC> X qtaaq tc :t:caqqqcaaq< K rg t^caqqqqctq toq fca c tq tq q a q a q a a a q a a q q q a a q a tq g to a c rq tc c c a c a q a a q tc tq a a c c c a q q q q tq q q
gattagggcagattaggctt.agaattcgcagagaaaaagtatttcatcacccaaagatcccacacgtctcttagatagagaggaac:agcaagaactgggccttgaatttcagt.ctctagagt.ctgtCGCt^cta
cctagcaaaggtcttgactctatt.cct.acctaggggct.ttgccatgcgatggaccaggcact.agagtttggggacctgagtcagtGtgctctgacctcccaccaccaccaaggcccctgccagtgcctagggt
ccctcagattaaactctaatcccctcacctatccaggtcttactttgaaaagtcaaaggagcagctgacacGcctgatcaagaaggct:ggaacggaact.ggt:taactt.cttgagc:t.atttcgtggaaGtt.gga
acacagcctgccacccagtgaatcgatgcggccgcagtgtccagaccattgtctt.ccaaccccagctggcctctagaacacccactggccagtcctagagcr^cct.gtccctacacactctttgctacaataaa
tgctgaatgaatccagctctgagcctggtatgtttgggggactgggaaaagtaggggagtaagggaggagaagaggaaggaaaaggdaaaatctgcttctagaaggagagaggtttgagtgt-ggaggggtgaa
gaaaggattgaagacacaactgatgaaaatgacaggatgagggtgccatgattctccaaacccagaqtctcGtacccgcggcctt
B t g a a a a g a g ( G T )  j ^ g g c a g  
IVS2
Gl 02 G3 
g t a a q t c t c a q q q c a a q q q a t t c a q q g q c t q t q q
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Figure 2.24. Effect of G runs mutations within Apo AH exon 3 flanking intron 3. A) ApoAII full sequence. 
In red are indicated runs of G localized in intron 3. The region encompassing the ApoAII exon 3 is bolded. B) 
Scheme of exon 3 plus flanking introns showing the G runs that were mutagenized, mutG3CTG: ggggctg- 
>gagctta, AG1-G2; gggcaagggg->tcacaagcgc, AG1-G2-G3: gggcaaggggttcaggggctg->tgtcaagcattcatgcgctgt C) 
RT-PCR analysis by agarose gel electrophoresis of the transfected constructs carrying mutations in the G runs 
within intron 3. No effect on exon 3 splicing is observed after mutagenesis of the G runs in the exon 3.
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A series of deletions was then made within both introns in the pApo-wt and the pApo-A97T 
constructs first deleting 127nt-deletion of intron 2 (A1554-1681) along with a 91nt-deletion of 
intron 3 (A1931-2022) (Fig. 2.25A).
Figure 2.25B shows no differences in the exon 3 splicing pattern of the pApo-wt and the 
pApo-wt (2XA) constructs. However comparing the splicing pattern of pApo-A97T with 
pApo-A97T (2XA), we can observe that the simultaneous intronic deletions were able to 
counteract the effects of the ESE mutation within exon 3.
pApo-»t
1554 1681
pApo-M
(2XA)
pApo-A97T
pApo-A97T
(2XA)
B
exon 3 exon 4
Q □
5 ^  xS-
O k - -H 3  
 H U
- H U
(ex+)-
(ex-)-
Figure 2.25. Effect of simultaneous deletions of intron 2 and 3 on Apo A ll exon 3 inclusion. A) Constructs 
pApo-wt, pApo-wt (2XA), pApo-A97T and pApo-A97T (2XA) with the intact introns (the first two) and with 
deletions of 127 and 91 nt in intron 2 and intron 3, respectively. B) Splicing pattern analysis by denaturing gel 
electrophoresis of the transfected constructs in Hep 3B cells by RT-PCR. The effect of A97T mutation disappears 
when deletions are introduced in both introns.
At this point, we designed a series of pApo-wt and pApo-A97T mutants carrying either the 
A1554-1681 deletion within intron 2 or the A1931-2022 deletion within intron 3 to map and 
characterize the cis-acting elements within each intron (Fig.2.26. The single deletions affect 
differently the exon 3 processing. The A1554-1681 deletion alone neutralized the effects of the 
ESE mutation (Fig.2.26B, lanes 1 and 2), whereas the A1931-2022 deletion alone caused exon
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3 skipping even in presence of the wild type ESE (Fig.2.26B, lanes 3 and 4) indicating a 
complex interplay between intronic and exonic sequences during the splicing process.
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Figure 2.26. Effect of single deletion either of intron 2 or intron 3 on Apo A ll exon 3 splicing. A) Constructs 
pApo-wt A1554-1681, pApo-A97T A1554-1681 and pApo-wt A1931-2022, pApo-A97T A1931-2022 with the 
deletion of intron 2 and intron 3, respectively. B) Splicing pattern analysis by denaturing gel electrophoresis of 
the transfected constructs in Hep 3B cells by RT-PCR. A1554-1681 deletion neutralizes the effects of A97T 
mutation whereas A1931-2022 deletion causes exon 3 skipping even in presence of the wild type ESE.
In order to map more finely the region responsible for these effects we first decided to add 
progressively the rest of the intron 2 in order to restore the whole sequence. Figure 2.27 shows 
that the effect of the A97T mutation within the ApoAII exon 3 FSE was recovered when the 
20 bp were added (lane 6, fig 2.27). The same is observed if the next 20 bp are added (lane 4 
Fig 2.27).
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Figure 2.27. Effect of restoring intron 2 sequence on Apo A ll exon 3 splicing. A) Scheme of the constructs 
showing the partial restoring of the intron 2 sequence. The 20 bp sequence able to restore the effect of the A97T 
mutation in the exon 3 ESE is indicated. B) Splicing pattern analysis by denaturing gel electrophoresis of the 
transfected constructs in Hep 3B cells by RT-PCR. Addition of the 20bp in construct pApoA97T A1554-1660 
was able to restore the effect of the mutation A97T in exon 3 ESE.
The intron 3 element was also subjected to further analysis and our interest focused on a 26 bp 
polypurine rich region between nucleotides 1941-1967. Since many exonic and intronic 
splicing enhancers are purine rich, we tested the effect of a deletion covering only the 
polypurine tract. Figure 2.28 shows that the deletion of this tract continue to cause exon 3 
skipping even when the exon 3 ESE is intact.
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Figure 2.28. Effect of poly purine sequence deletion in intron 3 on Apo A ll exon 3 splicing. A) Constructs 
used for transfection. The 26bp poly purine rich sequence deleted in the construct pApo-wtA 1941 -1967 in intron 
3 is indicated. B) Splicing pattern analysis by denaturing gel electrophoresis of the transfected constructs in Hep 
3B cells by RT-PCR. Deletion A1941-1967 in intron 3 causes exon 3 skipping even though the ESE in exon 3 is 
intact.
These results clearly indicate the presence of different accessory elements within both flanking 
introns. The effects of the A1554-1681 deletion might depend on the removal of a silencer-like 
sequence but, in principle, we cannot exclude that it might depend on the increase of the 
splicing efficiency due to the shortening of intron 2. Conversely, the effects of the A1941-1967 
deletion suggest the presence of an intronic splicing enhancer-like sequence within that region.
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3. DISCUSSION
The splicing of nuclear pre-mRNA is a highly regulated process where introns are accurately 
removed to produce mature mRNA. The selection of the splicing sites in the alternative and 
constitutive splicing is determined by complex RNA-RNA, RNA-proteins and protein-protein 
interactions. This thesis has been focused on the mapping of cis-acting elements and the 
characterization of trans-acting factors involved in the recognition of human ApoAII exon 3 a 
peculiar exon with an unusual 3’ splice site.
An Evolutionary point of view
At the genomic level, the structure of the ApoAII gene in different species is substantially well 
conserved. At the mRNA level the degree of homology interspecies ranges between a 
minimum of 70% to a maximum of 83.2% (Fig. 3.1).
Organism-Gene Organism-Gene Percent ID
M.musculus -ApoAII R.norvegicus - ApoAII 83.2
M.musculus -ApoAII S.scrofa - Ss.3703 80.0
M.musculus -ApoAII H.sapiens - ApoAII 76.5
M.musculus -ApoAII B.taurus - Bt. 10573 71.6
H.sapiens -ApoAII S.scrofa - Ss.3703 83.0
R.norvegicus -ApoAII S.scrofa - Ss.3703 78.8
R.norvegicus -ApoAII H.sapiens - ApoAII 76.7
S.scrofa -Ss.3703 B.taurus - Bt. 10573 70.0
Figure 3.1 Comparison of ApoAII genes identity among different species. The nucleotide sequence 
comparisons used in determining homology are listed. The pairs represent reciprocal best hits; each alignment is 
the best one for both organisms. The percent ID represents identity over an aligned region.
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The second intron of the human ApoAII gene contains a polymorphic microsatellite sequence 
consisting of repetitive (GT) motifs. Recent population studies identified at least 10 different 
alleles of this polymorphism, ranging from 12 to 21 (GT)n repeats (Brousseau et al., 2002). 
Figure 3.2 shows a comparison of ApoAII exon 3 and the flanking IVS2 and IVS3 sequence in 
different species. A high level of homology of both introns and exon 3 is observed among all 
species except for rat, where the high homology is just limited to the exon 3.
In fact, the size of exon 3 is conserved in all species (i.e. 133bp), and the dimensions of both 
intron 2 and intron 3 are similar in Human, Macaca, Chimpanzee and Mouse. The dimension 
of rat introns is instead twice that of the other species (Fig.3.2 A). It can be seen that the 
intron/exon junctions share a high degree of similarity, and the splice donor-acceptor sites are 
identical in all species (Fig.3.2 B).
Interestingly, the (GT) tract within intron 2 is present in all Primates but not in Rodents. In 
Human and in Chimpanzee there are a similar number of repeats in a row (i.e. 16) whereas in 
Macaca fascicularia there are just 7 repeats. Conversely, both Mouse and Rat present 5 (GT) 
repeats clustered in the 3’ end of intron 2 but there is no continuous (GT)n sequence.
The high degree of ApoAII gene conservation among Primates and Rodents at the exon level 
and at the intron/exon junctions suggests that this gene is a result of an ancient event typical of 
constitutive exons. These observations are consistent with recent studies on the comparison of 
alternative splicing in human and mouse, which found that alternatively spliced exons are 
mostly not conserved and thus are the product of recent exon creation or loss events (Modrek 
and Lee, 2003).
Microsatellite sequences, such as (GT)n repeats, are probably one of the best sources of 
multiallelic polymorphisms in the human genome (Tautz and Renz, 1984; Weber and May, 
1989). Although the function of these repeats is unknown, it has been suggested that they can
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act as hot spots for recombination (Heilman et al., 1988) or be involved in gene regulation 
(Wittig et al., 1992).
It is also possible that in the primates the GT tract is perhaps related to recent transposon 
activity and not to any selective improvement of the gene expression efficiency.
B
IVS2 Exon 3 IVS3
Rat 643 133 587
Mouse 299 133 343
Macaca 273 133 394
Human 296 133 397
Chimpanzee 293 133 395
Rat tgtggagtgtgaggggagatggggattcattgctggcaatccaaatacaa
Mouse tgtggggtgtgaggggagaccgggattcattgctggcagtctacatgcag
Macaca ctggcagaggtatggcaagaggccaagattcattgctgtggacccagctg
Homo ggccaggattcactgctgtggacccagctgaaaagagtgtgtgtgtgtgt
Chimp ggccaggattcattgctgtggacccagctgaaaagagtgtgtgtgtgtgt
Rat agactgtgatatgtgtttgtgtagGAGCTTTGGTTCGGAGACAGGCAGCG
Mouse aggctgtgatctatgtttgtgtagGAOCTTTGGTTAAGAGACAGGCGGAC
Macaca aaaagagtgtgtgtgtgtgtgcagGAGCTTTGGTTCGGAGACAGGCAGAG
Homo gtgtgtgtgtgtgtgtgtgggcagGAGCTTTGGTTCGGAGACAGGCAAAG
Chimp gtgtgtgtgtgtgtgtgtgtgcagGAGCTTTGGTTCGGAGACAGGCAAAG
Rat GA6ACGGATGTGCA6ACCCT6TTCAGCCA6TATCTTCA6AGTTTAACTGA
Mouse G6ACAG6ATATGCAGAGCCTGTTCACTCA6TACTTTCA6AGCATGACTGA
Macaca 6AGCCAA6TGTG6AGAGCCTGGTTTCTCAGTACTTCCAGACGGTGACT6A
Homo GAGCCATGT6TGGA6AGCCTGGTTTCTCA6TACTTCCA6ACC6TGACTGA
Chimp 6AGCCATGTGTG6ACAACCTG6TTTCTCAGTACTTCCA6ACCGTGACTGA
Rat CTATGGCAAGGATTTGATGGAGAAGGCCCAGCCCTCA6AGATTCA6AACC
Mouse ATATGGCAAAGATTTG6TG6AGAAGGCCAAGACCTCAGAGATTCAGAGCC
Macaca CTACGGCAAGGACCT6ATGGA6AAGGTCAA6AGCCCA6AGCTTCAGGCCC
Homo CTATGGCAAGGACCT6ATGGAGAAGGTCAA6AGCCCAGAGCTTCAGGCCG
Chimp CTATGGCAAGGACCTGATGGAGAAGGTCAAGAGCCCAGAGCTTCAGGCCG
Rat AAGCCAAgtaagtctctctgggagagagctcaaagggctacaggactgct
Mouse AGGCCAAgtaagtctctgggagagaactcaaagggctacaggactgcttc
Macaca AGGCCAAgtaagtctaagggcaaggagttcaggggctgtggaactgtgga
Homo AGGCCAAgtaagtctcagggcaaggggttcaggggctgtggaactgtgga
Chimp AGGCCAAgtaagtctcagagcaaggagttcaggggctgtggaactgtgga
Rat ttcttttttttttctttttcttttcttttttttttttttaagatttattt
Mouse agggagggagggaggtctcccaggaatcttaactcaggggttggggttag
Macaca aaggaagaagggaagatgagaggccccacagaagactgaacccaggggtg
Homo gagaaagaagggaagatgagaggtcccacagaagtctgaacccaggggtg
Chimp gagaaagaagggaagatgagaggtcccacagaagtctgaacccaggggtg
Figure 3.2 Comparison of ApoAII exon 3 in different species (Rat, Human, Mouse, Macaca fascicularia and 
Chimpanzee). A) comparison of ApoAII exon 3 and flanking introns size in different species (Rat, Human, Mouse, Macaca 
fascicularia and Chimpanzee). B) alignment of ApoAII exon 3 and Banking introns size in different species, red uppercase 
letters indicate exon 3 sequence. Lowercase letters indicate intron 2 and intron 3 sequences.
97
Correlations among different sequence features of ApoAII exon 3 and CFTR exon 9
Human ApoAII exon 3 and its flanking introns share only partially the canonical features of 
splicing sites. In fact, the 5’ splice junction of intron 3 is well defined and resembles the 
consensus sequences (Lopez, 1998), whereas the 3’ splice junction of intron 2 contains instead 
of a classical polypyrimidine tract a polymorphic sequence made of alternating pyrimidines 
and purines.
Regarding the branch point, we focused the attention on a putative site placed at 44 bases 
upstream of the 3’ splice site and conserved in all Primates. According to the literature data, 
most of the known branch points are placed in the range of 18-40 bp upstream of the 3’ splice 
site, so we favour the hypothesis that the sequence at the position of -44 might be a functional 
branch point. However, a functional mapping should be carried out to confirm this hypothesis. 
At least 2 other genes, human CFTR intron 8 and human cardiac alpha-actin intron 4 share 
with ApoAII the presence of this peculiar (GT) tract at or near the 3’ splice site. The structure 
of human CFTR intron 8 polypyrimidine tract is composed by a combination of both (GT) and 
(T) polymorphic repeats. On the other hand, the architecture of the 3’ splice site of the cardiac 
alpha-actin intron 4 is very similar to that of the ApoAII intron 2, since it also lacks a 
polypyrimidine tract and in its place we find a (GT) polymorphic repeat.
CFTR exon 9 undergoes alternative splicing whereas the ApoAII exon 3 and alpha-actin exon 
5 are constitutively spliced. These observations, along with previous studies about the splicing 
of the ApoAII exon 3 (Shelley and Baralle, 1987), suggest that the alternated stretch of U and 
G forms a fully functional “polypyrimidine tract”. Moreover, in vitro studies by Coolidge and 
co-workers have shown that a GU tract is able to work as a polypyrimidine tract also in other 
contexts (Coolidge et al., 1997).
However, this is not true for CFTR because when the (U)n tract located immediately 
downstream of the stretch of GU is removed, the total exclusion of exon 9 occurred (Niksic et
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al., 1999). Furthermore, our studies demonstrated that the replacement of the polypyrimidine 
tract of the mouse fibronectin EDA exon with the (GU)16 repeats of ApoAII second intron 
caused skipping of this exon (Figure 2.8). Hence, the GU tract by itself does not act as a 
functional “polypyrimidine tract” in all the contexts.
Comparison of splice sites strength of human ApoAII exon 3 and human CFTR exon 9 has 
outlined an apparent contradiction between the splicing behaviour of the two exons and the 
strength of the splice sites. In fact, both the 3’ and the 5’ splice sites of CFTR exon 9 display a 
good match with the consensus but exon 9 is alternatively spliced. Conversely, the match of 
the ApoAII exon 3 splice site with the consensus is not good. In fact, if we applied the Splice 
Site Prediction by Neural Network program to the 5’ and 3’ splice site of exon 3 we obtained 
the authentic exon 3 donor site as the best possible, whereas the score of the authentic exon 3 
acceptor site was very low and was not considered by the program as a putative 3’ splice site. 
Nevertheless, the ApoAII exon 3 is constitutively spliced.
It is likely that in the ApoAII exon 3 and its flanking introns there are cis-acting elements 
different from those present in the CFTR exon 9 context that allow the constitutive inclusion 
of exon 3 in the mRNA. This striking contrast in splicing pattern prompted us to investigate 
the mechanisms underlying the constitutive splicing of ApoAII exon 3 and, in particular, to 
characterize the cis-acting elements and the trans-acting factors involved in ApoAII exon 3 
definition to assure its constitutive splicing.
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Influence of the 3’ splice site on splicing of ApoAII exon 3
Taking advantage of the compact size of the human ApoAII gene, we were able to create an 
“in vivo” expression system that includes the whole 1173bp-promoter, the 1226bp-coding 
region encompassing 4 exons and 3 introns and the 320bp-3’-UTR where the polyadenylation 
signal is located. In this way, it was possible to study the exon 3 splicing within its original 
context. This represents a clear advantage in comparison with the minigene trap system, 
widely used to study other splicing models, where only one exon and its flanking regions are 
cloned in an heterologous gene context. Thus the splicing efficiency of a specific exon might 
be influenced not only by the elements under investigation, but also by elements that belong to 
the heterologous system. The ApoAII expression system that we generated instead, contains 
all the elements necessary for its transcription and RNA processing that are present in the 
endogenous ApoAII gene.
The first approach toward the characterization of the cis-acting elements involved in ApoAII 
exon 3 definition, was to confirm the relevance of the (GT) tract in our controlled system. 
Both the deletion or the replacement of the (GT)16 tract with its complementary (CA)16 tract 
resulted in 90% exclusion of exon 3 from ApoAII mRNA (Figure 2.7).
It is well known that there is a great flexibility in the specific sequence within the 
polypyrimidine tract. In fact, it was shown that the introduction of purines into the 
polypyrimidine tract is detrimental to splicing only if the length of the tract is shortened and if 
there is a reduction in the number of consecutive uridine residues (Norton, 1994; Reed, 1989; 
Roscigno et al., 1993). Our results concerning the replacement of (GU) with (CA) repeats are 
consistent with previous studies by other authors indicating that Uridine and Cytidine do not 
appear to be functionally equivalent for the 3’ splice site recognition. (Bouck et al., 1995; Fu 
et al., 1988; Roscigno et al., 1993).
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Our in vivo results are coherent also with previous in vitro studies on tracts containing 
alternating pyrimidine and purine residues, which found that they are functional. Coolidge et 
al designed a splicing competition construct in which two polypyrimidine tracts were placed 
adjacent to identical branch point sequences and allowed to compete for branch point 
selection. The competition construct was derived from exons 2 and 3 of the rat alpha- 
Tropomyosin gene and their intervening sequence.
Using a “polypyrimidine tract” consisting of alternating guanosine and uridine residues 
(G U )ll, they found that it was chosen 61% of the time (Coolidge et al., 1997). The authors 
suggested that uridine in every other position within a polypyrimidine tract might form an 
entirely functional polypyrimidine tract, though the competitive efficiency of such a tract is 
only slightly higher than that of the competing original polypyrimidine tract and lower than 
seven of the other 13 tracts tested in this study. However, it should be noted that the privileged 
position immediately adjacent to the exon 3 of the tested (G U )ll “polypyrimidine tract”, 
might have led to overestimate its relative strength. In fact, a similar experiment made with a 
construct where the original polypyrimidine tract was duplicated as a test polypyrimidine tract 
showed that the acceptor splice site of exon 3 just downstream of the test tract is favoured.
On the other hand, we demonstrated that the replacement of the authentic polypyrimidine tract 
of the EDA exon with the ApoAII (GU)16 “polypyrimidine tract” is not functionally 
equivalent in vivo. Our experiments suggest that a (GU)n “polypyrimidine tract” is weak and 
other cis-acting elements within the ApoAII gene must exist to increase the splicing efficiency 
of ApoAII exon 3.
As mentioned above, the peculiar (GU) repeats within the 3’ splice site of ApoAII exon 3 is 
also present in the CFTR exon 9 3’ splice site. Buratti and coworkers have demonstrated that 
TDP-43, a protein that originally had been shown to bind HIV-1 TAR DNA (Ou et al., 1995), 
binds to UG tracts (Buratti et al., 2001). We have demonstrated that TDP-43 is able to bind the
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(UG)16 repeats within ApoAII intron 2. Buratti et al have shown that TDP-43 is involved in 
the formation of the 50-52 kDa complex that assembles on the (UG)m element at the 3' splice 
site of CFTR exon 9 (Buratti et al., 2001). Then, on one hand, overexpression of this protein in 
transfection experiments was shown to inhibit CFTR exon 9 splicing and this inhibitory role 
was more evident with a decrease in the number of (U)n repeats, a result consistent with 
previous studies on the (UG)m(U)n interdependence (Niksic et al., 1999; Pagani et al., 2000). 
On the other hand, Buratti et al. showed that inhibition of TDP-43 expression in cultured cells 
by antisense PS-oligodeoxynucleotide treatment leads to an increase in exon 9 recognition.
Our preliminary cotransfection experiments of the pApo-A97T construct (that presents nearly 
85% of exon 3 skipping) with the same antisense phosphorotioate (PS)-oligonucleotide used 
by Buratti et al. strengthen the putative inhibitory effect of TDP-43 on the usage of 3’ splice 
sites adjacent to the (UG)n repeats. In fact, we observed a slight reduction of exon 3 skipping 
(60%) following the cotransfection of the TDP-43 specific antisense oligo but not with a not 
related antisense oligo. However, further experiments are required to elucidate the precise role 
that this factor is playing in the splicing of ApoAII exon 3.
5’ splice site involvement in the recognition of the ApoAII exon 3
The above considerations led us to consider the relevance of the 5’ splice site in the splicing of 
the ApoAII exon 3. In principle, the abrogation by mutagenesis of the 5’ splice site is used to 
test the mechanism of splice site recognition. If the 5’ splice site mutations results in retention 
of the downstream intron, this is indicative that the splicing occurs through an “intron 
definition” pattern. Alternatively, if the 5’ splice site mutations causes skipping of the 
upstream exon, this indicates that the splicing occurs through an “exon definition” pattern.
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In the ApoAII gene context, we found that the abrogation of the donor site of exon 3 causes 
the exclusion of exon 3 from mRNA. Therefore the exon 3 splicing seems to follow an “exon 
definition” pattern.
Other models have shown a relationship between splice site strength and splicing pattern. In 
particular, Talerico and Berget found that in small Drosophila introns with pyrimidine poor 3’ 
splice sites, the “intron definition” pattern of splicing was usually seen, while an “exon 
definition” pattern was favoured when the 3’ splice site was pyrimidine rich (Talerico and 
Berget, 1994). Thus, the ApoAII exon 3 disagrees with that model since its (GU) based 
“polypyrimidine tract” is weak. This suggests that the splice site strength is not sufficient to 
explain the “exon definition” splicing pattern, and that other parameters (such as accessory 
cis-acting elements) can influence the splicing model. Then, the evaluation of the splice site 
strength has shown that the 5’ splice site of human ApoAII exon 3 is stronger than that of 
human CFTR exon 9 (SSPNN scores 1.0 versus 0.83). We took advantage of this difference to 
test the effects of lowering the strength of 5’ splice site of ApoAII exon 3. Therefore, the 
observation that the replacement of the ApoAII exon 3 with the CFTR exon 9 donor site 
resulted in an increase of exon skipping suggests the possibility that the strong 5’ splice site of 
ApoAII exon 3 might compensate for its weak 3’ splice site. The possible explanation of the 
mechanism of compensation is given by an indirect communication between U1 snRNP and 
U2AF. In fact, Hoffman and Grabowski have indicated that a strong 5’ splice site can 
compensate for a weak 3’ splice site. Indeed, they found that in the case of the rat 
preprotachykinin pre-mRNA, the essential splicing factor U2AF65 might be targeted to a 
weak 3’ splice site in a manner that is facilitated by U1 snRNP particles and the downstream 
5’ splice site. It was shown the importance of the presence of an intact 3’ splice site, since U1 
snRNP binding to the 5’ splice site was not sufficient to target U2AF65 binding when the 
upstream tract was destroyed by mutation (Hoffman and Grabowski, 1992). Thus, the ApoAII
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exon 3 splicing mechanism does fit with this model based on the indirect communication 
between splice sites across the exon.
These observations point to the existence of accessory cis-acting elements placed within the 
exon that might work as a bridge between the exon borders.
ApoAII exon 3 sequences and splicing regulation
Studies on regulated alternative splicing have identified exonic cis-acting elements, referred to 
as exonic splicing enhancers (ESEs) that facilitate the process of exon definition. These 
elements are capable of activating weak splice sites in adjacent introns. However, it is now 
clear that ESEs are not only components of regulated exons but also of constitutively spliced 
exons (Mayeda et al., 1999; Schaal and Maniatis, 1999a).
Two classes of exonic splicing enhancers have been reported. The AC-rich elements (ACE) 
are a class of ESE identified by in vivo selection experiments and were found to stimulate 
splicing both in vivo and in vitro (Coulter et al., 1997). AC-rich ESEs have been shown to be 
involved in the regulated splicing of both viral and cellular genes (Coulter et al., 1997; 
Gersappe and Pintel, 1999). The mechanism of action of AC-rich ESEs remains largely 
unknown, although these elements have been proposed to function in a manner similar to that 
of the purine-rich ESEs.
The purine-rich ESEs are the most common and are usually located downstream of a 
suboptimal 3’ splice site. Through interactions with serine-arginine-rich (SR) proteins, purine- 
rich ESEs recruit U2AF to suboptimal 3’ splice sites and stimulate spliceosome assembly 
(Graveley et al., 1998; Lavigueur et al., 1993; Nagel et al., 1998; Ramchatesingh et al., 1995; 
Sun et al., 1993; Tanaka et al., 1994; Zheng et al., 1997; Zuo and Maniatis, 1996). Purine-rich 
ESEs can also suppress splicing of a pre-mRNA when they are located in a regulated intron
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(Gallego et al., 1997; Kanopka et al., 1996; Pagani et al., 2000). Thus, a purine-rich ESE can 
function as a splicing enhancer or a splicing suppressor depending on its location.
The accessory cis acting elements within the exon 3 were initially investigated by the 
progressive replacement of ApoAII exon 3 with CFTR exon 9 sequences. This approach was 
favoured to a deletion-based analysis, because our good knowledge of CFTR exon elements 
(Pagani et al., 2003) and to preserve the spatial arrangements of the splice sites. Indeed 
previous mapping analysis of human CFTR exon 9 for intraexonic regulatory elements carried 
out in our laboratory were based on the creation of human /mouse exon 9 hybrids because of 
the different exon 9 splicing outcome in human and mouse. The use of murine ApoAII gene 
was not possible in this case because murine and human ApoAII exon 3 have an identical 
splicing pattern.
The progressive replacement of ApoAII by CFTR sequences lead to the identification of a 
region between nucleotides 87 to 113 of human ApoAII exon 3 as essential for its inclusion in 
mRNA. Further mapping studies by overlapping deletions in that region permitted to identify a 
9nt-core region with enhancer-like activity, located in the region spanning from nucleotide 91 
to 99 of exon 3. Considering the base composition of this 9nt-core region (TGATGGAGA) 
this sequence would belong to a purine-rich ESE category.
In order to map more finely the 9nt-core region, we then evaluated the effect of point 
mutations within the core region on the exon 3 definition. Our results showed that single 
nucleotide substitutions may have a profound effect on the splicing efficiency inducing 
skipping. This peculiar sensitivity to splicing variations may be related to the weak definition 
of the ApoAII exon 3. This observation strengthen the hypothesis of the possible relationships 
between the definition of the exon 3 mediated by the strength of the 3’ splice site and the 
exonic regulatory structures affected by the site-directed mutants. Another possibility that we 
cannot rule out is that the mutations A97T, A99T and G92C (fig.2.15) create a silencer like
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sequence, rather than an enhancer. However the 9nt putative enhancer sequence 
(TGATGGAGA), contains the motif GGAGA, which has been found in many other purine- 
rich enhancer elements and has been recovered from a random screen (Schaal and Maniatis, 
1999b). Two other studies based on in vitro selection had previously identified consensus 
sequences for splicing enhancers that depend on specific SR proteins (Liu et al., 2000; Liu et 
al., 1998). Following these considerations, we decided to investigate the possible trans-acting 
factors able to bind specifically the ApoAII exon 3 ESE.
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Trans acting factors and ApoAII exon 3 splicing
It has been suggested that exonic splicing controlling elements affected by point mutations 
contain consensus sequences derived from SR-specific score matrices that mediate exon 
splicing efficiency (Cartegni L, 2002; Liu et al., 2001; Liu et al., 2000; Liu et al., 1998). In 
order to identify the trans acting factors able to bind the putative enhancer sequence, we tested 
the presence of SR protein binding sites within both wild type and A97T ApoAII exon 3 using 
the four available SF2/ASF, SC35, SRp40, and SRp55 motif-scoring matrices.
We found that the wild type ApoAII exon 3 contains 8 high score motifs for ASF/SF2, six for 
SC35, seven for SRp40, and four for SRp55. Interestingly, we found one ASF/SF2 potential 
site starting at nucleotide 90 (CTGATGG), that overlaps with the putative enhancer mapped 
functionally between nucleotides 91-97. However, no differences in the calculated matrix 
scores for the four SR proteins were apparent for the substitutions (A97T, G92C and A99T) 
that were found to affect “in vivo” the ApoAII exon 3 splicing pattern.
This is also in contrast with the SR protein binding data. Indeed whilst the wild type (wt) and 
A97T ESE sequences have both a high score for ASF/SF2, our binding experiments show an 
extremely clear difference with good binding to the wt ESE that is abolished by the A97T 
mutation.
The SR score matrices have been previously found to show a relationship with the splicing 
phenotype in other gene systems (Cartegni and Krainer, 2002; Liu et al., 2001). However, 
Pagani and co-workers when tried to correlate the SR protein matrices scores calculated for 
human CFTR exon 9 with the results of transfections of mutants generated by site-directed 
mutagenesis of exon 9, found a lack of general predictive value of the SR matrices for the 
identification of cw-acting elements in this context (Pagani et al., 2003). Another study of ESE 
analysis scored binding potentials for the different SR proteins in the dystrophin gene and 
could not find a relationship for the observed splicing patterns. In fact, in many cases exons
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that were found to be skipped in at least one alternative transcript displayed high SR protein 
binding potentials (Sironi et al., 2002).
Therefore, the “in silico” cannot be taken as a general prediction of SR binding sites and in 
particular does not seem to apply to ApoAII exon 3 cw-acting elements as observed also by 
Pagani et. al. and Sironi et. al. for other contexts. Hence, their weight in splicing regulation 
cannot be taken into consideration without a proper evaluation that should necessarily include 
binding and functional splicing assays in each specific system.
Considering that SR proteins others than those tested by matrix scores might be involved in 
the splicing of ApoAII exon 3, we tested the effects of overexpression of different factors on 
the splicing efficiency of this exon. It was necessary to test positive effects on a construct 
different from the wild type that already displays almost 100% inclusion. Therefore the 1866-, 
86 deletion that produces 55% of exon exclusion was used.
Among the tested factors (SRp20, SRp55, SRp75, ASF/SF2, SC35 and hnRNP A l), 
overexpression of SRp55, SRp75, ASF/SF2 and SC35 resulted in a slight increase of exon 3 
inclusion, whereas SRp20 and hnRNP A1 had a negative effect causing decreasing of exon 3 
inclusion. Our results with SRp55 and SRp75 are consistent with literature data since SRp55 
(Tran et al., 2003; Tran and Roesser, 2003) and SRp75 (Ramchatesingh et al., 1995; Zheng et 
al., 1997) are known as SR proteins binding to active enhancers.
The smaller than expected effect of ASF/SF2 and SC35 overexpression might be due to the 
fact that the 1866-86 deletion, occurring just 5nt downstream of the ApoAII exon 3 ESE, 
partially alters the RNA secondary structure of the region so interfering with the correct 
display of the ESE.
Concerning the negative effect on exon 3 splicing caused by SRp20 overexpression, we can 
speculate that might be the effect of a putative interaction with a decoy target site. This 
putative site could be an intron silencer that would cause the displacement of the spliceosomal
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machinery from the “true” exon 3 to a “decoy exon”, so preventing the constitutive inclusion 
of exon 3 at a certain extent. This explanation has already been proposed by Pagani et al, in 
the study on the modulation of CFTR exon 9 skipping (Gallego et al., 1997; Kanopka et al., 
1996; Pagani et al., 2000).
The negative effect of the overexpression of SRp20 is interesting as this factor is generally 
associated with a positive effect on exon inclusion (Galiana-Amoux et al., 2003; Lou et al., 
1998; Schaal and Maniatis, 1999b).
On the other hand the effect of hnRNP A1 on ApoAII exon 3 splicing is consistent with the 
general inhibitory effect described for this factor (Caceres et al., 1994; Mayeda and Krainer, 
1992).
Binding studies by UV-crosslinking alone did not evidence clear interactions of proteins in the 
molecular weight range of the SR proteins of interest (SRp 20, 55 and 75). Therefore, future 
experiments combining UV-crosslinking with immunoprécipitation using other monoclonal 
antibodies (such as Mabl04 or 1H4) that recognize different SR proteins might highlight 
putative interactions of SR proteins others than SC35 and ASF/SF2 with ApoAII exon 3 and 
its flanking introns.
109
Secondary structure
Since RNA molecules are generally sequence-dependent folded structures rather than simple 
strings of nucleotides, we included a secondary structure analysis of ApoAII exon 3 plus parts 
of its flanking introns in order to have a spatial prediction of the cis acting elements studied so 
far.
Current evidence concerning protein-RNA interaction suggests that proteins often make 
sequence-specific contacts with single-stranded residues in loops, while base-paired regions 
are often necessary for presentation of single-stranded nucleotides in the correct configuration. 
Several studies have suggested that some splicing events might be explained by structural 
alterations in possible higher free-energy structures of the pre-mRNA at specific enhancer or 
silencer elements (Balvay et al., 1993). Here in, it was hypothesized that when an alternative 
structure is too different from the “ground state” (lowest free-energy structure) this sequence 
can be differently recognized by the splicing machinery.
In order to highlight the possible relevance of the secondary structure for the ESE within the 
ApoAII exon 3, we elaborated this hypothesis analyzing the lowest free-energy structures of 
the ApoAII exon 3 wild-type (WT) using the mfold Server (http://BiBiServ.TechPak.Uni- 
Bielefeld.DE/mfold/) (Fig.3.3).
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Figure 3.3. Lowest free-energy structure of the ApoAII exon 3 wild-type (WT). The structure was obtained 
using the Mfold Server. Black circles highlight the 5’splice site and the ESE within exon 3. The 3 ’splice site is 
indicated by the white arrow.
The computer analysis shows that both the acceptor and the donor splice site of exon 3 are 
included in a loop and therefore are accessible to splicing factors. Moreover, the region of the 
putative enhancer is also included in a stem-loop structure (nucleotides 190-200 in figure 3.3). 
This is consistent with a role of the 91-99 nucleotide range as an enhancer like sequence 
folded to form a loop structure able to interact with possible trans-acting factors (Muro et al., 
1999).
The fact that both the acceptor and the donor sites are placed within a loop-structure that
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should facilitate their utilization is consistent with previous studies regarding the splicing 
patterns of the human growth hormone transcript, in which two bases in the vicinity of the 
exon 3 major splice-acceptor site (B) facilitate the utilization of a competing downstream 
acceptor (B'). In this case it was demonstrated that these two bases function by stabilizing a 
specific stem-loop structure in the native transcript indicating that a specific secondary 
structure within the native human growth hormone transcript controls the relative utilization of 
two competing splice-acceptor sites with the consequent generation of two functionally 
distinct hormone isoforms (Estes et al., 1992).
Another example regards the alternative splicing of the calcitonin/CGRP pre-mRNA. Here, 
both computer analysis and structure specific RNase digestion analysis of the RNA containing 
the 3’ splice acceptor of the calcitonin-specific exon 4, predicted that this region has the 
potential to form a thermodynamically stable stem-loop, acting as a crucial cis-element 
involved in proper splice site selection (Coleman and Roesser, 1998).
Then, our attention was focused on the ApoAII exon 3 region including the ESE. In our 
model, to maximize the structural information provided by the RNA molecule in an RNA- 
protein interface for the prediction of the ApoAII exon 3 secondary structure, the region used 
for the computer analysis included all the exon. The ESE is included within a hairpin loop 
structure available to interact with trans-acting factors as shown for other models.
In fact, different examples of accessory splicing factor binding dependent on the secondary 
structure of target sequence, have already been reported. It was shown that binding affinities 
of both human and drosophila SRp55 are strongly influenced by the structural features of the 
target RNA (Shi et al., 1997). Then, the binding of hnRNP A l (its well known antagonistic 
factor) has been recently observed to be affected by RNA secondary structure in the removal 
of the second intron in the HIV-1 rev/tat pre-mRNAs (Damgaard et al., 2002).
112
The position of the ESE within ApoAII exon 3 is crucial
The “in vitro” splicing experiments carried out in order to investigate the possible 
relationships of the ApoAII exon 3 ESE with the flanking 3’splice site did not show any 
difference in the splicing pattern either with the ESE wild type or with the A97T point 
mutation (Fig. 2.21). Although a putative influence of the PY7 minigene’s context cannot be 
ruled out, the fact that the ESE is located within the “last” exon in this minigene, may affect 
the function of the ESE, normally placed within an internal exon. In addition, our “in vivo” 
experiments have shown that the ApoAII exon 3 ESE works properly only when it is located 
within an internal exon (Fig. 2.23).
It is important to note that the splicing mechanisms of the first and the last exons are peculiar 
since first exons contain an m7GpppG 5’ cap structure instead of a 3’ splice site and last exons 
contain a poly A signal instead of a 5’ splice site.
The 5’ cap structure of a mammalian pre-mRNA is necessary for the efficient utilization of the 
adjacent 5' splice site for definition of the first exon and removal of the first intron (Izaurralde 
et al., 1994). Efficient recognition of the cap-proximal 5' splice site by the U1 snRNP is 
facilitated by the nuclear cap binding complex (CBC) (Lewis et al., 1996). This CBC-directed 
definition of the first exon is believed to be one of the earliest steps in pre-mRNA recognition 
and appears to involve an interaction between the CBC (bound to the cap) and the U1 snRNP 
(which binds at the 5’ splice site). On the other hand, processing of the last exon and removal 
of the last intron involve interactions between splicing components at the 3’ splice site of the 
last exon and components of the Polyadenylation (PA) complex at the poly A signal (Lutz and 
Alwine, 1994; Nesic et al., 1993; Niwa and Berget, 1991; Niwa et al., 1990).
In principle, the repositioning of ApoAII exon 3 ESE within the last exon does not imply 
necessarily an alteration of its function. In fact, there are examples of last-exon splicing that 
depends on the presence of an enhancer within the last exon. Splicing of the last intron (intron
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D) of the bovine growth hormone (bGH) pre-mRNA requires the presence of a downstream 
splicing enhancer in the last exon (Dirksen et al., 1994; Hampson et al., 1989).
Therefore, our observation that the ApoAII exon 3 ESE works properly only when it is located 
within an internal exon (fig. 2.23), implies the existence of other regulatory elements placed 
within the flanking introns.
Mapping of cis-acting elements within intronic regions flanking ApoAII exon 3
There are several splicing control elements located within introns (Smith and Valcarcel, 2000). 
They can be involved in recognition of the appropriate splice site or in the suppression or 
enhancement of certain splice site usage, particularly in alternative splicing cases. It is difficult 
to make a clear distinction between splicing recognition and regulation, since an element may 
serve as a constitutive splicing enhancer/suppressor or promote alternative splicing, depending 
on the expression pattern of the gene and the availability of trans-acting associated factors. 
Relatively little is known about the nature of the intronic splicing regulatory elements (ISRE). 
Generally, they do not obey defined consensus rules and are known to consist of diverse 
sequences (Fairbrother and Chasin, 2000). Although some common ISRE have been observed, 
such as the GGG triplet (Carlo et al., 1996; McCullough and Berget, 1997; Romano et al., 
2002), purine-rich elements (Hastings et al., 2001; McCullough and Schuler, 1997), or 
polypyrimidine tracts commonly present in the 3’ intronic regions (Hastings and Krainer, 
2 0 0 1 ), most newly discovered elements tend to consist of entirely new motifs, rather than 
belong to known groups (Blencowe, 2000).
When we analyzed the sequence of the ApoAII intron 3 scanning for possible ISREs, we 
noticed the presence of three G runs between nucleotide 10 and 28 downstream of the 5’ splice 
site of intron 3. However, our results of Gs runs mutagenesis excluded their involvement in 
the splicing control of ApoAII exon 3 (Fig. 2.25).
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Then, to evaluate the functional significance of the human ApoAII intron 2 and 3 in 
modulating splicing efficiency of exon 3, intronic sequences were progressively deleted and 
the corresponding mutant minigenes were transiently transfected in Hep3B cells and the 
resulting mRNA analyzed by RTPCR.
It is known that the potential localization of ISREs is extremely variable. In fact, they are most 
likely present in the vicinity of a splice site but have also been found as far away as 150 bp 
(McCullough and Schuler, 1997; Rowen et al., 2002; Zheng et al., 2000).
We therefore considered the possible presence of regulatory elements in a range of 2 1 Ont 
upstream of the exon 3 acceptor site and I I 6 nt downstream of the exon 3 donor site, as this 
was the cassette originally designed in order to facilitate sequence replacements within exon 3 
and its flanking intronic sequences.
The deletions within introns had two opposite effects on exon 3 splicing. On one hand, the 
I27nt-deletion within intron 2 (A1554-I681) caused full inclusion of the exon 3, regardless the 
point mutation A97T within the exonic splicing enhancer (fig.2.26). On the other hand, both 
the 90 nt-deletion in intron 3 (AI931-2022) and a narrower one (AI94I-1967) caused exon 3 
skipping even when the wild type ApoAII exon 3 ESE was present (fig.2.27 and 2.29). 
Concerning the effects of the 127 nt-deletion within intron 2, it may indicate the presence of a 
silencer-like intronic regulatory element placed within the deleted region. However this 
possibility should be taken with caution because variations in the length of an intron are 
known to influence the efficiency of the splicing. In fact a compensatory relationship between 
exon and intron sizes has been previously described (Chen and Chasin, 1994; Sterner et al., 
1996). These authors found that expanding small introns flanking a large exon causes exon 
skipping. They concluded that large exons bordered by large introns create an exon/intron 
architecture that is problematic for splice site recognition. Moreover, Bell and coworkers 
proposed a kinetic probability model in which short introns may overcome the poor
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recognition of alternatively spliced exons (Bell et al., 1998). Using the murine CD44 V3 exon 
as a splicing model, the authors demonstrated a relationship between intron length and V3 
exon exclusion. In fact, it was showed that the splicing of V3 is reduced as intron length is 
increased (Bell et al., 1998)
Conversely, Bai and coworkers showed that the expansion of introns can be associated with an 
increase of the splicing efficiency. In fact, using the adenine phosphoribosyltransferase gene 
model, they have shown that the expansion of intron 3 from 154 to 424nt greatly reduced exon 
4 skipping when transfected into CHO cells (Bai et al., 1999). In consequence the increase of 
ApoAII exon 3 splicing efficiency might be due simply to shortening of the intron 2 by the 
127nt-deletion or to an intronic splicing silencer present in that sequence. Future studies based 
on a point mutation strategy should be helpful to elucidate the possible presence of a 
regulatory element within ApoAII intron 2.
On the other hand, the observation that the 26nt-deletion within intron 3 cause exon 3 skipping 
even in presence of the wild type ESE, strongly indicates that a cis acting element that 
positively regulate the inclusion of exon 3 is localized in that sequence. There are several 
examples of intronic splicing enhancers (ISEs) that affect splicing of exons. The high contents 
of purines also might be indicative of a regulatory sequence since it seems to be the hallmark 
of these elements (Blencowe, 2000). The fact that this region might be regulating positively 
exon 3 inclusion is also reinforced by preliminary UV crosslinking analysis (data not shown) 
indicating four proteins specifically bound to the transcript with the intact ISE and absent 
when that sequence was mutagenized. This suggests that some trans acting factors might be 
acting through the binding to the ISE in intron 3 in order to positively regulate the inclusion of 
the exon 3. Nevertheless, further experiments also in this case, are necessary in order to map 
finely the 26nt-region by point mutation and to identify the trans-acting factors able to bind 
the putative ISE.
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Models of human ApoAII exon 3 constitutive splicing
On the basis of our data, we can try to depict a model to explain the constitutive splicing of the 
human ApoAII exon 3. Different lines of evidence indicate the peculiarity of the exon 3 
splicing mechanism. Firstly, a series of studies suggest that a (GU) repeats is unable to directly 
bind the constitutive splicing factor U2AF65 (Singh et al., 1995; Zamore and Green, 1991; 
Zamore et al., 1992). Moreover, our results demonstrated that the “polypyrimidine tract” of 
ApoAII intron 2 based on (GU) repeats are able to interact with TDP-43 and that this protein 
affects negatively ApoAII exon 3 inclusion, as also shown in the CFTR context. Secondly, we 
have identified one enhancer-like sequence localized within exon 3 and at least one intronic 
enhancer-like sequence localized within intron 3. Thirdly, the analysis of the introns removal 
order suggests that intron 2 is the last one to be processed. Figure 3.4 summarizes the cis- 
acting elements and trans acting factors identified during this study along with their possible 
effects on the ApoAII exon 3 splicing.
On the basis of our data we propose that the weak polypyrimidine tract of intron 2 might be 
unable to recruit directly the constitutive splicing factor U2AF65. In fact, the interaction of 
TDP-43 with the (GU) repeats might hamper the binding of U2AF65 with the 3’ splice site of 
intron 2. Moreover, the presence of a strong 5’ splice site is not sufficient to compensate the 
weak 3’ splice site. Therefore, both the exonic and the intronic enhancers might have a pivotal 
role in definition of exon 3. The binding of ASF/SF2 (and/or SC35) to the enhancer within 
exon 3 and the interaction of yet unknown splicing factors to the regulatory element within 
intron 3 might be crucial to recruit the constitutive splicing factors U2AF35 and U2AF65 
essential to define the 3’ splice site of intron 2. In this way, a bridge-like structure among 
components bound to the 5' and 3' splice sites would be formed to define exon 3. A large body 
of evidences indicates that U2AF35 is required for constitutive splicing and also works as a 
mediator of enhancer-dependent splicing. In vitro protein-RNA interaction studies with pre-
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mRNAs containing either a constitutive or regulated splicing enhancer have shown that 
U2AF35 directly mediates interactions between U2AF65 and proteins bound to the enhancers 
(Zuo and Maniatis, 1996). Thus, U2AF35 recruits U2AF65 acting as a bridge between this 
molecule and the enhancer complex. Without the enhancer, U2AF65 should not bind, due to 
the weakness of the polypyrimidine tract.
Interestingly, the observation that intron 2 seems to be the last one to be processed led us to 
hypothesize that this delay might be necessary to permit, through an unknown mechanism that 
might involve the factors interacting with the regulatory elements placed within exon 3 and its 
flanking introns, the displacement of TDP-43 from the (UG) repeats within the 3’ splice site of 
intron 2 , so permitting the processing of this intron.
In conclusion, in the mammalian genomes there are abundant traces of recombination events 
via transposons or retroviruses that resulted in substantial changes in specific regions of the 
genomes (Kazazian, 1998; Kazazian and Moran, 1998). As mentioned above, the polymorphic 
(GT) tract within ApoAII intron 2 is present in all Primates but not in Rodents suggesting that 
exon 3 and its flanking introns are the result of ancient insertion- and rearrangement- events, 
similarly to what happened for CFTR intron 8 . These events would have placed the new 
polymorphic cis-acting element in proximity of the 3’ splice junction of ApoAII intron 2 
which interferes with efficient splicing of exon 3 and may have activated an evolutionary 
selection of different mechanism of splicing in order to preserve the constitutive inclusion of 
ApoAII exon 3.
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Figure 3.4 Scheme of the cis-acting elements and trans acting factors involved in the human ApoAII exon 3 
definition. TDP-43 was found to interact with the (UG)16 in the 3 ’splice site of ApoAII intron 2. ASF/SF2 and 
SC35 were found to bind the FSF within the exon 3. The sequences of the putative cis-acting elements localized 
within the intron 2 and 3 are indicated. The positive or negative effects of each cis-acting element on the exon 3 
splicing is shown
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Future directions
The effect observed upon deletions of the 1554-1681 region within intron 2 might be 
indicative of the presence of an intronic splicing silencer. However an intron-size effect due to 
the shortening of the introns cannot be excluded. Therefore, a strategy involving point 
mutations in that region without altering the size of the introns might be used in order to 
confirm the presence of the putative cis-acting elements within the intron 2 .
Then, the preliminary results of the UV crosslinking experiments with the wild type or the 
mutated 26nt polypurine rich region within intron 3 could be confirmed through UV 
crosslinking competition assays. If is possible to highlight a specific protein able to bind the 
1941-1967 region within intron 3, RNA-affinity purification and microsequencing by mass 
spectrometry might be carried out for the identification of such a protein.
In order to investigate more in detail the role of TDP-43 in the ApoAII exon 3 splicing, an in 
vitro splicing assay where ApoAII A1866-86 transcripts should be incubated with TDP-43 
immuno-depleted HeLa nuclear extracts might be set up. In such a way, the effects of TDP-43 
depletion and complementation on the splicing efficiency of ApoAII exon 3 might be tested.
It was speculated that the interaction of TDP-43 to the UG repeats close to the 3’ splice site 
might interfere with the recruitment of U2AF65 that is essential for the recognition of the 
acceptor splice site. Thus, an UV-crosslinking assay followed by immunoprécipitation 
experiments using antibodies anti-U2AF65 might clarify whether this factor is directly or 
indirectly recruited to the ApoAII intron 2 polypyrimidine tract.
A new tool called CLIP (ultraviolet cross-linking and immunoprécipitation) to investigate the 
in vivo RNA-protein interaction has been recently described. This technique is based on in 
vivo UV-irradiation to form covalent bonds between proteins and RNAs that are in direct 
contact (within angstroms); the relatively low efficiency of this reaction is compensated by
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PCR amplification. The covalent binding allows not only to obtain highly purified protein- 
RNA complexes, but also to partially digest the RNA while retaining the core element 
involved in protein binding (generally 60- to 100-nucleotide). The protein component is 
removed from the complex with proteinase K, and the RNA cloned with the use of linker 
ligation and reverse transcription RTPCR, in that way, both the identification of bound RNA 
species and location of the binding site may be carried out [Ule, 2003 #1656]. In order to gain 
further insight into the role this factor is playing in the ApoAII exon 3 splicing mechanism, a 
similar procedure might be used to in vivo confirm the binding of TDP-43 with the (GU)n 
repeats in the ApoAII context.
Finally, both the positive effects shown by SRp55 and SRp75 on exon 3 inclusion and the 
negative effect of SRp20 suggested the possibility that also these splicing factors might be 
playing a role in the splicing mechanism of exon 3. Also in this case, UV-crosslinking assays 
combined with immunoprécipitation using other monoclonal antibodies that recognize 
different SR proteins (such as Mabl04 or 1H4) might be useful to map the sequences of 
ApoAII exon 3 and its flanking introns interacting with these SR proteins.
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4. MATERIALS AND METHODS
Chemical reagents
General chemicals were purchased from Sigma Chemical Co., Merck, Gibco BRL, Boehringer 
Mannheim, Carlo Erba and Serva.
Standard solutions
All solutions are identified in the text except for the following:
a) TE: 10 mM Tris-HCl (pH 7.4), 1 mM EDTA (pH 7.4)
b) PBS: 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HP04, 1.8 mM KH2 PO4 , pH 7.4
c) lOX TBE: 108 g/1 Tris, 55 g/1 Boric acid, 9.5 g/1 EDTA
d) 6 X DNA sample buffer: 0.25 % w/v bromophenol blue, 0.25 % w/v xylene cyanol FF,
30 % v/v glycerol in H2 O.
e) lOX protein sample buffer: 20 % w/v SDS, 1 M DTT, 0.63 M Tris-HCl (pH 7), 0.2 % 
w/v bromophenol blue, 20 % v/v glycerol, 10 mM EDTA (pH 7).
Enzymes
Restriction enzymes were from New England Biolabs, Inc. DNA modifying enzymes such as 
Tag Polymerase, DNase I RNase free, and T4 DNA ligase were obtained from Roche 
Diagnostic. Klenow fragment of E. coli DNA polymerase I and T4 polynucleotide Kinase 
were from New England Biolabs, Inc. RNase A was purchased from Sigma Chemicals Ltd. A 
10 mg/ml solution of RNase A was prepared in sterile water and boiled for 10 minutes to 
destroy trace amounts of DNase activity. All enzymes were used following manufacturer’s 
instructions.
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Synthetic oligonucleotides
Synthetic DNA oligonucleotydes were purchased from Sigma-Genosys Ltd.
Radioactive isotopes
32
Radioactive a- P-UTP were supplied by Amersham U.K. Ltd.
Bacterial culture
The E. Coli K12 strain DH5a was transformed with the plasmids described in this study and 
used for their amplification. Plasmids were maintained in the short term as single colonies on 
agar plates at 4 °C but for long term storage they were kept on glycerol stocks made by adding 
sterile glycerol to a final 30% v/v concentration to liquid bacterial cultures. Glycerol stocks 
were stored at -80°C. When necessary, from the glycerol stocks an overnight culture of 
bacteria was grown in Luria-Bertani medium [LB medium: per litre: 10 g Difco 
Bactotryptone, 5 g Oxoid yeast extract, 10 g NaCl, (pH 7.5)]. Bacterial growth media were 
sterilized before use by autoclaving. When appropriate, ampicillin was added to the media at a 
final concentration of 200 pg /ml.
Cell culture
The cell line used for transfection and cotransfection experiments were HepSB: human, 
hepatocellular carcinoma fibroblast-like, HeLa and the mouse fibroblast NIK 3T3 cell line.
DNA preparation
Small scale preparation of plasmid DNA from bacterial cultures
Rapid purification of small amounts of recombinant plasmid DNA was performed with the 
method previously described by Sambrook (Sambrook et al., 1989). Briefly, alkaline lysis of
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recombinant bacteria was performed by resuspending the bacterial pellet in 200 pi of ddH20; 
150 pi of solution II (0.2 M NaOH, 1 % w/v SDS) were then added and the contents mixed by 
inversion. 250pl of solution III (3 M potassium acetate pH 5.2) were then added and the 
contents mixed by inversion. The bacterial lysate was then centrifuged in an Eppendorf 
microcentrifuge at maximum speed and the supernatant transferred to a new tube. An equal 
volume of 1:1 v/v phenol:chloroform solution was added to the supernatant. The tube was then 
vortexed and centrifuged as above. The aqueous phase containing the DNA was transferred to 
a new tube. An equal volume of chloroform was added to the supernatant. The tube was then 
vortexed and centrifuged as above. The aqueous phase containing the DNA was then 
recovered and the DNA pelleted by ethanol precipitation. The final pellet was resuspended in 
50 pi of ddH20 and 5 pi of such preparation were routinely taken for analysis by restriction 
enzyme digests.
Large scale preparations of plasmid DNA from bacterial cultures
For large-scale preparations of plasmid DNA that was necessary for the transfection 
experiments, JetStar purification kit (Genomed) was used according to the manufacturer’s 
instructions. In order to get a good amount of plasmid, we left a 30 ml of overnight bacterial 
culture using TB medium.
Preparation of genomic DNA
Peripheral blood (5 ml) was treated with 20 ml of Lysis Buffer (Sucrose 0.32 M, Tris-HCl 10 
mM pH 7.5, MgClj 5 mM, Triton X-100 1%) and incubated on ice for 15 min. The mix was 
centrifuged 10 min at lOOOxg at 4 °C. The pellet was washed three times with Fisio Buffer 
(NaCl 0.075 M, FDTA 0.025 M pH 8) and resuspended in 1 ml of Resuspension Buffer (Tris- 
HCl 10 mM pH 7.5-8, NaCl 0.4 M, FDTA 2 mM). 200 pi of SDS 10% were added and the
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mixture was incubated at 37 °C overnight to facilitate the extraction. The following day 600 pi 
of NaCl saturated water solution was added and the samples were mixed for 15 seconds to 
allow the proteins precipitation. The mix was centrifuged 15 min at 1500g to pellet the 
proteins. The supernatant was recovered and the centrifugation repeated a second time. 
Finally, 1 volume of isopropanol was added to the supernatant to precipitate the DNA. 
Precipitated DNA was removed with a Pasteur, washed in 1ml of 70% ethanol and 
resuspended in 500 pi of water. The DNA was then checked by electrophoresis on a 0.8% w/v 
agarose gel, quantified by spectrophotometer and stored at 4 °C until use for PCRs.
RNA preparation from cultured cells
Cultured cells were washed with PBS and then RNAwiz provided from Ambion inc. was 
added. Then, chloroform extraction was performed. Supernatant was precipitated with 
isopropanol. The pellet was resuspended in 100 pi of ddH20 and digested with lU  of DNase 
RNase free. The mix was incubated at 37 °C for 30 minutes, and then the RNA was purified 
by acid phenol extraction. The final pellet was resuspended in 35 pi of ddH20 and frozen at 
-80 °C. The RNA quality was checked by electrophoresis on 1% agarose gels.
Estimation of nucleic acid concentration
An optical density of 1.0 at 260 nm is usually taken to be equivalent to a concentration of 50 
pg/ml for double stranded DNA, 40 pg/ml for single stranded DNA and RNA, and 
approximately 20 pg/ml for single-stranded oligonucleotides samples. The ratio of values for 
optical densities measured at 260 nm and 280 nm is considered as 1.8 for pure sample of DNA 
and 2 for RNA and these are reduced by protein contaminants (Sambrook et al., 1989). 
Therefore, these values were used to determinate not only the concentration but also the purity 
of the samples.
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Enzymatic modification of DNA
Restriction enzymes
Restriction endonucleases were used in the construction and analysis of recombinant plasmids. 
Each restriction enzyme functions optimally in a buffer of specific ionic strength. All buffers 
were supplied by the same company that supplied the enzymes and were used according to the 
manufacturer’s instructions.
For analytical digests 100-500 ng of DNA were digested in a volume of 20 pi containing 6 U 
of the appropriate restriction enzyme. The reaction was incubated for 3-6 hours at 37 °C. 
Preparative digestion was made of 5-20 pg DNA using the above conditions and 2 U of 
restriction enzyme for pg of DNA in 200 pi reaction volume.
Large fragment ofE. coli Polymerase I  and T4 Polynucleotide Kinase 
These enzymes were used to treat PCR products for blunt-end ligation during construction of 
recombinant plasmids. The large fragment of DNA Polymerase I (Klenow) is a proteolytic 
product of E. coli DNA Polymerase I. It retains polymerization and 3’->5’ exonuclease 
activity, but has lost 5’->3’ exonuclease activity. This was useful for digesting a specific A 
residues added by Taq DNA polymerase at the 3’ terminus to create compatible ends for 
ligation. T4 Polynucleotide Kinase catalyses the transfer of phosphate from ATP to the 5’ 
hydroxyl terminus of DNA. It was useful for the addition of 5’-phosphate to PCR products to 
allow subsequent ligation. Klenow fragment (2.5 U) was added to 23 pi of PCR product in 5 
mM MgClz buffer. The mixture was incubated at room temperature for 10 minutes. FDTA to a 
final concentration of 0.2 mM, ATP to a final concentration of 1 mM, 10 U of T4 
Polynucleotide Kinase and the proper quantity of Kinase buffer were added to the above
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mixture and incubated at 37 °C for 30 min. The enzymes were inactivated by incubation at 80 
°C for 20 min.
T4 DNA ligase
T4 DNA ligase catalyses the formation of a phosphodiester bond between adjacent 3’ 
hydroxyl and 5’ phosphoryl termini in DNA, requiring ATP as a cofactor in this reaction. This 
enzyme was used to join double stranded DNA fragments with compatible sticky or blunt 
ends, during generation of recombinant plasmid DNAs.
20 ng of linearized vector were ligated with a 5-10 fold molar excess of insert in a total 
volume of 30 pi containing IX ligase buffer and lU  of T4 DNA ligase. Reaction was carried 
out at room temperature for 6-12 hours.
In some reactions synthetic oligonucleotide were included in the reaction. In these cases, the 
amounts added to each reaction to obtain inclusion of oligonucleotides in the resulting plasmid 
were about 100 fold molar excess over the DNA vector.
Agarose gel electrophoresis of DNA
DNA samples were size fractionated by electrophoresis in agarose gels ranging in 
concentrations from 0.8 % w/v (large fragments) to 2 % w/v (small fragments). The gels 
contained ethidium bromide (0.5 pg /ml) and IX TBE. Horizontal gels were routinely used for 
fast analysis of DNA restriction enzyme digests, estimation of DNA concentration, or DNA 
fragment separation prior to elution from the gel. Samples of 20 pi containing IX DNA 
loading buffer were loaded into submerged wells. The gels were electrophoresed at 50-80 mA 
in IX TBE running buffer for a time depending on the fragment length expected and gel 
concentration. DNA was visualized by UV transillumination and the result recorded by digital 
photography.
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Elution and purification of DNA fragments from agarose gels
This protocol was used to purify small amounts (less than 1 pg) of DNA for sub-cloning. The 
DNA samples were electrophoresed onto an agarose gel as described previously. The DNA 
was visualized with UV light and the required DNA fragment band was excised from the gel. 
This slab was cut into pieces, and the JETquick Spin Column Technique (Genomed) was used 
according to the manufacturer’s instructions. Briefly, 300 pi of gel solubilisation solution LI 
(NaClO^, Na acetate and TBE) were added for each 100 mg of the gel slice pieces and 
incubated at 65 °C for 15 min vortexing every 5 min. The mixture was loaded into a prepared 
JETquick column and it was centrifuged at maximum speed for 2 min. The flowthrough was 
discarded. 700 pi of washing and reconstituted solution L2 (ethanol, NaCl, EDTA and Tris- 
HCl) were added into the spin column and after 5 min, the column was centrifuged in the same 
conditions twice. The flowthrough was again discarded both times. To elute the bound DNA, 
30-50 pi of sterile water were added onto the centre of the silica matrix of the spin column and 
the system was centrifuged for 2 min. The amount of DNA recovered was approximately 
calculated by UV fluorescence of intercalated ethidium bromide in an agarose gel 
electrophoresis.
Preparation of bacterial competent cells
Bacterial competent cells were prepared following the method described by Chung and 
Niemela (Chung et al., 1989). E. Coli strains were grown overnight in 3 ml of LB at 37°C. The 
following day, 300 ml of fresh LB were added and the cells were grown at room temperature 
for 4-5 h until the OD^ qo was 0.3-0.4. The cells were then put in ice and centrifuged at 4 °C 
and lOOOg for 15 min. The pellet was resuspended in 30 ml of cold TSS solution (10% w/v 
PEG, 5% v/v DMSO, 35mM Mg CI2 , pH 6.5 in LB medium). The cells were aliquoted, rapidly
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freeze in liquid nitrogen and stored at -80°C. Competence was determined by transformation 
with 0.1 ng of pUC19 and was deemed satisfactory if this procedure resulted in more than 100 
colonies.
Transformation of bacteria
Transformations of ligation reactions were performed using 1/2 of the reaction volume. 
Transformation of clones was carried out using 1 ng of the plasmid DNA. The DNA was 
incubated with 60 pi of competent cells for 20 min on ice and at 42°C for 2 minutes. At this 
point 60 pi of LB were added and the bacteria allowed to recover for 10 min at 37 °C. The 
cells were then spread onto agarose plates containing the appropriate antibiotic. The plates 
were then incubated for 12-15 hours.
When DNA inserts were cloned into p-galactosidase-based virgin plasmids, 30 pi of IPTG 
100 mM and 20 pi of X-Gal (4 % w/v in dimethylformamide) were spread onto the surface of 
the agarose before plating to facilitate screening of positive clones (white colonies) through 
identification of p-galactosidase activity (blue colonies).
Amplification of selected DNA fragments
The polymerase chain reaction was performed on genomic or plasmid DNA following the 
basic protocols of the Roche Diagnostic Taq DNA Polymerases. The volume of the reaction 
was 50 pi. The reaction buffer was: IX Taq buffer, dNTP mix 200 pM each, oligonucleotide 
primers 100 nM each, Taq DNA Polymerase 2.5 U. As DNA template, 0.1 ng of plasmid or 
100-500 ng of genomic DNA were used for amplification. When a DNA fragment longer than 
2000bp was amplified, DMSO 3% was also added to the mixture. The amplification 
conditions are described for each particular PCR. The amplifications were performed on a
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Cetus DNA Thermal Cycler (Perkin Elmer) or on a Gene Amp PCR System (Applied 
Biosystems).
Sequence analysis for cloning purpose
Sequence analysis of plasmid DNA was performed using the CEQ 2000 sequencer (Beckman 
Coulter). The plasmid DNA of interest (approximately 100 ng) was purified through a 
MicroSpin S-400 HR Column (Amersham Pharmacia Biotech). The DNA was then amplified 
using fluorescent labeled dideoxy nucleotide terminators according to the manufacturer’s 
instructions. The samples were analized by loading them into the automatic sequencer.
Reconstruction of the whole Apo A ll gene sequence
In order to study the mechanism of the Apo All exon 3 splicing the full sequence of the gene 
was cloned XhoI-SacII in pBluescript. Each fragment of the complete Apo All gene was 
amplified by PCR (94 °C 30 sec, 56 °C 1 min, 72 °C 1 min, 35 cycles) using approximately 
200-400 ng of genomic DNA as template. After amplification, the PCR products were purified 
through a MicroSpin S-400 HR Column (Amersham Pharmacia Biotech, Sweden). The DNA 
was then directly sequenced by CEQ 2000 sequencer (Beckman) according to the 
manufacturer’s instructions as described above for sequence analysis of plasmid DNA. The 
oligonucleotides listed below were used to amplify the whole Apo All sequence from genomic 
DNA.
Name of the oligo Sequence of the oligo (5’-3’)
hApoAII-1173XhoI5’ tccgctcgagcccgggaggtggaggttgca
hApoAII intron2/Sal I 3’ tttggttgccagtcgacctggatataaga
h Apo All intron2/Sal I 5’ tcttatatccaggtcgactggcaaccaaa
h Apo All intron3/EcoR 1 3’ tttctctgcgaattctaagcctaatct
h Apo All intron3/EcoR 1 5’ agattaggcttagaattcgcagagaaa
hApoAII stop as+Cla/Not aatggtctggacactgcggccgcatcgattcactgggtggcaggc
h Apo All stop 5’+Cla/Not agcctgccacccagtgaatcgatgcggccgcagtgtccagaccatt
hApoAII poly A SacII 3’ ttccccgcgggtaggagactctgggtttgga
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Each fragment was then ligated to the next up to totally reconstruct the gene (named as pApo- 
wt). Suitable Sail, EcoRI and Notl-Clal restriction sites were included in intron 2, intron 3 and 
exon 4 respectively. The first two to create an interchangeable cassette to test the mutations or 
replacing made in the exon 3 and/or its flanking introns, whereas Notl-Clal in exon 4 to 
differentiate pApo-wt from the endogenous Apo All.
Oligos sequence of the different construct
Generation o f CF/Apo hybrids
The oligos used to create the CF/Apo hybrids were:
Name of the oligo Sequence of the oligo (5’-3’)
Apo/CF short Sense aacagggatttggggaattatttaggcaaaggagccatgtgtgg
Apo/CF short AS ccacacatggctcctttgcctaaataattccccaaatccctgtt
Apo/CF long Sense ctcacttcttggtactcctgtcctgagcttcaggccgaggccaagt
Apo/CF long AS acttggcctcggcctgaagctcaggacaggagtaccaagaagtgag
hCF 9 +60 / hAII Sense atagaaaaacttctaattccagaccgtgactgac
hC F9+60/hA IIA S gtcagtcacggtctggaattagaagtttttctat
HAPO-CF SHORT/MEDIUM S agcaaaacaaaacaatagagcctggtttct
HAPO-CF SHORT/MEDIUM AS agaaaccaggctctattgttttgttttgct
HAPO-CF MEDIUM/LONG S ctcttcttcagtaatacctgatggagaagg
HAPO-CF MEDIUM/LONG AS ccttctccatcaggtattactgaagaagag
Generation o f overlapping deletion within Apo A ll  exon 3 
The oligos used to create the overlapping deletions were:
Name of the oligo Sequence of the oligo (5’-3’)
ApoAII-Ex3 D1840-61 S accgtgactgactatgtcaagagcccagag
ApoAII-Ex3 D1840-61 AS ctctgggctcttgacatagtcagtcacggt
ApoAII-Ex3 D1854-75 S tatggcaaggacctggagcttcaggccgag
ApoAII-Ex3 D1854-75 AS ctcggcctgaagctccaggtccttgccata
ApoAII-Ex3 D1866-86 S ctgatggagaaggtcgaggccaagtaagtc
ApoAII-Ex3 D1866-86 AS gacttacttggcctcgaccttctccatcag
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Generation of point mutation within Apo A ll exon 3 ESE
The oligos used to point mutate the Apo All exon 3 ESE were:
Name of the oligo Sequence of the oligo (5’-3’)
91-T->A S tggcaaggaccagatggagaaggtcaaga
91-T->A AS tcttgaccttctccatctggtccttgcca
92-G->C S tggcaaggaccacatggagaaggtcaaga
92-G->C AS tcttgaccttctccatgtggtccttgcca
93-A->T S tggcaaggaccagttggagaaggtcaaga
93-A->T AS tcttgaccttctccaactggtccttgcca
94-T->A S tggcaaggaccagaaggagaaggtcaaga
94-T->A AS tcttgaccttctccttctggtccttgcca
95-G->C S tggcaaggaccagatcgagaaggtcaaga
95-G->C AS tcttgaccttctcgatctggtccttgcca
96-G->C S tggcaaggaccagatgcagaaggtcaaga
96-G->C AS tcttgaccttctgcatctggtccttgcca
97-A->T S tggcaaggaccagatggtgaaggtcaaga
97-T->A AS tcttgaccttcaccatctggtccttgcca
98-G->C S tggcaaggaccagatggacaaggtcaaga
98-G->C AS tcttgaccttgtccatctggtccttgcca
99-A->T S tggcaaggaccagatggagtaggtcaaga
99-A->T AS tcttgacctactccatctggtccttgcca
Generation of mutagenesis of G runs in intron 3
The oligos used to mutagenize the Gs runs in Apo All intron 3 were:
Name of the oligo Sequence of the oligo (5’-3’)
Apo m IVS3 Gn S gtaagtctcatcacaagcgcttca-
Apo m IVS3 Gn AS tgaagcgcttgtgatgagacttac
Apo IVS3 mut Gl-3 S gtaagtctcatgtcaagcattcatgcgctgtg
Apo IVS3 mut Gl-3 AS cacagcgcatgaatgcttgacatgagacttac
ApoAII-Delta G4CTG 5’ ggcaaggggttcagagcttatggaactgtggaga
ApoAII-Delta G4CTG 3’ tctccacagttccataagctctgaaccccttgcc
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Generation of Apo A ll  exon 3 5^ splice site mutants
The oligos used to mutagenize the Apo All exon 3 5’splice site were:
Name of the oligo Sequence of the oligo (5’-3’)
ApoAII-Ex3 D5’ S caggccgaggccgacatactctcagggcaa
ApoAII-Ex3 D5’ AS ttgccctgagagtatgtcggcctcggcctg
Replacement of EDA pY tract by GT repeats
Wild type pY tract of the EDA exon in the a-globin/fibronectin reporter system (Muro et aL, 
1998) was replaced by (GT)16 repeats. Sense and anti sense oligos carrying a (GT)16 were 
designed such that annealed at the flanking sequences of the EDA pY tract. A first PCR 
reaction (94°C-30sec, 60°C-30sec, 72°C-30sec for 30 cycles) was performed by using a sense 
oligo annealing at -1 EDA exon and the antisense oligo carrying the (GT)16 sequence. A 
second reaction (same PCR conditions) was carried out by using the sense oligo carrying the 
(GT)16 sequence and the antisense oligo annealing at +1 EDAexon. Afterward a third PCR 
reaction was carried out (same conditions) by using the primers annealing at the extremes Ex- 
IS and Ex+IAS and as a template, IpL of reaction 1 and reaction 2. The final “extended 
product” was visualized in a 1.0% agarose gel, purified, cloned and the plasmid transfected in 
NIH 3T3 cells. The primers utilized to generate this construct are listed below:
Reaction n° Name of the 
oligo
Sequence of the oligo (5’-3’)
1 Ex-lS atcaaacagaaatgacc attga
1 FN-EDArev atcaatgtctgttaggcaaattaatggtaagaggttatgtgaaaagcaagttgtg
1 FN-AII rev atcaatgtctgcacacacacacacacacacacacacacacacactctgttgtg
2 FN-EDAdir cacaacttgcttttcacataacctcttaccattaatttgcctaacagacattgat
2 FN-AII dir cacaacagagtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgcagacattgat
2 Ex+IAS ctctttcgggttcacccgca
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Intron removal order experiment
In order to determine the order in which ApoAII introns are processed during the splicing 
reaction a similar strategy used by Kessler et al (Kessler et al., 1993). was carried out. PCR 
amplification (94°C-30sec, 60°C-1.0 min, 72°C-1.5 min for 35 cycles) of a Hep3B non­
transfected cells cDNA, was performed by using the oligonucleotides listed below annealing 
in the exon 1 / intron 3 (reaction 1) and intron 2/ exon 4 (reaction 2).
Reaction n° Name of the oligo Sequence of the oligo (5’-3’)
1 Ex 1-1221 S accaaggacagagacgctggct
1 ApoAII-IVS3_1910-36AS ccacagttccacagcccctga
2 ApoAII-IVS2_1565-75S agggctcaaaaggaagatca
2 Rev Cla/Not ttttgcggccgcatcgattcactcggtggcaggctgtgttccaa
Oligo antisense for TDP-43 (TI01318)
The antisense phosphorotioate (PS)-oligonucleotides sequence was:
Name of the oligo Sequence of the oligo (5’-3’)
TI01318 ctgtctacattccccagcca
Oligos for Electro Mobility Shift Assay (EMS A)
Name of the oligo Sequence of the oligo (5’-3’)
ESE wt S ggtacctatggcaaggacctgatggagaaggtcaagagaagctt
ESE wt AS aagcttctcttgaccttctccatcaggtccttgccataggtacc
AESES ggtacctatggcaaggaccaggtcaagagaagctt
AESE AS aagcttctcttgacctggtccttgccataggtacc
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Oligos for UV crosslinking
Name of the oligo Sequence of the oligo (5’-3’)
ESE wt S ggtacctatggcaaggacctgatggagaaggtcaagagaagctt
ESE wt AS aagcttctcttgaccttctccatcaggtccttgccataggtacc
AESES ggtacctatggcaaggaccaggtcaagagaagctt
AESE AS aagcttctcttgacctggtccttgccataggtacc
ESE A97T S ggtacctatggcaaggacctgatggtgaaggtcaagagaagctt
ESE A97T AS aagcttctcttgaccttcaccatcaggtccttgccataggtacc
Oligos for UV crosslinking (ISE within intron 3)
Name of the oligo Sequence of the oligo (5’-3’)
IVS3-ISE-S gcgtaatacgactcactatagggagactgtggaactgtggagagaaagaagggaagatgagaggt
cccacagaagtctgaaccca
IVS3-ISE-AS tgggttcagacttctgtgggacctctcatcttcccttctttctctccacagttcc
acagtctccctatagtgagtcgtattacgc
IVS3-ISE-Mut-S gcgtaatacgactcactatagggagactgtggaactgtcgtgacaatgacggtaacatta
gcggtcccacagaagtctgaaccca
IVS3-ISE-Mut-AS tgggttcagacttctgtgggaccgctaatgttaccgtcattgtcacgacag
ttccacagtctccctatagtgagtcgtattacgc
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Construction of the minigene system
Apo A ll exon 2-intron 2-exon 3 minigene used for UV-crosslinking
The 629bp human Apo All sequence encompassing part of exon 2 (base 1401) to intron 3 
(base 2029) was amplified from pApo-wt by PCR (94 °C 30 sec, 60 °C 30 sec, 72 °C 30 sec, 
30 cycles by using the oligonucleotides listed below
Name of the oligo Sequence of the oligo (5’-3’)
SXhoI cccgctcgagcactgttaccaacatgaagct
Hindlll/SacII ttttccgcggaagcttctctgcgaattctaagcctaatctgccctaa
The first and second oligo include Xhol and Uindlll-SacII target site respectively. PCR 
product was digested XhoI-SacII and cloned in pBluescript. Sequencing excluded the presence 
of mutations within the insert. Plasmid was then Hindlll linearized for in vitro transcription 
with T7 RNApolymerase.
Maintenance and analysis of cells in culture
Hep3B, NIH3t3 and HeLa cell lines were grown in Dulbecco’s Mem with Glutamax I (Gibco) 
(Dulbecco’s modified Eagle’s medium with glutamine, sodium pyruvate, pyridoxine and 4.5 
g/1 glucose) supplemented with 10% foetal calf serum (Euro Clone) and Antibiotic 
Antimycotic (Sigma) according to the manufacturer’s instructions.
Plates containing a confluent monolayer of cells were treated with 0.1% w/v trypsin as 
follows. Cells washed with PBS solution, were incubated at 37 °C with 1-2 ml of 
PBS/EDTA/trypsin solution (PBS containing 0.04% w/v EDTA and 0.1% w/v trypsin) for 2 
minutes or until cells were dislodged. After adding 10 ml of media, cells were pelleted by 
centrifugation and resuspended in 5 ml pre-warmed medium. 1-2 ml of this cell suspension 
was added to 10 ml medium in a fresh plate and was gently mixed before incubation.
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Transfections
The DNA used for transfections was prepared with JetStar purification kit (Genomed) as 
previously described. Liposome-mediated transfections of 3x10^ human hepatocarcinoma 
Hep3B cells were performed using DOTAP Liposomal Transfection Reagent (Alexis 
Biochemicals). 3 pg of construct DNA was mixed with 5 pg of DOTAP for each transfection 
and the mixture was incubated at room temperature for 15 minutes to allow the formation of 
DNA-liposome complexes. The mixture was added to the cells in 3 ml of serum free culture 
medium and incubated at 37 °C. After 12 h the medium was replaced with fresh medium and 
24 h later, the cells were harvested. RNA isolation followed as described.
Cotransfections
In cotransfection experiments, cells were transfected with 4pg of pApo-wt or pApo-A97T and 
the PS-oligo TI01318 at a final concentration of 7,2pM or with 3pg of the TDP-43 expressing 
plasmid. For the SR proteins and hnRNPAl overexpression experiments, construct A1866-86 
(2pg) was cotransfected with 1 and 2pg of SRp 20, SRp55 and SRp75. Construct pApo-wt 
(2pg) was cotransfected with 1 and 2pg of SR proteins ASF/SF2, SC35 and hnRNPAl.
mRNA Analysis by Polymerase Chain Reaction 
cDNA synthesis
In order to synthesize cDNA, the 3 pg of total RNA extracted from cells were mixed with Not 
I-d(T)i8 primer (Pharmacia) in a final volume of 20 pi. After dénaturation at 90°C the RNA 
and the primer were incubated for 1 hour at 37 °C in the following solution: IX First Strand 
Buffer (Gibco), 10 mM DTT, 1 mM dNTPs, RNase inhibitor 20 U (Ambion) and Moloney 
murine leukemia virus reverse transcriptase 100 U (Gibco). Ipl of the cDNA reaction mix was 
used for the PCR analysis.
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cDNA analysis
PCR analysis of cDNA was carried out for 35 cycles (94 °C 30 sec, 60 °C 1 min, 72 °C 1,5 
min) in 50 pi reaction volumes. ApoAII full sequence and mutations/deletions in the different 
constructs were tested by these specific oligonucleotides:
Name of the oligo Sequence of the oligo (5’-3’)
Ex 1-1221 S accaaggacagagacgctggct
Not/Cla rev tctggacactgcggccgcatcg
For amplification of the endogenous ApoAII, the oligos used were:
Name of the oligo Sequence of the oligo (5’-3’)
Ex 1-1221 S accaaggacagagacgctggct
Rev Cla/Not ttttgcggccgcatcgattcactcggtggcaggctgtgttccaa
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Denaturing polyacrylamide gel electrophoresis (SDS-PAGE)
Protein samples were added to protein sample buffer (2X final). Conventional slab gel SDS 
PAGE (Laemmli, 1970) was performed in vertical gels with the required percentage of 
polyacrylamide (37,5:1 acrylamide:bis-acrylamide, ProtoGel, National Diagnostics), 
depending on each case. The gels were run at 40 mA in IX SDS-PAGE running buffer (50 
mM Tris, 0.38 M glycine, 0.1 % w/v SDS). After running, gels were either stained with 
coomassie Blue R250 in methanol-water-acetic acid 45:45:10 (v/v/v).
RNA preparation
DNA template for in vitro transcription used for UV crosslinking experiments, EMSA and in 
vitro splicing experiments, were prepared with oligos detailed above.
The templates for EMSA and UV-crosslinking were cloned into Kpn I and Hind III digested 
pBluescript SK under the T7 promoter control in pBluescript, whereas the templates for in 
vitro splicing were cloned into XhoI-PvuII (for the polypyrimidine tract replacement by GT 
repeats) or XhoI-BamHI (when the Tropomyosin exon 3 besides its pY tract were replaced by 
the Apo exon 3 and the (GU)n, respectively) digested PY7 under the SP6 promoter control. 
Transcription with T7 or SP6 RNA polymerase (Promega) was performed using 1-2 \ig of
linearized plasmid, in the presence of a - P-UTP. The reaction consisted of IX transcription 
buffer (Promega), 40 U of RNase inhibitor (Ambion), 1.5 mM each of the three NTPs (-UTP), 
and 10 U of T7 RNA polymerase (Promega) in a final volume of 20 |l i 1. Following incubation 
for 1 h at 37 °C the labeled RNA was then purified on a Nick column (Pharmacia), 
precipitated and resuspended in RNAse-free water. The specific activities were in the range of
4x10^ c.p.m./mg of RNA.
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RNA EMSA
The Electrophoretic Mobility Shift Assay (EMSA) method is described in Figure 4.1. In vitro 
T7 transcribed ^^P-labeled RNA (4-6 fmol) was incubated with 5.2 mM Hepes pH 7.9, 1 mM 
MgCl^, 0.8 mM magnesium acetate, 0.52 mM DTT, 3.8% glycerol, 0,75 mM ATP, 1 mM 
GTP, 0.5 pg/|il of heparin and 30 [iig HeLa Nuclear
EMSA analysis of RNA-protein complexes
1. in vitro transcription 
of labelled RNA
1
6> ©
^  O q O _ 2. Incubation with
_  O ^  O  ^  nuclear extract
^  C 0 O ç ^ c O
I
3. PAGE analysis in non-denaturing 
conditions of the RNA-protein mix
RNA-protein
complex
band-shifP
free RNA
Figure 4.1 Electrophoretic Mobility Shift Assay (EMSA).
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extract (4C Biotech) in a final volume of 20 pi for 20 min at room temperature. Following the 
addition of 5 pi of 50% (v/v) glycerol and tracking dye, complexes were resolved on a 4% 
polyacrylamide gel (ratio of 19:1 acrylamiderbis) in 75 mM Tris-Glycine buffer (75 mM Tris, 
75 mM Glycine) at 15-25 mA for 3-4 h at 4 C. Gels were dried and exposed to X-OMAT AR 
films for 1-3 h.
UV cross-linking
The UV cross-linking technique is described in Figure 4.2. The assays were carried out with 
nuclear extracts. Apo All mini genes cloned in pBluescripts SK plasmids were linearized by 
Flind III digestion and labelled RNAs were transcribed as described previously. ^^P-labeled 
RNA (1x10^ cpm per incubation) was incubated with 30 pg HeLa Nuclear extract (4C 
Biotech) in 20 pi final volume.
UV-crosslinking assay for the identification 
of RNA-binding proteins
l in e a r iz e d  D N A  s e q u e n c e
1
1. In vitro transcription of 
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Figure 4.2 Scheme of UV cross-linking assay.
141
Final binding conditions were 5.2 mM Hepes pH 7.9, 1 mM MgClj, 0.8 mM magnesium 
acetate, 0.52 mM DTT, 3.8% glycerol, 0,75 mM ATP and 1 mM GTP. When UV cross- 
linking assays were performed with ISE-wt and ISB-mut constructs, also heparin at a 5pg/pl 
final concentration was added to the binding mixture. The mixture was incubated for 15 min at 
30 °C. Following incubation, the samples were irradiated with UV light on ice (0.8 joules, 5 
min) using a UV Linker (Euroclone). Unbound RNA was removed by digestion with 1 U of 
RNase A at 37 °C for 30 min. The resulting ^^P-labeled proteins were resolved by 10% SDS- 
PAGE in the presence of molecular weight markers. The gel was dried and exposed to X- 
OMAT-AR film for 2-5 days.
Immunoprécipitation of SR proteins following UV-crosslinking.
The RNAs probes used in this study (ESE-wt, ESEA97T and AESE) were obtained by cloning 
in Bluescript SK+ the human ApoAII sequence ranging from intron 2 (nt 1549) to intron 3 (nt 
2022) with the wild type ESE, mutation A97T ESE and AESE. Construct carrying the EDA 
exon (from nucleotide 107 to 270) was used as a positive control. The UV cross- 
linking/immunoprecipitation assay is described in Figure 4.3. Each plasmid was then 
linearized with the appropriate restriction enzyme and transcribed using T7 RNA polymerase 
according to standard conditions. The UV crosslinking of [a^^P]-UTP labelled RNAs with 
commercial HeLa nuclear extracct (C4, Biotech) were performed as describe before. To each 
sample we added 150 pL of IP buffer (20 mM Tris pH=8.0, BOOmM NaCl, ImM EDTA, 
0.25% NP-40) together with 1/xg of monoclonal antibodies and incubated for 2 hours at 4°C 
on a rotator wheel. Anti-SF2/ASF (mAb96) and Anti-SC35 monoclonal antibodies were 
purchased from Zymed Laboratories Inc and Sigma respectively. After 2 hours icubation we 
added to each sample 30/tL of protein A7G-Plus Agarose (Santa Cruz Biotechnologies) and 
the incubation was left at 4°C overnight. The following morning the beads were subjected to
142
four washing cycles with 1.5mL of IP buffer and were then loaded on a 10% SDS-PAGE gel. 
Gels were run at a constant 30mA for approx. 3 hours and a half, were dried and then exposed 
for 4-6 days with a Biomax Screen (Kodak).
c n d - la h e ll in g  w ith  o f
tiirsiv i R N A /D N A  o ligo
4. R N A si t r e a tm e n t
2. In c u b a t io n  w ith  
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7. W a s h in g  cy c les
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Figure 4.3 UV cross-linking/Iminunopreclpitatlon assay
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In vitro splicing assays
HeLa cell nuclear was purchased from C4, Biotech. Standard conditions were used for the 
splicing reactions (Mayeda and Krainer, 1999). 20 fmol (usually 0.1-0.4 /xL) of ^^P-labeled 7- 
CH3 GpppG-capped SP6 transcripts was incubated in 10-/xL splicing reactions. Each reaction 
contained 1.0/xL of a 25X ATP/CP mixture, 1.0/xL of 80 mM MgC12 (at a final concentration 
of 3.2mM), 1.25j[iL of 0,4 M HEPES-KOH, 30% HeLa nuclear extract, pH 7.3, 5/xL of 13% 
PVA (added last) and Milli-Q water to 25/xL total. After incubation at 30°C for 2-4 hr, the 
RNA was extracted and analyzed on 8% polyacrylamide denaturing gels, followed by 
autoradiography.
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